---
title: "Descartes-08 in Generalized myasthenia gravis: Product information and disease description"
description: "Formulary evidence on Descartes-08 in Generalized myasthenia gravis: Product information and disease description. Covers Product description and Place of product in therapy. 302 evidence topics quoted from 138 sources."
canonical: "https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis/product-information-and-disease-description"
published: "2026-11-19T12:09:07-05:00"
modified: "2026-11-19T12:09:07-05:00"
---

# Descartes-08 in Generalized myasthenia gravis: Product information and disease description

<a id="product-information-and-disease-description"></a>

## 2 Product Information and Disease Description

<a id="heading-2.1"></a>

### 2.1 Product Description

<a id="heading-2.1.1"></a>

#### 2.1.1 Phase of Product Development

<a id="topic-2.1.1-1"></a>

##### Summary: development and regulatory status

- Regulatory status: The company states that it has no products approved for sale and has not generated any product sales. The FDA designated Descartes-08 an orphan drug for the treatment of myasthenia gravis on 11/08/2022 (not FDA approved for the orphan indication), and the company announced Regenerative Medicine Advanced Therapy designation for MG on May 22, 2024. A Rare Pediatric Disease Designation for juvenile dermatomyositis (JDM) was granted in September 2024; the company states that approval in JDM may qualify it for a priority review voucher.
- Special Protocol Assessment: On January 27, 2025, the company announced written agreement from the FDA under the Special Protocol Assessment process on the overall design of the phase 3 AURORA trial, which the company states the FDA determined acceptable to support a future biologics license application (BLA) in MG, subject to the outcome of the trial.
- Earlier development: The company has completed a phase 1/2 trial in MG with phase 1b, phase 2a, and phase 2b portions; phase 2a results were published in the Lancet Neurology in July 2023, phase 2b results were presented in December 2024, and 12-month data were reported in April 2025 and published in Nature Medicine in January 2026. As of December 31, 2025, Descartes-08 had been administered to over 100 patients with MG, multiple myeloma, and other diseases.
- AURORA status: The first participant was enrolled in May 2025 (registry actual study start 2025-05-06). The company describes approximately 100 participants with AChR antibody-positive MG; the registry record last updated 2026-09-01 lists actual enrollment of 128, a status of active, not recruiting, estimated primary completion on 2026-12-30, and estimated study completion on 2027-09-30. The company expects topline data in the first quarter of 2027 and plans a BLA filing in mid-2027, and states that it has expanded its medical affairs and commercial teams for launch readiness.
- Financing: Cash, cash equivalents, and restricted cash were $124.7 million as of September 30, 2026, including the initial $50 million tranche of non-dilutive financing from K2 HealthVentures and $22.8 million raised year to date through the at-the-market program; the company expects these resources to support planned operations, including completion of AURORA, into 2028. The term loan facility provides up to $150.0 million in four tranches, of which $50.0 million had been borrowed as of September 30, 2026, and requires a minimum trailing three-month net product revenue of $40.0 million beginning on January 1, 2029. The accumulated deficit was $857.3 million, and approximately $75.5 million remained available under the at-the-market program. In its full year 2025 results (2026), the company had projected that $126.9 million as of December 31, 2025, would support operations into mid-2027.
- Other indications: The phase 2 TRITON trial in moderate to severe multi-refractory dermatomyositis and antisynthetase syndrome and the phase 1/2 HELIOS trial in children and young adults with autoimmune diseases, including JDM, are ongoing, with data from both expected in the first half of 2027. After topline data from a phase 2 trial in systemic lupus erythematosus in November 2025, the company decided to no longer pursue development in that indication.

Source: [Cartesian Therapeutics Form 10-Q, third quarter 2026 (2026)](https://www.sec.gov/Archives/edgar/data/1453687/000145368726000111/rnac-20260930.htm); [FDA Orphan Drug Designations and Approvals (2022)](https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=909722); [Cartesian Therapeutics RMAT designation press release (2024)](https://ir.cartesiantherapeutics.com/news-releases/news-release-details/cartesian-therapeutics-receives-fda-regenerative-medicine); [Cartesian Therapeutics corporate presentation, November 2026 (2026)](https://ir.cartesiantherapeutics.com/static-files/6ba3bfe0-f3be-4487-add3-b56dd535e456); [Cartesian Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1453687/000145368726000064/rnac-20251231.htm); [Cartesian Therapeutics Special Protocol Assessment press release (2025)](https://ir.cartesiantherapeutics.com/news-releases/news-release-details/cartesian-therapeutics-announces-fda-special-protocol-assessment); [Cartesian Therapeutics AURORA first participant press release (2025)](https://ir.cartesiantherapeutics.com/news-releases/news-release-details/cartesian-therapeutics-announces-first-participant-enrolled); [ClinicalTrials.gov NCT06799247](https://clinicaltrials.gov/study/NCT06799247); [Cartesian Therapeutics third quarter 2026 results (2026)](https://ir.cartesiantherapeutics.com/news-releases/news-release-details/cartesian-therapeutics-reports-third-quarter-2026-financial); [Cartesian Therapeutics K2 HealthVentures financing press release (2026)](https://ir.cartesiantherapeutics.com/news-releases/news-release-details/cartesian-therapeutics-secures-150-million-non-dilutive); [Cartesian Therapeutics full year 2025 results (2026)](https://ir.cartesiantherapeutics.com/news-releases/news-release-details/cartesian-therapeutics-reports-full-year-2025-financial-results)

<a id="topic-2.1.1-2"></a>

##### Regulatory status: Submission planned; BLA planned for mid-2027

> “Phase 3 AURORA trial of Descartes-08 in myasthenia gravis (MG) advances towards data readout expected in 1Q27 and biologics license application (BLA) filing planned for mid-2027”
> “Phase 3 AURORA Trial of Descartes-08 in Participants with MG Advances Towards Expected Data Readout in 1Q27, with BLA Planned for Mid-2027.”

Source: [Cartesian Therapeutics third quarter 2026 results (2026)](https://ir.cartesiantherapeutics.com/news-releases/news-release-details/cartesian-therapeutics-reports-third-quarter-2026-financial)

> “We do not have any products approved for sale and have not generated any product sales.”

Source: [Cartesian Therapeutics Form 10-Q, third quarter 2026 (2026)](https://www.sec.gov/Archives/edgar/data/1453687/000145368726000111/rnac-20260930.htm)

<a id="topic-2.1.1-3"></a>

##### Launch

No evidence found.

<a id="topic-2.1.1-4"></a>

##### Launch readiness: expanded medical affairs and commercial teams

> “Ahead of our anticipated BLA submission in mid-2027, we have expanded our medical affairs and commercial teams to drive launch readiness.”

Source: [Cartesian Therapeutics third quarter 2026 results (2026)](https://ir.cartesiantherapeutics.com/news-releases/news-release-details/cartesian-therapeutics-reports-third-quarter-2026-financial)

> “The proceeds from the initial tranche under the credit facility are expected to allow the Company to accelerate the ongoing investment in the commercial launch preparation activities for Descartes-08 in myasthenia gravis (MG) and myositis and to extend cash runway into 2028.”

Source: [Cartesian Therapeutics K2 HealthVentures financing press release (2026)](https://ir.cartesiantherapeutics.com/news-releases/news-release-details/cartesian-therapeutics-secures-150-million-non-dilutive)

<a id="topic-2.1.1-5"></a>

##### AURORA topline data and BLA timing: first quarter of 2027 and mid-2027

> “The Company anticipates reporting topline data from the Phase 3 AURORA trial in the first quarter of 2027 with BLA filing planned for mid-2027.”

Source: [Cartesian Therapeutics K2 HealthVentures financing press release (2026)](https://ir.cartesiantherapeutics.com/news-releases/news-release-details/cartesian-therapeutics-secures-150-million-non-dilutive)

> “Cartesian remains on track to readout topline data from its Phase 3 AURORA trial of Descartes-08 in MG in the first quarter of 2027, with a BLA filing expected in mid-2027.”

Source: [Cartesian Therapeutics retreatment data press release (2026)](https://ir.cartesiantherapeutics.com/news-releases/news-release-details/cartesian-therapeutics-announces-additional-retreatment-data)

<a id="topic-2.1.1-6"></a>

##### Orphan Drug Designation for myasthenia gravis: designated November 2022

| Field | Quoted record |
| --- | --- |
| Generic name | “autologous T-cells expressing a chimeric antigen receptor directed against B-Cell maturation antigen” |
| Date designated | “11/08/2022” |
| Orphan designation | “Treatment of Myasthenia Gravis” |
| Orphan designation status | “Designated” |
| FDA orphan approval status | “Not FDA Approved for Orphan Indication” |
| Sponsor | “Cartesian Therapeutics, Inc.” |

Source: [FDA Orphan Drug Designations and Approvals (2022)](https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=909722)

<a id="topic-2.1.1-7"></a>

##### Regenerative Medicine Advanced Therapy designation for myasthenia gravis: granted May 2024

> “GAITHERSBURG, Md., May 22, 2024 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company pioneering mRNA cell therapy for autoimmune diseases, today announced that the U.S. Food and Drug Administration (“FDA”) has granted Regenerative Medicine Advanced Therapy (“RMAT”) designation for Descartes-08 for the treatment of myasthenia gravis (“MG”).”
> “Receiving RMAT designation offers sponsor companies the benefits of the fast track and breakthrough therapy designation programs, allowing for early, close, and frequent interactions with the FDA with the goal of expediting drug development.”
> “Descartes-08 was previously granted Orphan Drug Designation by the FDA for the treatment of MG.”

Source: [Cartesian Therapeutics RMAT designation press release (2024)](https://ir.cartesiantherapeutics.com/news-releases/news-release-details/cartesian-therapeutics-receives-fda-regenerative-medicine)

<a id="topic-2.1.1-8"></a>

##### Special Protocol Assessment agreement on the AURORA design: January 2025

> “FREDERICK, Md., Jan. 27, 2025 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company pioneering mRNA cell therapy for autoimmune diseases, today announced that it has received written agreement from the U.S. Food and Drug Administration (FDA) under the Special Protocol Assessment (SPA) process on the overall design of the Company’s planned Phase 3 AURORA trial for Descartes-08, its lead mRNA cell therapy candidate, in myasthenia gravis (MG).”
> “The SPA agreement indicates that the FDA has determined that the proposed trial design is acceptable to support a future Biologics License Application for Descartes-08 in MG, subject to the ultimate outcome of the trial.”

Source: [Cartesian Therapeutics Special Protocol Assessment press release (2025)](https://ir.cartesiantherapeutics.com/news-releases/news-release-details/cartesian-therapeutics-announces-fda-special-protocol-assessment)

<a id="topic-2.1.1-9"></a>

##### Rare Pediatric Disease Designation for juvenile dermatomyositis: granted September 2024

> “Rare Pediatric Disease Designation for DC-08 in juvenile dermatomyositis granted in September 2024”

Source: [Cartesian Therapeutics corporate presentation, November 2026 (2026)](https://ir.cartesiantherapeutics.com/static-files/6ba3bfe0-f3be-4487-add3-b56dd535e456)

> “Under the FDA’s recently renewed Rare Pediatric Disease Designation and priority review voucher programs, if Descartes-08 is approved for marketing in JDM, Cartesian may qualify for a priority review voucher that can be redeemed to receive priority review of a subsequent marketing application for a different product candidate.”

Source: [Cartesian Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1453687/000145368726000064/rnac-20251231.htm)

<a id="topic-2.1.1-10"></a>

##### AURORA initiation: first participant enrolled May 2025

> “FREDERICK, Md., May 30, 2025 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (“Cartesian” or the “Company”), a clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases, today announced that the first participant has been enrolled in its Phase 3 AURORA trial of Descartes-08 in patients with myasthenia gravis (MG).”

Source: [Cartesian Therapeutics AURORA first participant press release (2025)](https://ir.cartesiantherapeutics.com/news-releases/news-release-details/cartesian-therapeutics-announces-first-participant-enrolled)

<a id="topic-2.1.1-11"></a>

##### Development history: phase 1b, phase 2a, and phase 2b portions of MG-001

> “To date, we have completed a Phase 1/2 trial of Descartes-08 in MG, which consisted of a Phase 1b portion, a Phase 2a portion, and a Phase 2b portion.”
> “The results of the Phase 2a portion of the trial, published in the Lancet Neurology in July 2023, indicated that after six weekly infusions of Descartes-08, the average improvement in all disease severity scores was three-to-five-fold greater than what is considered clinically meaningful by expert consensus.”
> “Follow-on results of the Phase 2b portion of the trial were presented in December 2024.”
> “In April, 2025, we reported updated, 12-month data from this trial and published this data in Nature Medicine in January 2026.”

Source: [Cartesian Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1453687/000145368726000064/rnac-20251231.htm)

<a id="topic-2.1.1-12"></a>

##### Clinical exposure across indications through December 2025

> “As of December 31, 2025, we have administered Descartes-08 to over 100 patients suffering from one of MG, multiple myeloma, and other diseases in open-label and randomized placebo-controlled trials on an outpatient basis.”

Source: [Cartesian Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1453687/000145368726000064/rnac-20251231.htm)

<a id="topic-2.1.1-13"></a>

##### Other indications: myositis (TRITON) and pediatric autoimmune diseases (HELIOS)

> “Phase 2 TRITON trial of Descartes-08 in myositis and Phase 1/2 HELIOS pediatric trial of Descartes-08 in juvenile dermatomyositis (JDM) continue to progress, with data from both trials expected in 1H27”
> “The randomized, double-blind, placebo-controlled Phase 2 TRITON trial in myositis is designed to assess Descartes-08 versus placebo (1:1 randomization) administered as six weekly outpatient infusions without preconditioning chemotherapy in patients with moderate to severe multi-refractory dermatomyositis and antisynthetase syndrome.”
> “Enrollment remains ongoing in the Phase 1/2 HELIOS pediatric trial of Descartes-08 in children and young adults with autoimmune diseases, including JDM.”

Source: [Cartesian Therapeutics third quarter 2026 results (2026)](https://ir.cartesiantherapeutics.com/news-releases/news-release-details/cartesian-therapeutics-reports-third-quarter-2026-financial)

<a id="topic-2.1.1-14"></a>

##### Systemic lupus erythematosus: development discontinued after November 2025 topline data

> “In November 2025, we announced topline data from our Phase 2 trial in SLE, a chronic autoimmune disease that causes systemic inflammation which affects multiple organ systems.”
> “We also announced a pause in further development of Descartes-08 in SLE, including further enrollment in the Phase 2 trial, in order to prioritize opportunities in MG and myositis.”
> “Shortly thereafter we made a further decision to no longer pursue development of Descartes-08 in SLE.”

Source: [Cartesian Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1453687/000145368726000064/rnac-20251231.htm)

<a id="topic-2.1.1-15"></a>

##### Cash position and runway into 2028, September 2026

> “Cash, cash equivalents and restricted cash as of September 30, 2026 was $124.7 million, inclusive of the initial $50 million tranche of non-dilutive financing from K2 HealthVentures (K2HV) and $22.8 million raised year to date after commissions and expenses through the Company’s at the market offering program.”
> “The Company’s current cash resources on hand are expected to support planned operations, including completion of the ongoing Phase 3 AURORA trial, into 2028.”

Source: [Cartesian Therapeutics third quarter 2026 results (2026)](https://ir.cartesiantherapeutics.com/news-releases/news-release-details/cartesian-therapeutics-reports-third-quarter-2026-financial)

> “The Company believes the cash, cash equivalents and restricted cash as of September 30, 2026 will enable it to fund its current planned operations for at least the next 12 months from the filing of this Quarterly Report.”
> “As of September 30, 2026, the Company had an accumulated deficit of $857.3 million.”
> “The successful development of product candidates requires substantial working capital, which may not be available to the Company on favorable terms or at all.”

Source: [Cartesian Therapeutics Form 10-Q, third quarter 2026 (2026)](https://www.sec.gov/Archives/edgar/data/1453687/000145368726000111/rnac-20260930.htm)

<a id="topic-2.1.1-16"></a>

##### Financing: K2 HealthVentures term loan facility and at-the-market program

> “On May 22, 2026, the Company entered into the Loan Agreement (as defined below) with K2HV (as defined below), providing for Term Loan Facility (as defined below) with aggregate commitments of up to $150.0 million available in four tranches, subject to the satisfaction of certain conditions precedent.”
> “As of September 30, 2026, the Company has borrowed $50.0 million under the Loan Agreement.”
> “Beginning on January 1, 2029, the Loan Agreement requires the Company to maintain compliance with a minimum trailing three-month net product revenue covenant of $40.0 million, tested as of the last day of each calendar quarter, with required quarter-over-quarter growth.”
> “As of September 30, 2026, approximately $75.5 million remains available under the at the market program.”

Source: [Cartesian Therapeutics Form 10-Q, third quarter 2026 (2026)](https://www.sec.gov/Archives/edgar/data/1453687/000145368726000111/rnac-20260930.htm)

<a id="topic-2.1.1-17"></a>

##### Cash runway into mid-2027, March 2026, superseded in May 2026

> “Cash, cash equivalents and restricted cash as of December 31, 2025 was $126.9 million and is expected to support planned operations, including completion of the ongoing Phase 3 AURORA trial and initiation of its Phase 2 TRITON trial in myositis, into mid-2027.”

Source: [Cartesian Therapeutics full year 2025 results (2026)](https://ir.cartesiantherapeutics.com/news-releases/news-release-details/cartesian-therapeutics-reports-full-year-2025-financial-results)

<a id="heading-2.1.2"></a>

#### 2.1.2 Product Information

<a id="heading-2.1.2.1"></a>

##### 2.1.2.1 Generic, Brand Name and Therapeutic Class of Product

<a id="topic-2.1.2.1-1"></a>

###### Manufacturer: Cartesian Therapeutics

> “Cartesian Therapeutics, Inc., or the Company, (formerly known as Selecta Biosciences, Inc., or Selecta) was incorporated in Delaware on December 10, 2007, and is headquartered in Frederick, Maryland.”

Source: [Cartesian Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1453687/000145368726000064/rnac-20251231.htm)

<a id="topic-2.1.2.1-2"></a>

###### Product description: autologous anti-BCMA CAR-T cell therapy in clinical development

> “Descartes-08, Cartesian’s lead cell therapy candidate, is an autologous CAR-T product targeting BCMA in clinical development for generalized MG and myositis, specifically dermatomyositis and antisynthetase syndrome.”
> “In contrast to conventional DNA-based CAR T-cell therapies, Cartesian’s CAR-T administration is designed to not require preconditioning chemotherapy, can be administered in the outpatient setting, and does not carry the risk of genomic integration associated with cancerous transformation.”

Source: [Cartesian Therapeutics third quarter 2026 results (2026)](https://ir.cartesiantherapeutics.com/news-releases/news-release-details/cartesian-therapeutics-reports-third-quarter-2026-financial)

<a id="topic-2.1.2.1-3"></a>

###### Engineering by mRNA transfection of autologous CD8+ T cells

> “Engineered by transfection of autologous CD8+ T cells with mRNA encoding anti-BCMA CAR”

Source: [Cartesian Therapeutics corporate presentation, November 2026 (2026)](https://ir.cartesiantherapeutics.com/static-files/6ba3bfe0-f3be-4487-add3-b56dd535e456)

<a id="topic-2.1.2.1-4"></a>

###### Nonproprietary name and code name in the NCI Drug Dictionary

| Field | Quoted record |
| --- | --- |
| Drug dictionary name | “autologous anti-BCMA-CAR-mRNA-transfected CD8+ T lymphocytes” |
| Code name | “Descartes-08” |
| Synonym | “anti-BCMA-CAR-mRNA-transfected autologous CD8+ T cells” |

Source: [NCI Drug Dictionary](https://www.cancer.gov/publications/dictionaries/cancer-drug/def/autologous-anti-bcma-car-mrna-transfected-cd8-t-lymphocytes)

<a id="topic-2.1.2.1-5"></a>

###### Manufacturing facility: in-house cGMP facility in Frederick, Maryland

> “We have established wholly-owned internal manufacturing and research and development capabilities, designed to allow us to optimize processes rapidly in an iterative manner and maintain control over the critical components of the supply chain.”
> “Our main manufacturing facility is located in Frederick, Maryland, and operates under current good manufacturing practice, or cGMP.”
> “This facility has sufficient capacity to support current clinical needs and can potentially transition to support commercial manufacturing of our maturing pipeline of innovative cell therapies for the treatment of autoimmune diseases.”

Source: [Cartesian Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1453687/000145368726000064/rnac-20251231.htm)

<a id="heading-2.1.2.2"></a>

##### 2.1.2.2 Dosage Forms and Strengths

<a id="topic-2.1.2.2-1"></a>

###### Target dose per infusion from a single apheresis: phase 2b

> “A single apheresis was sufficient to reach the target dose of 52.5 × 10⁶ viable CAR+ cells per kilogram ± 45% for each of six once-weekly infusions.”

Source: [Fedak et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13004674/)

<a id="topic-2.1.2.2-2"></a>

###### Product supplied as frozen aliquots tested before release: phase 1b/2a

> “The autologous product was divided into multiple aliquots, frozen, and tested for sterility, cell quality, CAR expression, and potency.”

Source: [Granit et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10416207/)

<a id="topic-2.1.2.2-3"></a>

###### Matched placebo presentation in the phase 2b trial

> “The placebo was matched to Descartes-08 in appearance and supplied in identical containers.”

Source: [Vu et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13004676/)

<a id="topic-2.1.2.2-4"></a>

###### Patient-specific manufacture

> “Our autologous cell therapy product candidates, including Descartes-08, are manufactured on a patient-by-patient basis.”

Source: [Cartesian Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1453687/000145368726000064/rnac-20251231.htm)

<a id="heading-2.1.2.3"></a>

##### 2.1.2.3 Average Sales Price and Wholesale Acquisition Cost

Not applicable.

<a id="heading-2.1.2.4"></a>

##### 2.1.2.4 American Hospital Formulary Service (AHFS), or Other Drug Classification

<a id="topic-2.1.2.4-1"></a>

###### NCI Thesaurus classification

| Field | Quoted record |
| --- | --- |
| NCI Thesaurus code | “C156706” |
| Preferred name | “Autologous Anti-BCMA-CAR-mRNA-transfected CD8+ T-lymphocytes” |
| Parent concept | “Anti-BCMA CAR T Cells Preparation” |
| Parent concept | “Autologous CAR-T Cells” |

Source: [NCI Thesaurus (2026)](https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C156706)

<a id="topic-2.1.2.4-2"></a>

###### NCI Drug Dictionary definition

> “A preparation of autologous CD8-positive T lymphocytes that have been genetically modified via transient mRNA transfection to express a chimeric antigen receptor (CAR) specific for the tumor-associated antigen (TAA) human B-cell maturation antigen (BCMA; tumor necrosis factor receptor superfamily member 17; TNFRSF17) and containing, as of yet undisclosed co-stimulatory signaling domains, with potential immunostimulating and antineoplastic activities.”

Source: [NCI Drug Dictionary](https://www.cancer.gov/publications/dictionaries/cancer-drug/def/autologous-anti-bcma-car-mrna-transfected-cd8-t-lymphocytes)

<a id="heading-2.1.2.5"></a>

##### 2.1.2.5 Indication

<a id="topic-2.1.2.5-1"></a>

###### Indication under study in AURORA: acetylcholine receptor autoantibody-positive generalized myasthenia gravis

> “The randomized, double-blind, placebo-controlled Phase 3 AURORA trial is designed to assess Descartes-08 versus placebo (1:1 randomization) administered as six once weekly infusions without preconditioning chemotherapy in approximately 100 participants with acetylcholine receptor autoantibody positive (AChR Ab+) MG.”

Source: [Cartesian Therapeutics Special Protocol Assessment press release (2025)](https://ir.cartesiantherapeutics.com/news-releases/news-release-details/cartesian-therapeutics-announces-fda-special-protocol-assessment)

<a id="heading-2.1.2.6"></a>

##### 2.1.2.6 Pharmacology

<a id="heading-2.1.2.6.1"></a>

###### 2.1.2.6.1 Mechanism of Action

<a id="topic-2.1.2.6.1-1"></a>

###### Transient CAR expression from RNA without genomic modification

> “Engineering of cells using RNA offers distinct advantages toward this goal by exploiting transient CAR expression.”
> “This characteristic enables dosing at levels that are immediately therapeutic and that exhibit a built-in proliferative check: CAR RNA degrades during cell division.”
> “As a result, RNA cell therapy can be administered without lymphodepletion and in the outpatient setting, also eliminating the risk of secondary malignancies because no genomic modification occurs.”

Source: [Fedak et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13004674/)

> “Unlike DNA, mRNA degrades naturally over time without integrating into the cell’s genetic material.”

Source: [Cartesian Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1453687/000145368726000064/rnac-20251231.htm)

<a id="topic-2.1.2.6.1-2"></a>

###### CAR-positive cell load limited by the administered dose

> “Since the CAR-encoding mRNA does not replicate together with the activated and proliferating rCAR T-cells, the load of CAR+ cells is determined and limited by the administered dose, and declines over time, potentially enabling more precise PK control over the therapy.”
> “Because our approach uses ex vivo T-cell proliferation, it does not require the specific cytokine environment induced by lymphodepletion.”
> “Only CD8+ T-cells are used for manufacturing since CD4+ T-cells are known for their memory function, rather than direct killing function, which is not relevant to RNA-transfected CAR T-cells that express the CAR molecule over days.”

Source: [Granit et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10416207/)

<a id="topic-2.1.2.6.1-3"></a>

###### Target antigen: BCMA on plasma cells

> “BCMA, a tumor-specific antigen and a receptor for both a proliferation-inducing ligand (APRIL) and B-cell activating factor (BAFF), is a member of the tumor necrosis factor receptor superfamily (TNFRSF) and plays a key role in plasma cell survival.”

Source: [NCI Drug Dictionary](https://www.cancer.gov/publications/dictionaries/cancer-drug/def/autologous-anti-bcma-car-mrna-transfected-cd8-t-lymphocytes)

> “Descartes-08 targets BCMA+ cells, among which PCs and pDCs are most abundant9; these are also populations involved in autoimmune pathogenicity, including PCs that produce autoantibodies in MG37.”

Source: [Fedak et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13004674/)

<a id="topic-2.1.2.6.1-4"></a>

###### Proposed mechanism: preferential depletion of BCMA-high plasma cells and a precision immune reset

> “Potential mechanisms could involve precision ablation (for example, direct cytotoxicity) or interference (for example, trogocytosis) on the BCMAhi subset comprising pathogenic PCs and other cells such as pDCs.”
> “Functionally, therefore, Descartes-08 may preferentially deplete PCs expressing high levels of BCMA, which, in patients with autoimmune disease, is preferential to PCs producing pathogenic autoantibodies.”
> “Directly testing these hypotheses is a clinical challenge in the context of autoimmunity because the key target cells are predominantly located outside of circulation—PCs resident in the bone marrow and activated pDCs and B cells in inflamed tissue or lymphatics11,37,41–43.”

Source: [Fedak et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13004674/)

<a id="topic-2.1.2.6.1-5"></a>

###### Mechanism compared with complement inhibitors, FcRn inhibitors, and DNA-based CAR-T cell therapies

> “These technologies include FcRn inhibitors and complement inhibitors that directly target circulating antibodies and antibody effector function, respectively; both technologies involve ongoing treatment to maintain effect48–50.”
> “Further, emerging T cell therapies often involve lymphodepletion, viral vectors and targeting of CD19 that result in non-specific depletion of B cells and, consequently, immunoglobulins and vaccine titers2,45,46.”

Source: [Fedak et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13004674/)

<a id="heading-2.1.2.6.2"></a>

###### 2.1.2.6.2 Pharmacodynamics

<a id="topic-2.1.2.6.2-1"></a>

###### Preclinical activity: CAR expression peaks on day 1 and BCMA-positive cells are killed

> “To confirm function, the Descartes-08 RNA payload was electroporated into CD8+ T cells.”
> “CAR RNA was rapidly detected and then gradually waned to baseline (Fig. 1e), consistent with expression that peaked on day 1 (Fig. 1f).”
> “Descartes-08 also efficiently depleted autologous PCs from healthy individuals or patients with MG (Fig. 1h,i and Supplementary Fig. 2).”

Source: [Fedak et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13004674/)

> “The magnitude of cytolysis correlates with anti-BCMA CAR expression duration, indicating a temporal limit in activity.”

Source: [Lin et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7785573/)

<a id="topic-2.1.2.6.2-2"></a>

###### Plasmablast BCMA and pDC activation markers after treatment compared with placebo: phase 2b

> “Intriguingly, analysis of plasmablasts after Descartes-08 treatment revealed significant reductions in BCMA expression on plasmablasts at month 3 (n = 6) (P = 0.035) compared to placebo.”
> “Similarly, CD86 was significantly reduced on pDCs at month 1 (n = 11) (P < 0.001) relative to placebo and also trended downward at month 3 (Fig. 3e,f).”
> “Interestingly, at month 12, the decrease in CD86 levels persisted among the Descartes-08 cohort (Extended Data Fig. 2), although fewer samples were available at month 12 (n = 7).”
> “Despite the changes in activation state, the frequency of plasmablasts and circulating pDCs remained unchanged (Fig. 3g,h), consistent with the normal levels observed at screen (Fig. 3a,b).”

Source: [Fedak et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13004674/)

<a id="topic-2.1.2.6.2-3"></a>

###### Autoantibody repertoire and anti-AChR antibody titers: phase 2b

> “By contrast, Descartes-08 was associated with a greater change in the autoreactome (r value median = 0.72) compared to placebo (r value median = 0.89) at month 3 compared to day 1; this change persisted through month 6 (r value median = 0.74) (Fig. 3j).”
> “Furthermore, despite the dramatic changes in autoreactome, we did not observe a significant change in the anti-AChR antibody titer (Fig. 3m).”

Source: [Fedak et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13004674/)

<a id="topic-2.1.2.6.2-4"></a>

###### Anti-AChR antibody reductions in the phase 2a portion

> “All three participants with detectable anti-acetylcholine receptor antibody levels before treatment had an average 42% reduction in antibody levels by Month 6.”
> “These reductions deepened to 68% by Month 9 and persisted at Month 12.”

Source: [Cartesian Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1453687/000145368726000064/rnac-20251231.htm)

<a id="topic-2.1.2.6.2-5"></a>

###### Immune cell populations, immunoglobulins, and vaccine titers at month 3 and month 12: phase 2b

> “In line with our hypothesis, no significant changes were observed between placebo and Descartes-08 when assessing broad immune populations, including the change in frequency of B cells, T cells, natural killer cells and monocytes (Fig. 4a–e and Supplementary Fig. 8).”
> “Likewise, total immunoglobulins (Fig. 4f–h and Extended Data Table 3) and common vaccine titers (Fig. 4i–m and Extended Data Table 4) were preserved at month 3 and month 12.”

Source: [Fedak et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13004674/)

<a id="topic-2.1.2.6.2-6"></a>

###### Disease-associated cytokines after infusion: phase 2b

> “Descartes-08 infusion was not associated with indicators of CAR-T cell therapy-induced inflammation.”
> “In particular, IL-6, IL-24, CCL19 and artemin (ARTN), all of which are involved in autoimmunity, decreased at month 3 as well as at month 1 and month 12 for some analytes.”
> “Importantly, IL-6 is a key indicator of MG severity, and this cytokine was significantly reduced at month 3 in patients receiving Descartes-08 (P = 0.019).”

Source: [Fedak et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13004674/)

<a id="topic-2.1.2.6.2-7"></a>

###### T cell receptor repertoire after treatment

> “TCR sequencing revealed that Descartes-08 increases clonal expansion and contraction compared to placebo (Fig. 6a,b).”
> “Together, these data indicate that Descartes-08 alters the TCR repertoire without significantly changing the broader phenotypic composition of the T cell compartment.”

Source: [Fedak et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13004674/)

<a id="heading-2.1.2.6.3"></a>

###### 2.1.2.6.3 Pharmacokinetics

<a id="topic-2.1.2.6.3-1"></a>

###### Duration of CAR expression: about 1 week in vitro

> “Descartes-08 express anti-BCMA CAR for 1 week, limiting risk of uncontrolled proliferation; produce inflammatory cytokines in response to myeloma target cells; and are highly cytolytic against myeloma cells regardless of presence of myeloma-protecting bone marrow stromal cells, exogenous a proliferation-inducing ligand, or drug resistance including IMiDs.”
> “The expression of BCMA CAR on Descartes-08 cells was sustained for approximately 1 week, and gradually declined until 9 days (9d) after thawing following their generation (Fig. 1c).”

Source: [Lin et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7785573/)

<a id="topic-2.1.2.6.3-2"></a>

###### Circulating CAR RNA after infusion: phase 1b/2a

> “CAR RNA was detected in peripheral blood 1–2 hours post-infusion and at no other time point (Figure s3A).”
> “Bone marrow biopsies are not customarily done on MG patients, so bone marrow was not assessed for the presence of CARs or CAR RNA.”
> “In accordance with time-restricted expression of RNA-based CAR molecules in vitro18, mRNA detection in our study was transient.”

Source: [Granit et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10416207/)

<a id="topic-2.1.2.6.3-3"></a>

###### Circulating CAR RNA after infusion and at month 3: phase 2b

> “Lastly, pharmacokinetic profiling using quantitative real-time polymerase chain reaction (qRT–PCR) revealed large, discrete increases in Descartes-08 RNA levels after infusion that were absent prior to infusion and at later times, such as month 3 (approximately 7 weeks after the final infusion) (n = 19) (Fig. 2f).”
> “Although some changes in cytokines associated with Descartes-08 did not persist at month 12, others, such as IL-6 and RANKL, did persist or did not become evident until this time (EN-RAGE, TRAIL and TNFSF14), even though CAR expression persists only for a period of days.”

Source: [Fedak et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13004674/)

<a id="topic-2.1.2.6.3-4"></a>

###### CAR expression in circulating T cells one day after infusion in a mouse xenograft model

> “One day after Descartes-08 infusion, CAR expression was detectable in more than 80% of circulating CD45+CD8+ T cells (Fig. 1j–l).”

Source: [Fedak et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13004674/)

<a id="heading-2.1.2.7"></a>

##### 2.1.2.7 Contraindications/Warnings/Precautions/Adverse Effects

<a id="heading-2.1.2.7.1"></a>

###### 2.1.2.7.1 Warnings and Precautions

Not applicable.

<a id="heading-2.1.2.8"></a>

##### 2.1.2.8 Special Populations

<a id="topic-2.1.2.8-1"></a>

###### Age: adults in the phase 2b trial

> “MG-001 part 3 was a prospective, double-blind, multicenter, randomized placebo-controlled phase 2b trial evaluating the safety and clinical activity of Descartes-08, RNA-engineered anti-BCMA CAR-T, in adults with generalized MG.”

Source: [Fedak et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13004674/)

<a id="topic-2.1.2.8-2"></a>

###### Pediatric population: HELIOS trial including juvenile myasthenia gravis

> “Safety, tolerability and efficacy of Descarte-08 in children, adolescents and young adults with childhood-onset systemic lupus erythematosus, ANCA-associated vasculitis, juvenile myasthenia gravis, and juvenile dermatomyositis”
> “At least age 12”

Source: [ClinicalTrials.gov NCT07089121](https://clinicaltrials.gov/study/NCT07089121)

> “Fully outpatient treatment with 1hr post-infusion monitoring”

Source: [Cartesian Therapeutics corporate presentation, November 2026 (2026)](https://ir.cartesiantherapeutics.com/static-files/6ba3bfe0-f3be-4487-add3-b56dd535e456)

<a id="topic-2.1.2.8-3"></a>

###### Contraception for women of childbearing potential in AURORA

> “Women of childbearing potential must agree to use highly effective birth control from Screening until 14 days post last dose of Descartes-08”

Source: [ClinicalTrials.gov NCT06799247](https://clinicaltrials.gov/study/NCT06799247)

<a id="topic-2.1.2.8-4"></a>

###### Male contraception in the phase 2b trial

> “Male patients were to agree to effective contraception (for example, condoms (male or female) with or without a spermicidal agent, a diaphragm or cervical cap with spermicide, or an intrauterine device) from screening through 14 days after the last dose of Descartes-08.”

Source: [Vu et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13004676/)

<a id="topic-2.1.2.8-5"></a>

###### Renal and hepatic impairment: phase 2b exclusion thresholds

> “alanine transaminase and/or aspartate transaminase levels more than three times above upper limit of normal; creatinine clearance less than 30 ml min⁻¹”

Source: [Vu et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13004676/)

<a id="heading-2.1.2.9"></a>

##### 2.1.2.9 Drug/Drug, Drug/disease Interactions

<a id="heading-2.1.2.9.1"></a>

###### 2.1.2.9.1 Effects of Other Drugs on Descartes-08

<a id="topic-2.1.2.9.1-1"></a>

###### Consistent product lots across participants with differing treatment histories: phase 2b

> “Despite patients with diversity in antibody serotype and treatment history (see companion paper6), all analyzed lots (n = 35 of 36 patients randomized) exhibited consistent characteristics with favorable viability, CD8+ cell frequencies and CAR expression (Fig. 2b–d).”

Source: [Fedak et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13004674/)

<a id="heading-2.1.2.9.2"></a>

###### 2.1.2.9.2 Effects of Descartes-08 on Other Drugs

<a id="topic-2.1.2.9.2-1"></a>

###### Vaccine titers after treatment compared with placebo: phase 2b

> “There were no other new AEs reported after Month 3 follow-up, including no hypogammaglobulinemia and other infections and there was no difference in vaccine titers between Descartes-08 and placebo.”

Source: [Cartesian Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1453687/000145368726000064/rnac-20251231.htm)

<a id="heading-2.1.2.10"></a>

##### 2.1.2.10 Dosing and Administration

<a id="heading-2.1.2.10.1"></a>

###### 2.1.2.10.1 Dosage

<a id="topic-2.1.2.10.1-1"></a>

###### Dose selected in the phase 1b portion and carried into the phase 2a portion

> “The primary objective of the Phase 2a portion of the trial was to determine the optimal dosing schedule for patients with MG using the highest dose level tested in Phase 1b (52.5 x10⁶ cells/kg).”

Source: [Cartesian Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1453687/000145368726000064/rnac-20251231.htm)

<a id="topic-2.1.2.10.1-2"></a>

###### Dose per infusion in the phase 2b trial

> “The dose of Descartes-08 was 52.5 × 10⁶ viable CAR+ cells per kg ± 45% per infusion, which was the dose tested in the phase 2a study.”

Source: [Vu et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13004676/)

<a id="topic-2.1.2.10.1-3"></a>

###### Retreatment course after symptom recurrence

> “Similar to the initial course of treatment, retreatment consisted of six once-weekly Descartes-08 infusions.”

Source: [Cartesian Therapeutics retreatment data press release (2026)](https://ir.cartesiantherapeutics.com/news-releases/news-release-details/cartesian-therapeutics-announces-additional-retreatment-data)

<a id="heading-2.1.2.10.2"></a>

###### 2.1.2.10.2 Administration

<a id="topic-2.1.2.10.2-1"></a>

###### Leukapheresis, then six once-weekly outpatient infusions without preconditioning chemotherapy

> “Patients underwent a single leukapheresis to collect cells used to prepare Descartes-08 (Fig. 2a) and then received six once-weekly infusions of Descartes-08 or placebo in an outpatient setting without preconditioning chemotherapy.”

Source: [Fedak et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13004674/)

<a id="topic-2.1.2.10.2-2"></a>

###### Personalized manufacture from the patient’s own collected cells

> “We aim to provide a personalized approach to treating patients that begins with the collection of a patient’s cells which we then use to manufacture our cell therapy product candidates.”
> “Once a patient’s cells have expanded in our process, we introduce mRNA to deliver a CAR into the cell.”

Source: [Cartesian Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1453687/000145368726000064/rnac-20251231.htm)

<a id="topic-2.1.2.10.2-3"></a>

###### Infusion duration, premedication, and post-infusion observation: phase 2b

> “Participants were then randomly assigned in a 1:1 ratio to receive intravenous treatment with Descartes-08 or placebo, administered once weekly for 6 weeks as an intravenous infusion over 20 min.”
> “Diphenhydramine (or an equivalent) and acetaminophen were administered 30 min before each infusion as premedications.”
> “Participants were observed for 1 h after each infusion.”

Source: [Vu et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13004676/)

<a id="heading-2.1.2.11"></a>

##### 2.1.2.11 Access and Distribution

<a id="topic-2.1.2.11-1"></a>

###### Centralized in-house manufacture and lot release time of about three weeks

> “We manufacture Descartes-08 in-house and are typically able to process and release lots for infusion within approximately three weeks.”
> “We have optimized our manufacturing processes through over 200 cGMP runs across all of our current and prior programs.”

Source: [Cartesian Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1453687/000145368726000064/rnac-20251231.htm)

> “Typical lot processed for infusion within as little as ~3 weeks”

Source: [Cartesian Therapeutics corporate presentation, November 2026 (2026)](https://ir.cartesiantherapeutics.com/static-files/6ba3bfe0-f3be-4487-add3-b56dd535e456)

<a id="topic-2.1.2.11-2"></a>

###### Manufacturing success: participants meeting manufacturing specifications in the phase 2b trial

> “Of the 45 patients who met the inclusion criteria, 36 were eligible to be randomized after meeting manufacturing specifications, of whom 20 were assigned to the active Descartes-08 arm, and 16 were assigned to the placebo arm.”

Source: [Fedak et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13004674/)

<a id="topic-2.1.2.11-3"></a>

###### Commercial infrastructure plans

> “We do not have a sales or marketing infrastructure and have no experience in the sale, marketing or distribution of pharmaceutical products.”
> “We expect to build a focused sales and marketing infrastructure to market or co-promote our product candidates in the United States and potentially elsewhere, if and when they are approved.”

Source: [Cartesian Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1453687/000145368726000064/rnac-20251231.htm)

> “As we advance toward this next phase of growth, an extended cash runway into 2028, supported by up to $150 million of non-dilutive financing through a credit facility with K2 HealthVentures (“K2HV”), allows us to continue investing in precommercial readiness activities in parallel with clinical execution.”

Source: [Cartesian Therapeutics second quarter 2026 results (2026)](https://ir.cartesiantherapeutics.com/news-releases/news-release-details/cartesian-therapeutics-reports-second-quarter-2026-financial)

<a id="topic-2.1.2.11-4"></a>

###### Community clinic administration as a design goal of the product

> “To broaden use of CAR T-cells in community clinics and in a frontline setting, we developed a novel CD8+ CAR T-cell product, Descartes-08, with predictable pharmacokinetics for treatment of multiple myeloma.”

Source: [Lin et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7785573/)

<a id="heading-2.1.2.12"></a>

##### 2.1.2.12 Co-prescribed/Concomitant Therapies

<a id="topic-2.1.2.12-1"></a>

###### Permitted concomitant medications and dose changes in the phase 2b trial

> “Permitted concomitant medications for gMG included pyridostigmine, corticosteroids (equivalent to ≤40 mg of prednisone per day), azathioprine, mycophenolate mofetil and complement inhibitors, provided the dose was stable for at least 8 weeks before the first infusion.”
> “No dosing changes were allowed for concomitant MG-specific medications during the study, other than corticosteroids.”
> “The dose of corticosteroids was not permitted to be increased, but it could be tapered at the site investigator’s discretion after month 6.”

Source: [Vu et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13004676/)

> “Per trial protocol, changes in other MG-specific medications were not permitted.”

Source: [Cartesian Therapeutics 2026 outlook press release (2026)](https://ir.cartesiantherapeutics.com/news-releases/news-release-details/cartesian-therapeutics-highlights-recent-progress-and-outlines)

<a id="heading-2.1.2.13"></a>

##### 2.1.2.13 Effect of Descartes-08 on Quality Measures

<a id="topic-2.1.2.13-1"></a>

###### AAN quality measure: immunosuppressive therapy for myasthenic crisis

> “Measure purpose: Rapidly initiate treatment for myasthenic crisis and thereby wean from mechanical ventilation, reduce likelihood of tracheostomy, and increase functional independence”
> “The numerator: Patients with myasthenic crisis that are given immunosuppressive therapies (Plasmapheresis (PE) or intravenous immunoglobulin (IVIG))”
> “The denominator: Patients admitted to inpatient facility with a diagnosis of myasthenic crisis”

Source: [American Academy of Neurology myasthenic crisis quality measure](https://www.aan.com/practice/immunosuppressive-therapy-myasthenic-crisis-quality-measure)

<a id="topic-2.1.2.13-2"></a>

###### Product-specific effect on quality measures

No evidence found.

<a id="heading-2.1.2.14"></a>

##### 2.1.2.14 Product comparison

<a id="topic-2.1.2.14-1"></a>

###### Descartes-08: mechanism, route, dosing schedule, and approval status

| Attribute | Quoted text |
| --- | --- |
| Product | “Descartes-08, our lead cell therapy product candidate, is an autologous CAR-T product targeting B-cell maturation antigen, or BCMA, in clinical development for the treatment of MG and myositis, specifically, moderate to severe multi-refractory dermatomyositis and antisynthetase syndrome.” |
| Mechanism of action | “Descartes-08 is specifically designed to target and destroy the pathogenic, self-reactive cells that are the underlying cause of the autoimmune disease, with the goal of creating a precision immune reset for the patient.” |
| Route and dosing schedule | “Once the manufacturing process is complete, we send the product candidate back to the treating physician where they administer six weekly infusions of our cell therapy to the patient.” |
| Dose | “Patients received six weekly infusions at the dose established in Phase 1b (52.5 x10⁶ cells/kg).” |
| Preconditioning and care setting | “In contrast to conventional DNA-based CAR T-cell therapies, our CAR-T administration has been observed to provide deep and durable benefits through 12 months, is designed to not require preconditioning chemotherapy, to be administered in the outpatient setting and does not carry the risk of genomic integration associated with cancerous transformation.” |
| Approval status | “Our most advanced product candidate, Descartes-08, is in Phase 3 clinical development.” |

Source: [Cartesian Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1453687/000145368726000064/rnac-20251231.htm)

<a id="topic-2.1.2.14-2"></a>

###### Complement C5 inhibitor: Soliris

| Attribute | Prescribing information |
| --- | --- |
| Product and route | “SOLIRIS® (eculizumab) injection, for intravenous use” |
| gMG indication | “the treatment of generalized myasthenia gravis (gMG) in adult and pediatric patients six years of age and older who are anti-acetylcholine receptor (AChR) antibody positive.” |
| Mechanism of action | “Eculizumab, the active ingredient in SOLIRIS, is a monoclonal antibody that specifically binds to the complement protein C5 with high affinity, thereby inhibiting its cleavage to C5a and C5b and preventing the generation of the terminal complement complex C5b-9.” |
| Adult dosing and interval in gMG | “900 mg weekly for the first 4 weeks, followed by” |
| Adult dosing and interval in gMG, continued | “1,200 mg every 2 weeks thereafter.” |
| Initial U.S. approval (any indication) | “Initial U.S. Approval: 2007” |

Source: [Soliris prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/125166s454lbl.pdf)

<a id="topic-2.1.2.14-3"></a>

###### Complement C5 inhibitor: Ultomiris

| Attribute | Prescribing information |
| --- | --- |
| Product and route | “ULTOMIRIS® (ravulizumab-cwvz) injection, for intravenous use” |
| gMG indication | “the treatment of adult patients with generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) antibody-positive.” |
| Mechanism of action | “Ravulizumab-cwvz is a terminal complement inhibitor that specifically binds to the complement protein C5 with high affinity” |
| Dosing interval | “maintenance doses administered every 4 or 8 weeks, starting 2 weeks after loading dose.” |
| Initial U.S. approval (any indication) | “Initial U.S. Approval: 2018” |

Source: [Ultomiris prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/761108s046lbl.pdf)

<a id="topic-2.1.2.14-4"></a>

###### Complement C5 inhibitor: Zilbrysq

| Attribute | Prescribing information |
| --- | --- |
| Product and route | “ZILBRYSQ® (zilucoplan) injection, for subcutaneous use” |
| gMG indication | “ZILBRYSQ is a complement inhibitor indicated for the treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) antibody positive.” |
| Mechanism of action | “Zilucoplan binds to the complement protein C5 and inhibits its cleavage to C5a and C5b, preventing the generation of the terminal complement complex, C5b-9.” |
| Dosing interval | “The recommended dosage of ZILBRYSQ is given once daily as a subcutaneous injection and is dependent on actual body weight” |
| Initial U.S. approval (any indication) | “Initial U.S. Approval: 2023” |

Source: [Zilbrysq prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/216834s015lbl.pdf)

<a id="topic-2.1.2.14-5"></a>

###### Neonatal Fc receptor blocker: Vyvgart

| Attribute | Prescribing information |
| --- | --- |
| Product and route | “VYVGART® (efgartigimod alfa-fcab) injection, for intravenous use” |
| gMG indication | “VYVGART is a neonatal Fc receptor blocker indicated for the treatment of adult patients with generalized myasthenia gravis (gMG).” |
| Mechanism of action | “Efgartigimod alfa-fcab is a human IgG1 antibody fragment that binds to the neonatal Fc receptor (FcRn), resulting in the reduction of circulating IgG.” |
| Dosing and interval | “The recommended dosage is 10 mg/kg administered as an intravenous infusion over one hour once weekly for 4 weeks.” |
| Treatment cycles | “Administer subsequent treatment cycles based on clinical evaluation.” |
| Initial U.S. approval (any indication) | “Initial U.S. Approval: 2021” |

Source: [Vyvgart prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/761195s016lbl.pdf)

<a id="topic-2.1.2.14-6"></a>

###### Neonatal Fc receptor blocker: Vyvgart Hytrulo

| Attribute | Prescribing information |
| --- | --- |
| Product | “VYVGART HYTRULO is a combination of efgartigimod alfa, a neonatal Fc receptor blocker, and hyaluronidase, an endoglycosidase” |
| gMG indication | “generalized myasthenia gravis (gMG)” |
| Mechanism of action | “Efgartigimod alfa is a human IgG1 antibody fragment that binds to the neonatal Fc receptor (FcRn), resulting in the reduction of circulating IgG.” |
| Route | “VYVGART HYTRULO is for subcutaneous use only.” |
| Self-administration | “Prefilled syringe can be administered by patients and/or caregivers.” |
| gMG dosing interval | “Administer in cycles of once weekly injections for 4 weeks.” |
| gMG dose, prefilled syringe | “Prefilled syringe: 1,000 mg efgartigimod alfa and 10,000 units hyaluronidase administered over 20 to 30 seconds.” |
| Initial U.S. approval (any indication) | “Initial U.S. Approval: 2023” |

Source: [Vyvgart Hytrulo prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/761304s018lbl.pdf)

<a id="topic-2.1.2.14-7"></a>

###### Neonatal Fc receptor blocker: Rystiggo

| Attribute | Prescribing information |
| --- | --- |
| Product and route | “RYSTIGGO® (rozanolixizumab-noli) injection, for subcutaneous use” |
| gMG indication | “RYSTIGGO (rozanolixizumab-noli) is a neonatal Fc receptor blocker indicated for the treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) or anti-muscle-specific tyrosine kinase (MuSK) antibody positive.” |
| Mechanism of action | “Rozanolixizumab-noli is a humanized IgG4 monoclonal antibody that binds to the neonatal Fc receptor (FcRn), resulting in the reduction of circulating IgG.” |
| Dosing interval | “The recommended dosage is administered as a subcutaneous infusion once weekly for 6 weeks.” |
| Initial U.S. approval (any indication) | “Initial U.S. Approval: 2023” |

Source: [Rystiggo prescribing information (2025)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/761286s007lbl.pdf)

<a id="topic-2.1.2.14-8"></a>

###### Neonatal Fc receptor blocker: Imaavy

| Attribute | Prescribing information |
| --- | --- |
| Product and route | “IMAAVY® (nipocalimab-aahu) injection, for intravenous use” |
| gMG indication | “generalized myasthenia gravis (gMG) in adult and pediatric patients 12 years of age and older who are anti-acetylcholine receptor (AChR) or anti-muscle-specific tyrosine kinase (MuSK) antibody positive.” |
| Mechanism of action | “Nipocalimab-aahu is a human IgG1 monoclonal antibody that binds to neonatal Fc receptor (FcRn), resulting in the reduction of circulating IgG levels.” |
| Dosing and interval | “gMG: The recommended initial dosage is 30 mg/kg once via intravenous infusion over at least 30 minutes. Two weeks after the initial dosage, administer a maintenance dosage of 15 mg/kg via intravenous infusion over at least 15 minutes, and continue every two weeks thereafter.” |
| Initial U.S. approval (any indication) | “Initial U.S. Approval: 2025” |

Source: [Imaavy prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/761430s002lbl.pdf)

<a id="topic-2.1.2.14-9"></a>

###### CD19-directed B-cell depleting antibody: Uplizna

| Attribute | Prescribing information |
| --- | --- |
| Product and route | “UPLIZNA® (inebilizumab-cdon) injection, for intravenous use” |
| gMG indication | “Generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) or anti-muscle specific tyrosine kinase (MuSK) antibody positive.” |
| Mechanism of action | “The mechanism by which inebilizumab-cdon exerts its therapeutic effects in NMOSD, IgG4-RD, and gMG is presumed to involve binding to CD19, a cell surface antigen presents on pre-B and mature B lymphocytes.” |
| Initial dosing | “Initial dose: 300 mg intravenous infusion followed two weeks later by a second 300 mg intravenous infusion.” |
| Dosing interval | “Subsequent doses (starting 6 months from the first infusion): single 300 mg intravenous infusion every 6 months.” |
| Initial U.S. approval (any indication) | “Initial U.S. Approval: 2020” |

Source: [Uplizna prescribing information (2025)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/761142s004lbl.pdf)

<a id="topic-2.1.2.14-10"></a>

###### Complement C5 inhibitor: Klygefa

| Attribute | Prescribing information |
| --- | --- |
| Product and route | “KLYGEFA™ (gefurulimab-gaks) injection, for subcutaneous use” |
| gMG indication | “KLYGEFA is indicated for the treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) antibody positive.” |
| Mechanism of action | “Gefurulimab-gaks is a terminal complement inhibitor that specifically binds both complement protein C5 and serum albumin.” |
| Dosing | “The recommended dosage of KLYGEFA is dependent on body weight and administered as a subcutaneous injection as shown in Table 1.” |
| Dosing interval | “The weekly maintenance dosage of KLYGEFA may be administered 1 day before the scheduled dose.” |
| Self-administration | “KLYGEFA is intended to be self-administered by the patient or injected by a caregiver.” |
| Restricted distribution | “KLYGEFA is available only through a restricted program called KLYGEFA REMS.” |
| Initial U.S. approval (any indication) | “Initial U.S. Approval: 2026” |

Source: [Klygefa prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/761488s000lbl.pdf)

<a id="heading-2.2"></a>

### 2.2 Place of Product in Therapy

<a id="heading-2.2.1"></a>

#### 2.2.1 Disease Description

<a id="heading-2.2.1.1"></a>

##### 2.2.1.1 Definition and Etiology

<a id="topic-2.2.1.1-1"></a>

###### Definition: autoantibody-mediated disorder of neuromuscular transmission

> “Myasthenia gravis (MG) is an autoimmune neurological disorder characterized by defective transmission at the neuromuscular junction.”
> “MG is considered a classic example of antibody-mediated autoimmune disease.”
> “These autoantibodies disrupt cholinergic transmission between nerve terminals and muscle fibers by causing downregulation, destruction, functional blocking of AChRs, or disrupting the clustering of AChRs in the postsynaptic membrane.”

Source: [Dresser et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8196750/)

> “Myasthenia gravis (MG) is an autoimmune disease caused by antibodies against the acetylcholine receptor (AChR), muscle-specific kinase (MuSK) or other AChR-related proteins in the postsynaptic muscle membrane.”
> “Localized or general muscle weakness is the predominant symptom and is induced by the antibodies.”
> “Patients are grouped according to the presence of antibodies, symptoms, age at onset and thymus pathology.”

Source: [Gilhus et al. (2019)](https://pubmed.ncbi.nlm.nih.gov/31048702/)

<a id="topic-2.2.1.1-2"></a>

###### Generalized and ocular forms

> “MG presents in two forms: ocular (oMG), affecting the levator palpebrae superioris, orbicularis oculi, and extraocular muscles, and generalized (gMG), involving bulbar, axial, limb, and respiratory muscles”

Source: [Barnett-Tapia et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13498700/)

> “Most patients have generalized weakness affecting the extraocular, bulbar, trunk, and extremity muscles.”
> “In 20% of MG patients, the muscle weakness remains confined to the extraocular muscles”

Source: [Gilhus et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11236053/)

> “It is the prototypic autoimmune disease most commonly caused by antibodies to the acetylcholine receptor (AChR) leading to characteristic fatigable weakness of the ocular, bulbar, respiratory, axial, and limb muscles.”

Source: [Hehir and Silvestri (2018)](https://pubmed.ncbi.nlm.nih.gov/29655448/)

<a id="topic-2.2.1.1-3"></a>

###### Etiology: autoantibody subgroups

> “Antibodies against the AChR are found in approximately 80% of MG patients.”
> “AChR antibodies are predominantly of the IgG1 and IgG3 subclasses”
> “Antibodies against MuSK are found in approximately 7–10% of all MG patients and up to 40% of patients with generalized MG who are seronegative for AChR Abs.”
> “Lrp4 antibodies are present in 2–50% of double seronegative MG cases”

Source: [Dresser et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8196750/)

> “In around 10% of patients with generalized MG, no antibodies are detected by standard testing.”
> “Many of these patients have low‐concentration or low‐affinity AChR antibodies when tested with more sensitive methods”

Source: [Gilhus et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11236053/)

<a id="topic-2.2.1.1-4"></a>

###### Etiology: thymus pathology and age at onset

> “Most MG patients have pathogenic autoantibodies against the extracellular part of acetylcholine receptors (AChR), commonly associated with an abnormal thymus.”
> “Thymoma is present in 10% of such patients, and thymic hyperplasia with ectopic germinal centers appears in most patients with symptom onset before age 50 years”

Source: [Gilhus et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11236053/)

> “Early-onset MG (EOMG) corresponds to patients presenting before age 50.”
> “Late-onset MG (LOMG) is defined by onset after the age of 50.”
> “MG is the most common paraneoplastic disorder associated with thymoma.”
> “Conversely, 10–20% of patients with MG have thymomas”

Source: [Dresser et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8196750/)

<a id="topic-2.2.1.1-5"></a>

###### Etiology: genetic susceptibility

> “There is frequent association of A1-B8-DR3 haplotype with early-onset MG”
> “A large genome-wide association study involving patients from North America and Italy identified different haplotypes across the HLA region, cytotoxic T-lymphocyte-associated protein 4 gene (CTLA4) and tumor necrosis factor receptor 4 superfamily, member 11a, (TNFRSF11A) and NFκB activator genes in early- and late-onset MG cases”

Source: [Dresser et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8196750/)

<a id="heading-2.2.1.2"></a>

##### 2.2.1.2 Epidemiology

<a id="heading-2.2.1.2.1"></a>

###### 2.2.1.2.1 Incidence of Generalized myasthenia gravis

<a id="topic-2.2.1.2.1-1"></a>

###### United States, 2021 claims and electronic health records: incidence of all myasthenia gravis

> “Data were extracted from the Clarivate Real-World Data Repository (2016-2021), a US claims and electronic health records database.”
> “While the incidence and prevalence of MG increased with age in both men and women, higher prevalence and incidence of MG were observed in younger women (<50 years) compared with men of matching age, and in older men (≥65 years) compared with women of the same age group.”

Source: [Rodrigues et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/38040629/)

<a id="topic-2.2.1.2.1-2"></a>

###### United States, 2017 commercial, Medicare, and Medicaid claims: incidence of all myasthenia gravis

> “From the US commercially/Medicare-insured cohort, we calculated an age-and sex-standardized incidence of 68.5 new cases per million person-years with an adjusted prevalence of 316.4 per million.”
> “Within the Medicaid-insured population, similar yet slightly lower numbers emerged: the adjusted incidence was 49.7 new cases per million person-years, and the adjusted prevalence rate was 203.7 cases per million.”
> “We extrapolated this to calculate the overall US prevalence of 320.2 per million people and an incidence of 54 per million person-years.”

Source: [Ye et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10907989/)

<a id="topic-2.2.1.2.1-3"></a>

###### United States, Medicare fee-for-service beneficiaries aged 65 years and older: incidence of all myasthenia gravis, 2008 to 2019

> “Study-eligible beneficiaries were aged 65 years and older, had at least 1 month of FFS Part A/B coverage, and were without any health maintenance organization insurance coverage.”
> “MG incidence increased from 12.2 to 13.3 per 100,000 PYs from 2008–2009 to 2018–2019 (p < 0.05).”

Source: [Bruckman et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11540456/)

<a id="topic-2.2.1.2.1-4"></a>

###### Taiwan, 2009 to 2019: incidence of generalized myasthenia gravis

> “There was no temporal trend in all-cause fatality rates (range 2.76–3.79/100 patients annually) or gMG incidence rates (2.4–3.17/100,000 population annually).”
> “In 2019, the annual prevalence of gMG was 11.18 per 100,000 population and the incidence rate was 2.95 per 100,000 population.”

Source: [Herr et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10327564/)

<a id="topic-2.2.1.2.1-5"></a>

###### Canada, Ontario, 2013 to 2020: incidence of all myasthenia gravis

> “Standardized incidence remained stable (3.2–4.0 per 100,000), while prevalence increased from 36 to 42 per 100,000 from 2013/14 to 2019/20.”

Source: [Barnett-Tapia et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13498700/)

<a id="topic-2.2.1.2.1-6"></a>

###### Global systematic review of studies through February 2024: incidence of all myasthenia gravis

> “Incidence rates ranged from 2.3 to 61.3 cases per million person-years, with a mean incidence of 15.7 (95% CI: 11.5–19.9) and a median of 13.3 cases.”
> “Studies showed increasing rates over the years (Fig. 4): considering the period 1967–2007, the mean IR was 8.7 (95% CI: 5.5–11.9; range: 2.3–21.3) cases per million person-years, and in the period 2008–2022, the mean IR has more than doubled: 22.9 (95% CI: 14.1–31.7; range: 6.3–61.3).”
> “The American countries showed the highest mean IR cases per million person-years with a value of 23.7 (95% CI: 6.5–40.9; range: 4.7–61.3).”

Source: [Sciancalepore et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12500283/)

<a id="topic-2.2.1.2.1-7"></a>

###### Pooled analysis of 55 studies performed from 1950 to 2007: incidence of all and AChR antibody-positive myasthenia gravis

> “55 studies performed between 1950 and 2007 were included, representing 1.7 billion population-years.”
> “IR ranged from 1.7 to 21.3 cases per million person-years”
> “Pooled estimate IR (eIR) was calculated as 5.3 per million person-years (C.I.: 4.41 - 6.12).”
> “AChR MG IR ranged from 4.3 to 18.0 per million person-years with a pooled AChR MG eIR of 7.3 per million person-years (C.I.: 5.5, 7.8).”

Source: [Carr et al. (2010)](https://pmc.ncbi.nlm.nih.gov/articles/PMC2905354/)

<a id="heading-2.2.1.2.2"></a>

###### 2.2.1.2.2 Prevalence of Generalized myasthenia gravis

<a id="topic-2.2.1.2.2-1"></a>

###### United States, 2021 claims and electronic health records: diagnosed prevalence of all myasthenia gravis

> “The diagnosed prevalence and incidence of MG in the United States in 2021 were calculated to be 37.0 per 100,000 persons and 3.1 per 100,000 persons, respectively.”
> “The updated prevalence and incidence of MG in the United States in 2021 are higher than previous reports from the 1980s and early 2000s, following a global trend of increased prevalence and incidence for this disorder in the last few decades.”

Source: [Rodrigues et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/38040629/)

<a id="topic-2.2.1.2.2-2"></a>

###### United States, 2017 claims and 2021 extrapolation: prevalence and number of adults with all myasthenia gravis

> “Using a previously validated algorithm, we identified cases of MG in two Truven Health MarketScan databases, which during 2017 included a sample of approximately 20 million commercially insured and Medicare recipients, plus 10 million Medicaid recipients.”
> “Given our results, we were able to estimate that there were approximately 82,715 US adults living with MG in 2021 (or an estimated 320.2 cases per million adults in the USA).”

Source: [Ye et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10907989/)

<a id="topic-2.2.1.2.2-3"></a>

###### United States, Medicare fee-for-service beneficiaries aged 65 years and older: prevalence of all myasthenia gravis, 2006 to 2019

> “The period prevalence of MG increased from 81 to 119 per 100,000 FFS A/B population from 2006–2007 to 2018–2019 (p < 0.001).”
> “Increasing trends of prevalence were observed in all sex (male/female), age (65–69/70–74/75–79/80+), race/ethnic (African American/Asian/Hispanics of any race/non-Hispanic White/other), and census region (Northeast/Midwest/South/West) subgroups.”

Source: [Bruckman et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11540456/)

<a id="topic-2.2.1.2.2-4"></a>

###### Global meta-analysis of 63 studies: prevalence of all myasthenia gravis

> “After deleting articles unrelated to the research question, finally, 63 articles with a sample size of 1,206,961,907 people were included in the meta-analysis.”
> “The prevalence of MG worldwide was estimated to be 12.4 people (95% CI 10.6–14.5) per 100,000 population.”
> “which has the highest prevalence in the Americas with 19 people (95% CI 15–23.8)”

Source: [Salari et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8686543/)

<a id="topic-2.2.1.2.2-5"></a>

###### Global systematic review of studies through February 2024: prevalence of all myasthenia gravis

> “Prevalence of MG ranged from 20 to 475 cases per million, with a mean prevalence of 173.3 (95% confidence interval [CI]: 129.7–215.5) cases per million and a median prevalence of 129.6 cases per million.”
> “The mean PR was 97.5 (95% CI: 59.9–141.9; range: 20–174.2) cases per million considering studies from 1952 to 2007 (the most recent period investigated by the last systematic review [7]), while the mean PR increased up to 220.1 (95% CI: 149.3–288.1; range: 78–475) cases per million considering the period 2008–2021.”
> “North America showed a mean PR of 341.4 (range: 142–475) cases per million”
> “Most of the included studies (81.9%) examined all types of MG (ALL MG), reporting prevalence (59 studies), incidence (50 studies), and mortality (16 studies).”

Source: [Sciancalepore et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12500283/)

<a id="topic-2.2.1.2.2-6"></a>

###### Pooled estimate across studies: prevalence of all myasthenia gravis

> “The observed PR ranged from 15 to 179 per million”
> “The estimated pooled PR is 77.7 cases per million (C.I.: 63.98, 94.30) but, as for IR there was marked heterogeneity with I2 = 98% (C.I.: 97-98%) observed across studies limiting interpretation.”

Source: [Carr et al. (2010)](https://pmc.ncbi.nlm.nih.gov/articles/PMC2905354/)

<a id="topic-2.2.1.2.2-7"></a>

###### Taiwan, 2009 to 2019: prevalence of generalized myasthenia gravis

> “The number of patients with gMG increased from 1,576 in 2009 to 2,638 in 2019 and the mean (standard deviation) age from 51.63 (17.32) to 55.38 (16.29) years.”
> “The prevalence of patients with gMG increased annually from 6.83/100,000 population in 2009 to 11.18/100,000 population in 2019 (p < 0.0001).”
> “The total number of patients with MG (ocular or generalized) increased from 3,647 in 2009 to 6,293 in 2019, with prevalence rates that increased annually from 15.80 per 100,000 population to 26.67 per 100,000 population, a 1.7-fold increase over the study period”

Source: [Herr et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10327564/)

<a id="topic-2.2.1.2.2-8"></a>

###### Canada, Ontario, 2013 to 2020: prevalence of all myasthenia gravis

> “MG prevalence increased from 36 to 42 per 100,000 over the study period.”

Source: [Barnett-Tapia et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13498700/)

<a id="topic-2.2.1.2.2-9"></a>

###### United States, ICER budget impact inputs: number of people with generalized myasthenia gravis (MGFA class II to IV)

> “To this end, we used inputs for the projected average US population size from 2021-2025 (339,640,651 individuals) and MG prevalence in the setting of MGFA clinical classification II-IV (20,000 MG cases per 100,000 US individuals, 69% of which with classification II-IV disease), yielding 46,870 gMG patients.”

Source: [ICER (2021)](https://icer.org/wp-content/uploads/2021/03/ICER_Myasthenia-Gravis_Final-Report_102021-1.pdf)

<a id="topic-2.2.1.2.2-10"></a>

###### Share of myasthenia gravis that becomes generalized and share of generalized disease with AChR antibodies: ICER review

> “The majority of patients (~80%) progress to some form of generalized disease, typically within the first two years of symptom onset.”
> “Approximately 80% of generalized MG patients have AChR autoantibodies.”

Source: [ICER (2021)](https://icer.org/wp-content/uploads/2021/03/ICER_Myasthenia-Gravis_Final-Report_102021-1.pdf)

<a id="topic-2.2.1.2.2-11"></a>

###### Antibody status of generalized myasthenia gravis: Spanish referral cohort of 220 participants diagnosed 1998 to 2020

> “We assessed 220 patients diagnosed with gMG (54.5% women; mean age at onset of 58 years; 84% anti-AChR, 6% anti-MuSK, 10% seronegative).”

Source: [Reyes-Leiva et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13714894/)

<a id="heading-2.2.1.3"></a>

##### 2.2.1.3 Natural History, Survival, and Mortality

<a id="topic-2.2.1.3-1"></a>

###### Natural history: progression from ocular to generalized disease

> “In addition, up to 80% of patients with ocular onset will go on to develop generalized symptoms, usually within two years of disease onset”
> “A recent population-based study conducted by the Mayo Clinic found that 51% of patients presented with ocular onset, and 55% of these developed generalized symptoms”
> “Of the remaining, 90% will continue to have ocular manifestations only.”
> “Hence, ocular MG is defined by isolated extra-ocular involvement for a period of ≥2 years.”

Source: [Dresser et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8196750/)

> “Most patients initially present with ocular symptoms, however approximately 80% progress to generalized disease”

Source: [Barnett-Tapia et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13498700/)

<a id="topic-2.2.1.3-2"></a>

###### Natural history: severity peaks early, and exacerbations recur

> “Between 1940 and 2000 a total of 1976 patients with myasthenia gravis (MG) were studied.”
> “The most severe level of weakness and high mortality occurred during the first 1 to 2 years of the disease, after which many patients experienced improvement.”

Source: [Grob et al. (2008)](https://pubmed.ncbi.nlm.nih.gov/18059039/)

> “Most patients with MG will experience at least 1 exacerbation of symptoms throughout the course of their illness.”

Source: [Hehir and Silvestri (2018)](https://pubmed.ncbi.nlm.nih.gov/29655448/)

> “Within any given year, approximately one third of patients with gMG experience myasthenic exacerbations (MEs), which are periods when muscle weakness worsens beyond the patient's usual symptoms level”

Source: [Grover et al. (2026c)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13724412/)

<a id="topic-2.2.1.3-3"></a>

###### Natural history: spontaneous remission

> “Spontaneous remissions for different lengths of time may occur in the course of adult-onset MG.”
> “In an earlier study conducted before the widespread use of steroids and other immunosuppressants, approximately one fourth of the patients had a complete or near complete spontaneous remission, lasting an average of 4.6 years and up to 17 years”
> “Half of the remissions occurred during the first year after onset.”

Source: [Dresser et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8196750/)

<a id="topic-2.2.1.3-4"></a>

###### Mortality rates across studies: pooled mean and range

> “showing a mean MR of 1.4 (95% CI: 0.8–2.1; range: 0.5–3.5) cases per million person-years.”
> “No trend was observed for MR over the years”

Source: [Sciancalepore et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12500283/)

> “MR range 0.1 to 0.9 per millions person-years.”

Source: [Carr et al. (2010)](https://pmc.ncbi.nlm.nih.gov/articles/PMC2905354/)

<a id="topic-2.2.1.3-5"></a>

###### Mortality: United States hospitalizations, 2010 to 2019

> “Mortality among patients aged 65 years or older was higher compared with that in all patients, averaging 5.0% across each of the study years.”

Source: [Habib et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/38165317/)

<a id="topic-2.2.1.3-6"></a>

###### Mortality: United States hospitalizations, 2000 to 2005

> “The overall in-hospital mortality rate was 2.2%, being higher in MG crisis (4.47%).”
> “Older age and respiratory failure were the predictors of death, with adjusted odds ratios of 9.28 (95% confidence interval [CI], 3.31, 26.0) and 3.58 (95% CI, 2.01, 6.38).”

Source: [Alshekhlee et al. (2009)](https://pubmed.ncbi.nlm.nih.gov/19414721/)

<a id="topic-2.2.1.3-7"></a>

###### Mortality and survival: United States Medicare beneficiaries aged 65 years and older

> “All-cause mortality among MG beneficiaries was stable from 6.26 deaths per 100 PYs in 2006–2007 to 5.67 in 2018–2019 (p = 0.18).”

Source: [Bruckman et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11540456/)

> “Cohorts of 6024 incident MG and 30,083 control beneficiaries were Included.”
> “The mortality rate was higher in the MG cohort compared to controls (66.8 vs. 57.1 per 1000-person-year, p < 0.0001).”
> “After adjusting for time-varying CCI, no significant difference in survival was observed between two cohorts (adjusted hazard ratio 1.09 [0.87-1.36], p = 0.47).”
> “Sixteen percent of deaths in the MG cohort were attributed to MG.”
> “Compared to the non-MG cohort, mortality rates (per 1000-person-year) specific to infections were higher among the MG cohort (2.0 vs. 1.2) while malignancies and dementia-specific mortality rates were lower (10.3 vs. 12.5 and 4.7 vs. 7.2), all p < 0.01.”

Source: [Li et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/41104507/)

<a id="topic-2.2.1.3-8"></a>

###### Mortality: Denmark nationwide cohort, 1985 to 2020

> “Our cohort encompassed 2,110 patients (50.2% female) and 21,100 from the general population, with 77.3% aged younger than 75 years.”
> “Short-term cumulative mortality was 4.8% in patients with MG and 2.6% in the general population, yielding a HR of 1.8 (95% CI 1.5-2.3). Long-term mortality was 1.3 (95% CI 1.1-1.5).”
> “Comorbidity-adjusted analyses decreased short-term mortality (HR 1.6, 95% CI 1.3-2.0), and long-term mortality aligned with the general population.”

Source: [Jul Jarbæk Nielsen et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/40460351/)

<a id="topic-2.2.1.3-9"></a>

###### Mortality: Taiwan, generalized myasthenia gravis, 2009 to 2019

> “The all-cause fatality rate ranged from 2.76 to 3.79 per 100 patients in each study year, with no consistent temporal trend observed.”

Source: [Herr et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10327564/)

<a id="topic-2.2.1.3-10"></a>

###### Survival: Ontario, Canada, with and without myasthenic crisis

> “5‐year overall survival was 75%, declining to 39% among those with crisis.”

Source: [Barnett-Tapia et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13498700/)

<a id="topic-2.2.1.3-11"></a>

###### Mortality: Israel, tertiary center cohort, 2000 to 2023

> “Myasthenia Gravis mortality was 14% at 5 years (61/422) and 21% at 10 years (87/422).”
> “Mortality was significantly higher than control groups (p < 0.001).”
> “Intubations during myasthenic crisis were linked to higher mortality (p = 0.002).”

Source: [Khateb et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12116355/)

<a id="heading-2.2.1.4"></a>

##### 2.2.1.4 Pathophysiology

<a id="topic-2.2.1.4-1"></a>

###### Neuromuscular junction: reduced acetylcholine receptors and sodium channels

> “In addition, there is a reduction in the number of AChRs and voltage-gated sodium channels as the result of complement-related injury to the postsynaptic membrane in MG.”
> “The resultant inefficient neuromuscular transmission is reflected in decremental response in the amplitude of compound muscle action potential (CMAP) during repetitive nerve stimulation (RNS) and abnormal jitter or blocking in single fiber EMG”

Source: [Dresser et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8196750/)

<a id="topic-2.2.1.4-2"></a>

###### AChR antibodies: complement fixation, antigenic modulation, and receptor blockade

> “The predominant mechanism is the binding of the antibody and activation of the complement cascade, leading to the formation of the membrane attack complex (MAC), which causes damage of the postsynaptic membrane and destruction of synaptic folds which contain AChRs and associated proteins, including voltage-gated sodium channels”
> “Other mechanisms of pathogenicity include: (1) antigenic modulation by the binding and crosslinking of AChRs, leading to increased endocytosis and degradation [37]; and (2) the impairment of AChR function, either by the blocking of ACh binding to the receptor [38] or the prevention of channel opening”

Source: [Dresser et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8196750/)

> “Anti-AChR autoantibodies belong to the IgG1 and IgG3 subclasses, that are the strongest activators of the complement system.”
> “Indeed, pathogenicity of these autoantibodies, but not that of anti-MuSK antibodies that belong to IgG4, is mainly due to complement fixation at the NMJ ultimately leading to postsynaptic membrane destruction and impairment of the neuromuscular transmission”

Source: [Cavalcante et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11187261/)

<a id="topic-2.2.1.4-3"></a>

###### Complement: classical pathway initiation at the endplate

> “In MG, complement-mediated damage of the NMJ occurs via the classical complement pathway, which starts with C1q binding to the Fc domain of the autoantibodies.”
> “Critical steps of the complement cascade are then the cleavage of C3 into C3a and C3b, and of C5 in C5a and C5b, the latter leading to the formation of the membrane attack complex (MAC, C5bC6C7C8C9 also known as C5b-9) that causes focal lysis of the post-synaptic membrane, disruption of post-junctional folds, and ultimately reduction of functional AChRs”

Source: [Cavalcante et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11187261/)

> “In MG, the classical pathway is involved by the initiation of the antigen/antibody complex being recognized by C1q.”
> “The C1q forms a pentameric complex with the C1r2C1s2 serine protease tetramer.”
> “C2 also becomes cleaved by C1s to form the C3 convertase (C4b2a).”

Source: [Kusner et al. (2012)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3531867/)

<a id="topic-2.2.1.4-4"></a>

###### Complement: deposition at the endplate in patients

> “In muscle biopsies from MG patients, IgG and C3 deposition was localized at identical sites of post-synaptic membrane, and specifically on debris of junctional folds in the synaptic clefts and disintegrating junctional folds”
> “Deposition of C9, the main component of the final and stable MAC, was also observed at the MG end plate regions, with the most intense depositions associated with the destroyed NMJs, indicating that NMJ loss may be largely due to complement activation”

Source: [Cavalcante et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11187261/)

> “Patients with anti-AChR+ MG have autoantibodies and MACs present at NMJs.”
> “Damaged NMJs are associated with more severe disease, fewer AChRs, and MACs in synaptic debris.”

Source: [Howard (2018)](https://pubmed.ncbi.nlm.nih.gov/29266249/)

<a id="topic-2.2.1.4-5"></a>

###### Complement: evidence from experimental autoimmune myasthenia gravis

> “Mice deficient in C3 and C4 demonstrate reduced clinical scores compared to their wild-type littermates during the course of active EAMG, with C3-knockout mice showing no signs of weakness.”
> “Complement-deficient EAMG animals showed a preservation of AChR density at the neuromuscular junction.”
> “C5-deficient mice demonstrated reduced incidence of disease compared to the C5-sufficient mice.”

Source: [Kusner et al. (2012)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3531867/)

> “Studies in animals lacking specific complement proteins have confirmed that MAC formation is required to induce experimental autoimmune MG (EAMG) and NMJ damage.”
> “Complement inhibition in EAMG models can prevent disease induction and reverse its progression.”

Source: [Howard (2018)](https://pubmed.ncbi.nlm.nih.gov/29266249/)

<a id="topic-2.2.1.4-6"></a>

###### Complement: C1s and classical pathway activation in patients

> “The C1-inhibitor (C1-INH) regulates the classical pathway and is a promising marker in other autoimmune disorders.”
> “Serum and plasma C1s-C1-INH levels were higher in MG patients than in matched healthy controls, supporting early classical pathway activation in most MG patients.”
> “These findings allow prospective validation studies of activated C1s as a putative treatment target and potential accompanying biomarker in MG.”

Source: [Huang et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/39255718/)

> “Circulating complement protein profile may be used as a biomarker for evaluating patient-specific complement activation: (i) Romi and colleagues found reduced C3 and C4 serum levels in AChR-MG patients with high autoantibody titers, indicating increased in vivo complement consumption”

Source: [Cavalcante et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11187261/)

<a id="topic-2.2.1.4-7"></a>

###### Complement: heterogeneity of complement dependence and response to C5 inhibition

> “By means of this system, they observed a subset of AChR-MG patients with high complement activity, who are likely patients in whom complement activation is the major disease mechanism, whereas the remaining patients showed low activity, reflecting possible complement-independent autoantibody-mediated mechanisms of NMJ damage”

Source: [Cavalcante et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11187261/)

> “It is important to note that in MG there is no evidence suggesting a role for C5a in the disease.”

Source: [Kaminski et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11178544/)

<a id="topic-2.2.1.4-8"></a>

###### MuSK and LRP4 antibodies: complement-independent mechanisms

> “MuSK antibodies belong mainly to the IgG4 subclass.”
> “They do not fix complement and are not strong activators of cell-mediated cytotoxicity”
> “The mechanism by which MuSK antibodies exert their pathogenic effect on the neuromuscular junction is via binding to the Ig-like domain of the protein, preventing its phosphorylation, and subsequently disrupting the Agrin-Lrp4-MuSK-Dok-7 signaling pathway.”

Source: [Dresser et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8196750/)

> “The LRP4 antibodies are primarily IgG1 and IgG2 subtypes and follow similar clinical presentation to a mild form of early-onset MG (22), inhibit clustering of AChR, and appear not to strongly activate complement”

Source: [Kaminski et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11178544/)

<a id="heading-2.2.1.5"></a>

##### 2.2.1.5 Diagnosis

<a id="topic-2.2.1.5-1"></a>

###### Clinical diagnosis and confirmatory testing

> “The diagnosis of autoimmune Myasthenia Gravis (MG) remains clinical and rests on the history and physical findings of fatigable, fluctuating muscle weakness in a specific distribution.”
> “Ancillary bedside tests and laboratory methods help confirm the synaptic disorder, define its type and severity, classify MG according to the causative antibodies, and assess the effect of treatment objectively.”

Source: [Rousseff (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8073361/)

> “Diagnosis is straightforward in most patients with typical symptoms and a positive antibody test, although a detailed clinical and neurophysiological examination is important in antibody-negative patients.”

Source: [Gilhus et al. (2019)](https://pubmed.ncbi.nlm.nih.gov/31048702/)

<a id="topic-2.2.1.5-2"></a>

###### Antibody testing: AChR antibodies

> “In a patient with clinical features of MG, serum testing for AChR-Ab is the first recommended step in diagnosis by most recent guidelines and expert opinions”
> “The test has a very high specificity, so the detection of elevated titers in the appropriate clinical setting is diagnostic of AChR-myasthenia, and further testing may not be necessary”
> “The RIPA for binding Ab is abnormal in up to 85% of adult patients with generalized MG, but only about 50% of patients with ocular MG”
> “The technique detects autoantibodies to clustered AChR in about 15% of RIPA-seronegative MG patients”

Source: [Rousseff (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8073361/)

<a id="topic-2.2.1.5-3"></a>

###### Antibody testing: MuSK and LRP4 antibodies and seronegative disease

> “MuSK-Ab are found in about 6–8% of all MG cases”

Source: [Rousseff (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8073361/)

> “In approximately 15% of patients with generalized MG and 50% of patients with ocular MG, both AChR and MuSK antibodies were absent.”
> “Detection rates in double-seronegative patients range from 2% to 50%, depending on the geographical origin, with LRP4-Ab being more frequent in non-Caucasian patients, and on the employed assay, with Live CBA being the most widely used”

Source: [Vinciguerra et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10526522/)

<a id="topic-2.2.1.5-4"></a>

###### Antibody testing: United States testing patterns after a new diagnosis

> “Of 5788 cases, 2590 (44.7 %) had at least one valid serology test result: 1453 (56.3 %) seronegative, 1094 (42.4 %) anti-AChR+, 28 (1.1 %) anti-MuSK+, and 5 (0.2 %) anti-LRP4+.”
> “Among the seronegative, 56.6 % were only tested for anti-AChR antibodies, 33.7 % tested both anti-AChR and anti-MuSK antibodies, and 5.0 % tested all three antibodies.”

Source: [Pesa et al. (2026a)](https://pubmed.ncbi.nlm.nih.gov/41455461/)

<a id="topic-2.2.1.5-5"></a>

###### Electrodiagnosis: repetitive nerve stimulation

> “In generalized MG, RNS of distal muscles is abnormal in 30–35% of patients, while in proximal muscles, it is abnormal 60–70%”
> “One should note as a standard feature the high specificity of RNS, which reaches about 97% in generalized MG and 94% in ocular MG”

Source: [Rousseff (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8073361/)

<a id="topic-2.2.1.5-6"></a>

###### Electrodiagnosis: single-fiber and concentric needle jitter

> “The jitter study is the most sensitive indicator of impaired neuromuscular transmission”
> “The CNE jitter is abnormal in 98–100% in generalized MG and above 90% in ocular MG.”
> “While highest in sensitivity, jitter measurements are not specific and may be abnormal in other synaptic disorders, in denervation and reinnervation processes (poly- and mononeuropathies), some myopathies, and with motor neuron disorder (MND) in particular”

Source: [Rousseff (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8073361/)

<a id="topic-2.2.1.5-7"></a>

###### Bedside tests: ice-pack and edrophonium tests

> “The test is used mostly in ocular MG and seems more popular among neuro-ophthalmologists; some authors report sensitivities equal to that of single-fiber electromyography (SFEMG) in patients presenting with ptosis and a very high negative predictive value”
> “However, others note much lower specificity at about 25%”
> “In the USA, edrophonium has been discontinued since 2018”

Source: [Rousseff (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8073361/)

<a id="topic-2.2.1.5-8"></a>

###### MGFA clinical classification

| Class | Quoted definition |
| --- | --- |
| Class I | “Any ocular muscle weakness; may have weakness of eye closure. All other muscle strength is normal.” |
| Class II | “Mild weakness affecting muscles other than ocular muscles; may also have ocular muscle weakness of any severity.” |
| Class IIa | “Predominantly affecting limb, axial muscles, or both. May also have lesser involvement of oropharyngeal muscles.” |
| Class IIb | “Predominantly affecting oropharyngeal, respiratory muscles, or both. May also have lesser or equal involvement of limb, axial muscles, or both.” |
| Class III | “Moderate weakness affecting muscles other than ocular muscles; may also have ocular muscle weakness of any severity.” |
| Class IV | “Severe weakness affecting muscles other than ocular muscles; may also have ocular muscle weakness of any severity.” |
| Class V | “Defined as intubation, with or without mechanical ventilation, except when employed during routine postoperative management. The use of a feeding tube without intubation places the patient in class IVb.” |

Source: [Myasthenia Gravis Foundation of America](https://myasthenia.org/wp-content/uploads/Portals/0/MGFA%20Classification.pdf)

<a id="topic-2.2.1.5-9"></a>

###### Consensus definitions: minimal manifestation status, impending crisis, and crisis

> “MMS: The patient has no symptoms or functional limitations from MG but has some weakness on examination of some muscles.”
> “Rapid clinical worsening of MG that, in the opinion of the treating physician, could lead to crisis in the short term (days to weeks).”
> “Worsening of myasthenic weakness requiring intubation or noninvasive ventilation to avoid intubation, except when these measures are employed during routine postoperative management”

Source: [Sanders et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4977114/)

<a id="topic-2.2.1.5-10"></a>

###### Diagnostic delay: United States patients with generalized myasthenia gravis

> “Quantitative surveys and qualitative interviews were conducted (January-May 2023) in patients with gMG (n = 71 surveys; n = 47 interviews) and clinicians in the United States treating patients with gMG (n = 12 surveys and interviews).”
> “Patients had mean (SD) diagnostic journey time of 11.8 (22.5) months from symptom onset to seeking care and 15.5 (36.7) months from seeking care to diagnosis.”
> “Sources of diagnostic journey delay (≥9.9 % patients) were: clinicians mistaking gMG symptoms as female health issues, difficulty accessing specialty care, and lack of gMG knowledge among HCPs.”

Source: [Jiang et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/41319378/)

<a id="heading-2.2.1.6"></a>

##### 2.2.1.6 Clinical Presentation - Signs and Symptoms

<a id="topic-2.2.1.6-1"></a>

###### Core feature: fatigable, fluctuating, predominantly proximal weakness

> “The core clinical manifestation of MG is fatigable muscle weakness, worsened by exertion and improved by rest.”

Source: [Dresser et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8196750/)

> “Muscle weakness fluctuates over time and increases with repeated or sustained muscle use.”
> “The weakness is more pronounced in proximal than distal muscles, and leg muscles are typically mildly weak or unaffected.”
> “The weakness is symmetrical, apart from the eyes.”

Source: [Gilhus et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11236053/)

> “Nearly all participants (96%) reported fluctuations in symptoms and severity.”

Source: [Jackson et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9837342/)

<a id="topic-2.2.1.6-2"></a>

###### Ocular symptoms: ptosis and diplopia

> “The most common presenting symptoms are ocular, with double vision and ptosis.”
> “Most patients will develop diplopia and/or ptosis some time during the course of their disease.”

Source: [Dresser et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8196750/)

<a id="topic-2.2.1.6-3"></a>

###### Bulbar symptoms: dysarthria, dysphagia, and facial and jaw weakness

> “Bulbar muscles are also frequently involved, resulting in flaccid dysarthria, dysphagia, and facial and jaw weakness”

Source: [Dresser et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8196750/)

> “Generalized MG (gMG) involves multiple muscle groups, including limb, axial, and bulbar muscles, and can present with difficulty chewing, talking, swallowing, or breathing”

Source: [Grover et al. (2026c)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13724412/)

<a id="topic-2.2.1.6-4"></a>

###### Axial symptoms: neck weakness and head drop

> “Axial weakness can also be present, with neck flexion weakness usually more common than weakness of neck extension.”
> “In a previous retrospective study from our center, about 10% of MG patients developed head-drop some time during the disease course”
> “Head-drop was associated with age >60 and male patients in that study.”

Source: [Dresser et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8196750/)

<a id="topic-2.2.1.6-5"></a>

###### Limb symptoms: proximal and, less often, distal weakness

> “Limb muscle weakness tends to be symmetric and proximal, and patients commonly complain of difficulty climbing stairs, getting up from chairs, and raising arms above their head.”
> “In some instances, distal muscles can be predominantly affected, either in a symmetric or asymmetric distribution.”

Source: [Dresser et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8196750/)

<a id="topic-2.2.1.6-6"></a>

###### Respiratory symptoms: respiratory muscle weakness

> “Finally, 15–20% of patients with AChR-MG can develop respiratory weakness requiring mechanical ventilation (MG crisis)”

Source: [Dresser et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8196750/)

<a id="topic-2.2.1.6-7"></a>

###### Patient-reported symptoms: frequency and most bothersome symptoms

> “Semi-structured, in-depth concept-elicitation interviews were conducted with 28 individuals diagnosed with gMG in the United States.”
> “Participants reported gMG symptoms that affected many body regions and functions, with an average of 16 symptoms per participant.”
> “The most frequently reported symptoms were eyelid drooping (93%), physical fatigue (89%), symptoms affecting the legs (82%), difficulty breathing (82%), and difficulty holding head up (82%).”
> “Participants’ most bothersome symptoms were blurry/double vision (43%), breathing difficulties (36%), all-over fatigue (36%), and swallowing problems (29%).”

Source: [Jackson et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9837342/)

<a id="topic-2.2.1.6-8"></a>

###### Fatigue and emotional symptoms

> “All participants reported emotional impacts and impacts on their work and finances.”

Source: [Jackson et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9837342/)

> “Even patients with only mild symptoms have a decreased quality of life because of fatigue, treatment side effects, and worries about exacerbations and complications”

Source: [Gilhus et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11236053/)

<a id="topic-2.2.1.6-9"></a>

###### Symptoms by antibody subgroup: MuSK antibody-positive disease

> “Muscle weakness preferentially affects cranial and bulbar muscles.”
> “Over 40% of patients present with bulbar weakness, usually associated with neck and respiratory involvement”
> “About 30% of patients present with diplopia and/or ptosis.”
> “Limb weakness can be uncommon, but when present it tends to be severe and associated with muscle atrophy.”

Source: [Dresser et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8196750/)

<a id="heading-2.2.1.7"></a>

##### 2.2.1.7 Long-term Morbidity

<a id="topic-2.2.1.7-1"></a>

###### Myasthenic crisis: frequency, triggers, and outcomes

> “Myasthenic crisis (MC) is a life-threatening manifestation of myasthenia gravis (MG) defined by respiratory insufficiency that requires the use of invasive or non-invasive ventilation.”
> “MC occurs in approximately 15%-20% of patients with MG usually within the first 2 to 3 y of the disease course.”
> “Many crises have a specific trigger with respiratory infections being most common; however, no specific trigger is found in 30%-40% of patients.”
> “MG patients with a history of MC, severe disease, oropharyngeal weakness, muscle-specific kinase (MuSK) antibodies and thymoma appear to be at higher risk.”
> “The mortality rate in United States cohorts is less than 5% and mortality in MC seems to be driven by age and other medical co-morbidities.”

Source: [Claytor et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/37114503/)

> “A myasthenic crisis (MC) is a more severe, life-threatening escalation of muscle weakness that leads to respiratory failure, necessitating intensive care unit admission with assisted ventilation, usually requiring an inpatient stay period of several weeks, often in the range of 2–4 weeks”
> “Approximately 20% of patients with gMG are estimated to experience MC during a period of 3 years or longer”

Source: [Grover et al. (2026c)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13724412/)

<a id="topic-2.2.1.7-2"></a>

###### Myasthenic crisis: Ontario, Canada, population-based incidence

> “Myasthenic crisis occurred in 8.9% of individuals over the study, with a post‐diagnosis incidence rate of 2.6 per 100 person‐years and 30‐day mortality of 28.1%.”

Source: [Barnett-Tapia et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13498700/)

<a id="topic-2.2.1.7-3"></a>

###### Exacerbations and crises: predictors, United States generalized myasthenia gravis

> “Among 6,195 patients with gMG (mean age: 61.1 years; female: 49.1%), higher event risk was associated with use of immunoglobulin [hazard ratio (HR) = 1.54], baseline dysarthria (HR = 1.45), general and other muscle-specific weaknesses (HR = 1.38), use of non-steroidal immunosuppressants (HR = 1.37), dysphagia (HR = 1.28), weight loss (HR=1.27), dyspnea (HR = 1.23), ptosis (HR = 1.20), absence of other autoimmune disorders (HR=1.18), and male sex (HR = 1.15; all p < 0.05).”

Source: [Grover et al. (2026c)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13724412/)

<a id="topic-2.2.1.7-4"></a>

###### Refractory disease: persistent moderate or severe weakness

> “However, 10%–20% of patients continue to have long‐standing moderate or severe weakness after treatment with at least two different immunosuppressive drugs at high doses”

Source: [Gilhus et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11236053/)

<a id="topic-2.2.1.7-5"></a>

###### Glucocorticoid toxicity: United States commercially insured adults with generalized myasthenia gravis

> “Among 8833 patients with gMG, 5076 (57.5%) had no GC use and 3757 (42.5%) had any GC use (≥5 mg/d: 1537 [40.9%]; ≥10 mg/d: 860 [22.9%]).”
> “During the study period, incident GC toxicities were more common among patients in the any GC use cohort than the no GC use cohort (61.9% vs 52.3% with ≥1 toxicity), with a trend of increasing incidence with increasing GC use (≥5 mg/d: 62.9%; ≥10 mg/d: 67.3%; all P < .001”
> “Additionally, a greater proportion of patients with any GC use than no GC use had ≥3 incident GC toxicities (16.5% vs 9.5%), with this proportion rising with mean PEDD ≥5 mg (18.9%) and mean PEDD ≥10 mg (22.8%; all P <.001).”
> “Both acute and chronic incident GC toxicities were more common in the any GC use cohort than the no GC use cohort (acute: 28.5% vs 19.1%; chronic: 51.9% vs 43.8%; both P <.001)”
> “Since claims data do not contain reasons for diagnoses, toxicities could not be confirmed to be related to GC use.”

Source: [Silvestri et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13008238/)

<a id="topic-2.2.1.7-6"></a>

###### Glucocorticoid toxicity: recognized adverse effects and higher-risk patients

> “However, long-term use of GCs is associated with potentially serious toxicities, including weight gain, cataracts, hypertension, diabetes, osteoporosis, infections, and neuropsychiatric symptoms”

Source: [Silvestri et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13008238/)

> “MG patients with osteoporosis, obesity, diabetes, and mental disorders have a particularly high risk of corticosteroid side effects.”

Source: [Gilhus et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11236053/)

<a id="topic-2.2.1.7-7"></a>

###### Refractory disease: share and crisis rates in U.S. administrative health plan data

> “Rates of myasthenic crises, exacerbations, inpatient hospitalizations, and emergency room (ER) visits over a 1-year period were measured for 403 refractory, 3,811 nonrefractory, and 403 non-MG control patients from two administrative health plan databases.”
> “Compared with nonrefractory patients, a significantly greater percentage of refractory patients had at least one myasthenic crisis (21.3% vs. 6.1%; P < 0.001) and at least one exacerbation (71.2% vs. 32.4%; P < 0.001) over a 1-year period.”

Source: [Engel-Nitz et al. (2018)](https://pubmed.ncbi.nlm.nih.gov/29486521/)

<a id="topic-2.2.1.7-8"></a>

###### Refractory disease: share and characteristics in a U.S. tertiary neuromuscular clinic, 2003 to 2011

> “A retrospective chart review was completed of 128 MG patients referred to a tertiary neuromuscular clinic from 2003 to 2011.”
> “Nineteen out of 128 patients were classified as refractory (14.8 percent). Compared to the non-refractory patients, the refractory patients were more likely to be younger at onset, female, thymomatous, and MuSK-antibody positive.”

Source: [Suh et al. (2013)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3670444/)

<a id="topic-2.2.1.7-9"></a>

###### Refractory disease: share assumed in the ICER evaluation

> “The population with gMG is 14-20 per 100,000, and if only 15% of this population is considered to have refractory gMG, the population now eligible for treatment with eculizumab is more than seven times as large as when the drug was first approved, yet the price has not come down.”

Source: [ICER (2021)](https://icer.org/wp-content/uploads/2021/03/ICER_Myasthenia-Gravis_Final-Report_102021-1.pdf)

<a id="topic-2.2.1.7-10"></a>

###### Persistently uncontrolled disease over 8 years of follow-up: Spanish referral cohort

> “The proportion adequately controlled (AC) patients increased from 62.0% at 2 years after first visit to 81.9% after 8 years of follow-up. 47.3% of patients remained AC in every observation, and 17.7% remained not adequately controlled (NC) in every observation.”
> “AE-related drug interruption rates were higher in NC patients (ranging from 50% to 100% during the study).”

Source: [Reyes-Leiva et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13714894/)

<a id="heading-2.2.1.8"></a>

##### 2.2.1.8 Burden of Generalized myasthenia gravis

<a id="heading-2.2.1.8.1"></a>

###### 2.2.1.8.1 Humanistic Burden and Health-related Quality of Life

<a id="topic-2.2.1.8.1-1"></a>

###### Patient-reported burden by MGFA class: MyRealWorld MG baseline, seven countries

> “Adult patients with MG from seven countries (USA, Japan, Germany, UK, Italy, Spain and Canada) downloaded a mobile application onto their phones and entered data about themselves and their MG.”
> “Baseline results of 841 participants (mean age 47 years, 70% women) are reported.”
> “The MGFA class was a strong predictor of all aspects of HRQoL, measured with disease-specific and with generic instruments. The domains in which patients with MG most frequently mentioned problems were usual activities, anxiety and depression, tiredness, breathing and vision.”
> “Mean baseline EQ-5D-5L utility was also associated with MGFA classes and was 0.817, 0.766, 0.648 and 0.530 for MGFA class I–IV.”
> “MG has a large impact on key aspects of health and HRQoL. The impact of this disease increases substantially with increasing disease severity.”

Source: [Dewilde et al. (2023a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9890761/)

<a id="topic-2.2.1.8.1-2"></a>

###### Health utilities and medical care use compared with the general population

> “In MRW ( n = 1859), 58.4% of respondents had moderate-to-severe MG. Average utility values were lower in MRW versus POPUP (0.739 vs. 0.843 for EQ-5D-5L; 0.493 vs. 0.746 for HUI3), and declined with more severe disease (0.872, 0.707, 0.511 EQ-5D-5L utilities and 0.695, 0.443, 0.168 HUI3 utilities for mild, moderate, and severe MG, respectively).”
> “Use of medical care was twice as likely in MRW in comparison with POPUP (51.9% vs. 24.6%).”

Source: [Dewilde et al. (2023b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10499690/)

<a id="topic-2.2.1.8.1-3"></a>

###### Quality of life and support needs in U.S. adults receiving standard of care without advanced biologics

> “Patients had received treatment with standard of care (acetylcholinesterase inhibitors, non-steroidal immunosuppressants, corticosteroids, rituximab, immunoglobulins, plasmapheresis) but not advanced biologics (eculizumab, ravulizumab, zilucoplan, efgartigimod, rozanolixizumab, nipocalimab).”
> “Overall, 157 eligible patients completed the survey (87.3% female, mean [SD] age 49.5 [14.4] years, mean [SD] time since diagnosis 11.0 [10.9] years). Mean (SD) MG-QoL-15R score was 16.2 (7.2), EQ5D-5L score was 0.6 (0.3), and FACIT-fatigue subscale score was 20.2 (11.3). Overall, 51.6% received additional support/care.”
> “Patients with moderate/severe gMG (136/157 [86.6%]) had greater symptom occurence, reduced treatment satisfaction, greater health-related quality of life impairment, and greater support/care needs, compared with patients with mild gMG.”

Source: [Pesa et al. (2026b)](https://pubmed.ncbi.nlm.nih.gov/43001852/)

<a id="topic-2.2.1.8.1-4"></a>

###### Life domains affected in U.S. patients and caregivers

> “across 8 life domains (occupation, financial, emotional, physical, sleep, social, planning and autonomy, and safety)”
> “Respondents included 239 patients with gMG (63%, aged 18–49 y; 69%, female) and 81 caregivers (58%, aged 18–49 y; 42% female).”
> “The 5 domains most impacted by gMG were occupational (mean domain score [SD]: 4.0 [1.2]), planning and autonomy (4.0 [1.1]), financial (3.9 [1.2]), physical (3.9 [1.1]), and sleep (3.9 [1.2]) for patients and financial (3.7 [1.2]), sleep (3.7 [1.1]), occupational (3.6 [1.2]), planning and autonomy (3.6 [1.1]), and safety (3.6 [1.1]) for caregivers.”
> “Eligible patients were aged ≥ 18 years currently living in the United States with a self-reported physician diagnosis of gMG regardless of antibody status.”

Source: [Narayanaswami et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13400517/)

<a id="topic-2.2.1.8.1-5"></a>

###### Systematic review of psychological symptoms and health-related quality of life

> “Sixty-seven publications were included in the SLR. Compared with the general population, patients with MG experienced worse HRQoL.”
> “However, in general those with more severe symptoms and hospitalization days had worse depression and anxiety, and fatigue and sleep improved with disease remission and/or improvement. Scores were worse for females compared with males and where evaluated, HRQoL scores generally improved following treatment.”

Source: [Gelinas et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/35486970/)

<a id="heading-2.2.1.8.2"></a>

###### 2.2.1.8.2 Economic Burden and Healthcare Resource Utilization

<a id="topic-2.2.1.8.2-1"></a>

###### Incremental annual costs of newly diagnosed gMG compared with matched controls: U.S. claims, 2017 to 2023

> “Adults with newly diagnosed gMG were identified from Komodo Research data (January 1, 2017, to September 30, 2023).”
> “The gMG cohort (mean follow-up = 32.7 months) compared with the non-MG cohort (mean follow-up = 31.3 months) had 2.4, 1.6, and 1.9 times more inpatient days, emergency department visits, and outpatient visits annually, respectively (all P < 0.001).”
> “Mean annual all-cause total health care costs in the gMG cohort were $43,872 higher than in the non-MG cohort ($58,341 vs $14,469; P < 0.001); 59.3% of the difference was driven by pharmacy costs (mostly immunoglobulin).”
> “Prediagnosis weakness and fatigue symptoms, exacerbation or crisis, and use of immunoglobulin were important factors significantly associated with high health care costs in the gMG cohort (all P < 0.001).”

Source: [Grover et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13293495/)

<a id="topic-2.2.1.8.2-2"></a>

###### Costs associated with exacerbations and crises in newly diagnosed gMG: U.S. claims

> “After re-weighting, patients with a clinical event had higher number of inpatient admissions [rate ratio (RR) = 6.02], emergency visits (RR = 1.91), and outpatient visits (RR = 1.58; all p < 0.05) in the 12 months post-index. Mean total healthcare costs were $70,792 higher among patients with a clinical event ($95,821 vs. $25,029, p < 0.001), driven by immunoglobulin and inpatient costs.”

Source: [Grover et al. (2026c)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13724412/)

<a id="topic-2.2.1.8.2-3"></a>

###### Incremental costs and event-related costs in prevalent and incident gMG: U.S. claims, 2017 to 2023

> “Analyses included 16,561 gMG patients (12,813 prevalent and 3748 incident) and 105,716 non-gMG controls. Among prevalent and incident gMG patients, respectively, MG exacerbation occurred during follow-up in 12.2 and 22.0% and myasthenic crisis in 6.0 and 12.4%.”
> “After weighting, gMG patients (median follow-up 696 days) experienced more frequent all-cause HCRU encounters and >4-fold higher healthcare costs ($5420 PPPM or ∼$65,000 per annum) versus non-gMG controls ($1298 PPPM or ∼$15,500 per annum).”
> “Among MG patients, those with MG exacerbation/myasthenic crisis, respectively, experienced means of 3.02/3.35 hospitalizations, 1.91/2.13 emergency department encounters, 12.70/13.39 skilled nursing facility encounters, and 67.86/75.52 outpatient encounters during follow-up; associated costs were $17,113/$18,640 PPPM (or ∼$205,000/$224,000 per annum).”

Source: [Jackson et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/41099443/)

<a id="topic-2.2.1.8.2-4"></a>

###### Incremental monthly costs and the effect of comorbidities and acute events: U.S. claims, 2017 to 2021

> “The gMG and matched non-MG cohorts each contained 2,739 patients. Mean incremental healthcare costs associated with MG were $4,155 (gMG: $5,567; non-MG: $1,411), with differences driven by incremental inpatient costs of $2,166 (gMG: $2,617; non-MG: $452); all p < 0.001.”
> “Among patients with gMG in cardiometabolic (n = 1,859), psychiatric (n = 1,308), and exacerbation/crisis (n = 419) subgroups, mean monthly healthcare costs were $6,660, $7,443, and $17,330, respectively.”

Source: [Zhdanava et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/38745448/)

<a id="topic-2.2.1.8.2-5"></a>

###### First-year costs after diagnosis by payer: U.S. commercial and Medicare claims, 2016 to 2021

> “The final analytic cohort included 3,700 patients with MG and 37,000 controls. On average, patients were aged 54 years, with 60% being female. The difference-in-difference estimates of the total health care cost for MG diagnosis in commercial and Medicare patients were $25,799 and $4,927, respectively (P < 0.01).”

Source: [Choi et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12039500/)

<a id="topic-2.2.1.8.2-6"></a>

###### Costs in newly diagnosed and previously diagnosed patients and around crisis events: U.S. claims, 2014 to 2019

> “Mean HCRU and costs were higher for newly diagnosed patients compared with previously diagnosed patients (hospitalizations: 0.46 vs. 0.34; all-cause costs: $26,419.20 vs. $24,941.47; direct costs for gMG treatments: $9,890.37 vs. $9,186.47) and further increased for patients with exacerbation events (hospitalizations: 0.72; all-cause costs: $43,734.15; direct costs for gMG treatments: $21,550.02).”
> “For patients who experienced crisis events, HCRU and costs markedly increased during the 12 months immediately before the crisis event (hospitalizations: 1.35; all-cause costs: $49,236.68) compared with the 2 preceding years and increased further during the 12 months following the crisis index date (hospitalizations: 2.78; all-cause costs: $173,956.99).”

Source: [Phillips et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8805609/)

<a id="topic-2.2.1.8.2-7"></a>

###### Costs in patients treated with chronic IVIg or multiple nonsteroidal immunosuppressants

> “Compared with the reference cohort (n = 2992), the MG crisis rate was approximately twice as high in both the chronic IVIg (n = 324) and multiple NSIST (n = 291) cohorts (p < 0.001); and the MG exacerbation rate was approximately four-fold higher in the chronic IVIg cohort (p < 0.001) and three-fold higher in the multiple NSIST cohort (p < 0.001).”
> “Median annual MG-related inflation-adjusted total healthcare costs were higher in the chronic IVIg ($81,900) and multiple NSIST ($30,300) cohorts than in the reference cohort ($2540).”

Source: [Parthan et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/38018505/)

<a id="topic-2.2.1.8.2-8"></a>

###### Costs by glucocorticoid exposure: U.S. commercial claims

> “Annual all-cause costs were >2x higher among patients with any GC use than those with no GC use ($76,381 vs $35,309). GC acute and chronic toxicities and costs tended to increase with increasing GC use.”

Source: [Silvestri et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13008238/)

<a id="topic-2.2.1.8.2-9"></a>

###### Hospitalization trends: U.S. Nationwide Inpatient Sample and Medicare, 2010 to 2019

> “Hospitalization rates for 19,715 unique adult patients and 56,822 admissions increased from 2010 to 2019 at an average annualized rate of 4.9% (MG noncrisis: 4.4%; MG crisis: 6.8%; all p < 0.001). Readmission rates were approximately 20% in each study year for both crisis and noncrisis hospitalizations; the in-hospital mortality rate averaged 1.8%.”
> “The average LOS was stable over the study period, ranging from 11.3 to 13.1 days, but was consistently longer for MG crisis admissions.”

Source: [Habib et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/38165317/)

<a id="topic-2.2.1.8.2-10"></a>

###### Range of direct and indirect costs across studies: systematic reviews

> “Across studies, the mean per-patient annual direct medical cost of illness was estimated at between $760 and $28,780, and cost per hospitalization between $2550 and $164,730. The indirect cost of illness was estimated at $80 and $3550.”
> “Costs varied considerably by patient characteristics, and drivers of the direct medical cost of illness included intravenous immunoglobulin and plasma exchange, myasthenic crisis, mechanical ventilatory support, and hospitalizations.”

Source: [Landfeldt et al. (2020)](https://pubmed.ncbi.nlm.nih.gov/32363541/)

> “1374 records were identified initially, and 44 were included in the final review.”
> “Direct costs include treatment and follow-up in the primary and specialist health care. They were estimated to €3 500–12 000 per MG patient per year in the Nordic countries, similar in other European countries, and higher in United States.”
> “Intangible costs include value of lost life-years and reduced quality of life, which are rarely assessed, but have been estimated to be half of the total societal MG costs.”

Source: [Gilhus et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13645850/)

<a id="topic-2.2.1.8.2-11"></a>

###### Treatment escalation and first-year MG-related costs in newly diagnosed adults: U.S. MarketScan claims, 2010 to 2018

> “Patients aged ≥ 18 years at MG diagnosis were included from two US Merative™ MarketScan® databases.”
> “The cohort included 4925 adults with newly diagnosed MG (1102 aged 18–49 and 3823 aged ≥ 50 at first MG diagnosis) from January 1, 2010 to December 31, 2018.”
> “Overall, 71.5% (3521/4925) of patients had ≥ 1 MG treatment escalation; escalation with high-dose corticosteroids was the most common type (64.8% [18–49 group] and 58.5% [≥ 50 group]).”
> “Healthcare resource utilization (HCRU) and costs were highest in Year 1, with mean MG-related costs per patient between $24,982 (≥ 50 group) and $33,023 (18–49 group).”

Source: [Pujades-Rodríguez et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12089002/)

<a id="topic-2.2.1.8.2-12"></a>

###### Out-of-pocket and aggregate costs of eculizumab for myasthenia gravis: U.S. commercial and Medicare supplemental claims

> “We used the Merative MarketScan commercial and Medicare supplemental databases to observe patients seen by a neurologist with neurologic diseases with newly FDA-approved medications from 2014 to 2021”
> “We identified 2,687 unique individuals with ALS, 38 with ATTR, 69 with DMD, 884 with HD, 9,984 with MG, 441,099 with migraine, 4,723 with OH, 1,266 with TD, and 17 with SMA.”
> “Eculizumab for MG was an extreme outlier, with OOP costs increasing by 4,099% ($413-$17,359) and aggregate OOP costs by 7,005% ($5,375-$381,894).”

Source: [Gusovsky Chevalier et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11874732/)

<a id="topic-2.2.1.8.2-13"></a>

###### Healthcare resource utilization before and after rozanolixizumab initiation: U.S. Komodo claims, July 2023 to March 2025

> “Patients were selected from de-identified claims data from the Komodo Healthcare Map® (July 2023–March 2025).”
> “The main study included 719 patients. Patients with ≥ 365 days since rozanolixizumab initiation (n = 287) started a mean (standard deviation) 2.9 (1.8) treatment cycles in Year 1. Total MG-related HCRU incidence rates per 100 person-years were 88.0 during baseline and 82.9 during follow-up, and 86.2 versus 80.8 for outpatient, 25.6 versus 17.3 for inpatient, and 24.9 versus 14.0 for emergency room visits.”

Source: [Kumar et al. (2026b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13396046/)

<a id="topic-2.2.1.8.2-14"></a>

###### Exacerbation rate and healthcare resource utilization by MG-ADL score: MGFA Global MG Patient Registry, United States, 2013 to 2022

> “Participants were based in the USA, aged ≥ 18 years, had a self-reported MG diagnosis and complete MG-ADL data, and were enrolled between July 1, 2013 and September 30, 2022.”
> “In total, 3416 patients (2092 [61.2%] females) were eligible; mean (standard deviation) age at diagnosis was 49.4 (17.4) years.”
> “For each additional point on the MG-ADL score, the rate of exacerbations increased by 13% (incidence rate ratio: 1.13; 95% confidence interval: 1.11–1.15; p < 0.001). At enrollment, 49.6% (n = 386/778) of patients who had one exacerbation had HCRU.”

Source: [Ting et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11906949/)

<a id="topic-2.2.1.8.2-15"></a>

###### Acute care utilization by race and ethnicity in the 2 years after diagnosis: U.S. Optum claims, 2010 to 2019

> “A retrospective cohort study was conducted among adults (≥18 years) with newly diagnosed MG in the United States using Optum’s de-identified Market Clarity Data from January 1, 2010, to December 31, 2019.”
> “Compared with patients identifying as Caucasian, those identifying as African American had 37% higher odds of having an emergency department visit in year 1, and those identifying as Hispanic had 70% increase in odds of having a hospitalization event in year 2 post-diagnosis. Among other covariates, Medicaid usage, exacerbation at index, and number of outpatient visits were significantly associated with acute care utilization.”

Source: [Qi et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11832025/)

<a id="heading-2.2.1.8.3"></a>

###### 2.2.1.8.3 Economic Impact of Generalized myasthenia gravis on Families

<a id="topic-2.2.1.8.3-1"></a>

###### Out-of-pocket costs and financial adjustments reported by U.S. patients and caregivers

> “Eight hundred people with MG and 238 caregivers responding on behalf of a person with MG completed the survey.”
> “70% reported making financial adjustments or seeking financial assistance. Annual out-of-pocket costs (mean, $15,798; median, $7750) were primarily driven by medications, cost to receive a diagnosis, and healthcare insurance premiums. People receiving infusions paid significantly more across all care domains.”

Source: [Yoder et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/39697037/)

<a id="topic-2.2.1.8.3-2"></a>

###### Patient and caregiver productivity losses by symptom severity: MyRealWorld MG

> “In the MyRealWorld-MG study, 36.5% of MG patients reported taking sick leave within the last month and 11.4% reported stopping work (or retiring early) due to MG. Furthermore, 36.0% required caregiver support with 14.6% of caregivers reducing working hours and 13.4% stopping work.”
> “Patients with severe MG incurred 3.8 times more productivity losses compared to patients with mild disease.”

Source: [Dewilde et al. (2025a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12062151/)

<a id="topic-2.2.1.8.3-3"></a>

###### Annual productivity losses per patient in the United States by MG-ADL category

| MG-ADL category | Patient productivity losses | Caregiver productivity losses | Grand total |
| --- | --- | --- | --- |
| Mild | “$8,160” | “$1,302” | “$9,462” |
| Moderate | “$9,063” | “$3,541” | “$12,604” |
| Severe | “$10,997” | “$3,791” | “$14,788” |
| All patients | “$9,468” | “$3,141” | “$12,609” |

Source: [Dewilde et al. (2025a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12062151/)

<a id="topic-2.2.1.8.3-4"></a>

###### Caregiver burden measured with the Zarit Burden Interview in five European countries

> “A cross-sectional study design collected patient and caregiver data in Germany, Italy, Spain, the UK, and France.”
> “Caregivers (N = 69) reported a mean ZBI-22 score of 24.3, with 40.6% reporting no burden, 47.8% mild-to-moderate burden, 8.7% moderate-to-severe burden, and 2.9% severe burden.”
> “Informal caregivers of MG patients experience a substantial burden, impacting their physical, emotional, and financial well-being.”

Source: [Dewilde et al. (2025b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12178031/)

<a id="topic-2.2.1.8.3-5"></a>

###### Sick leave and need for caregiver help compared with the general population

> “Taking sick leave in the past month was 2.6 times more frequent among people diagnosed with MG compared to the general population (34.4% vs. 13.2%) and four times more people diagnosed with MG reported needing help from a caregiver (34.8% vs. 8.3%).”

Source: [Dewilde et al. (2023b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10499690/)

<a id="topic-2.2.1.8.3-6"></a>

###### Economic concerns of U.S. adults with gMG facing social determinants of health barriers

> “The survey was completed by 38 individuals living with gMG, the majority of whom were enrolled in public insurance and not employed. The most commonly reported major economic concerns were managing funds for emergency care (66%), loss of income (61%), and non-medical expenses (58%), highlighting the diversity of economic challenges.”

Source: [Hughes et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10520715/)

<a id="heading-2.2.1.8.4"></a>

###### 2.2.1.8.4 Economic Impact of Diagnostic Testing

<a id="topic-2.2.1.8.4-1"></a>

###### Out-of-pocket cost of receiving a diagnosis reported by U.S. patients

> “Demographic disparities were observed, with people of color, women, and those on disability paying significantly more to receive a diagnosis than their counterparts.”

Source: [Yoder et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/39697037/)

<a id="topic-2.2.1.8.4-2"></a>

###### Medicaid payment rates for acetylcholine receptor and MuSK antibody tests: Massachusetts, January 2024

> “In accordance with 101 CMR 320.01(4)(c), the Executive Office of Health and Human Services (EOHHS) is adding new service codes effective for dates of service on and after January 1, 2024.”

Source: [Massachusetts Executive Office of Health and Human Services Administrative Bulletin 24-19 (2024)](https://www.mass.gov/doc/administrative-bulletin-24-19-101-cmr-32000-clinical-laboratory-services-2024-cpt-code-updates-effective-january-1-2024-0/download)

| Test | Code | Rate |
| --- | --- | --- |
| “Acetylcholine receptor (AChR); binding antibody” | “86041” | “$16.23” |
| “Acetylcholine receptor (AChR); blocking antibody” | “86042” | “$16.23” |
| “Acetylcholine receptor (AChR); modulating antibody” | “86043” | “$10.63” |
| “Muscle-specific kinase (MuSK) antibody” | “86366” | “$16.23” |

Source: [Massachusetts Executive Office of Health and Human Services Administrative Bulletin 24-19 (2024)](https://www.mass.gov/doc/administrative-bulletin-24-19-101-cmr-32000-clinical-laboratory-services-2024-cpt-code-updates-effective-january-1-2024-0/download)

<a id="heading-2.2.2"></a>

#### 2.2.2 Approaches to Treatment

<a id="heading-2.2.2.1"></a>

##### 2.2.2.1 Current Treatment Options and Standard of Care

<a id="heading-2.2.2.1.1"></a>

###### 2.2.2.1.1 Acetylcholinesterase Inhibitors

<a id="topic-2.2.2.1.1-1"></a>

###### Pyridostigmine as initial symptomatic treatment: international consensus guidance

> “Pyridostigmine should be part of the initial treatment in most patients with MG. Pyridostigmine dose should be adjusted as needed based on symptoms. The ability to discontinue pyridostigmine can be an indicator that the patient has met treatment goals and may guide the tapering of other therapies.”
> “Corticosteroids or IS therapy should be used in all patients with MG who have not met treatment goals after an adequate trial of pyridostigmine.”

Source: [Sanders et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4977114/)

<a id="topic-2.2.2.1.1-2"></a>

###### Pyridostigmine dosing, adverse effects, and second-line symptomatic agents: Nordic guidance

> “Pyridostigmine represents the first‐line symptomatic treatment, while ambenonium and beta adrenergic agonists are second‐line options.”
> “Pyridostigmine dosage is titrated individually, where 30–60 mg every 4–6 h is a typical adult dose”
> “In a Dutch–Belgian cohort, 91% reported side effects from pyridostigmine, and one in four discontinued the treatment mainly due to side effects”
> “Pyridostigmine in optimal dose should be given as a first‐line symptomatic treatment in most patients with MG. The optimal dose can vary according to activity needs and be adjusted by the patient accordingly. Terbutaline and salbutamol can be used as adjuvant symptomatic treatments.”

Source: [Gilhus et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11236053/)

<a id="topic-2.2.2.1.1-3"></a>

###### FDA-labeled indication and dosing: pyridostigmine

> “MESTINON is useful in the treatment of myasthenia gravis.”
> “The size and frequency of the dosage must be adjusted to the needs of the individual patient.”
> “The average dose is ten 60 mg tablets or ten 5 mL teaspoonfuls daily, spaced to provide maximum relief when maximum strength is needed.”

Source: [Mestinon prescribing information (2023)](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a851795e-b7a8-40c3-9922-5e79d3eb4d92)

<a id="heading-2.2.2.1.2"></a>

###### 2.2.2.1.2 Corticosteroids

<a id="topic-2.2.2.1.2-1"></a>

###### Corticosteroid use and tapering: international consensus guidance

> “Once patients achieve treatment goals, the corticosteroid dose should be gradually tapered. In many patients, continuing a low dose of corticosteroids long-term can help to maintain the treatment goal.”
> “Because corticosteroids may cause transient worsening of myasthenic weakness, it may be appropriate to wait several days for PLEX or IVIg to have a beneficial effect before starting corticosteroids”

Source: [Sanders et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4977114/)

<a id="topic-2.2.2.1.2-2"></a>

###### Corticosteroid dosing and combination with a steroid-sparing agent: Nordic guidance

> “Early high‐dose oral prednisone or prednisolone is recommended (0.75–1.00 mg/kg) in patients with moderate to severe generalized MG”
> “In patients with mild to moderate generalized MG, steroids can be given at lower doses (0.25 mg/kg), followed by gradual escalation depending on the clinical response.”
> “A gradual increase of steroid dose from 5 to 10 mg daily over a few weeks is recommended to avoid an initial worsening.”
> “In 75% of patients, steroids have an effect within 2–4 weeks.”
> “Due to the high risk of long‐term adverse effects and to further improve muscle weakness, corticosteroids should be combined with another immunosuppressive drug.”

Source: [Gilhus et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11236053/)

<a id="topic-2.2.2.1.2-3"></a>

###### Daily corticosteroid dosing as standard practice: British guideline update

> “The recommendation to prescribe daily steroids rather than the alternate day regimen is now standard practice.”

Source: [Jacob et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/40940171/)

<a id="topic-2.2.2.1.2-4"></a>

###### Glucocorticoid exposure in US commercially insured adults with generalized myasthenia gravis

> “Use of nonsteroidal immunosuppressants was higher among patients with GC use than those without (37.6% any GC use vs 19.6% no GC use).”

Source: [Silvestri et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13008238/)

<a id="heading-2.2.2.1.3"></a>

###### 2.2.2.1.3 Nonsteroidal Immunosuppressive Agents

<a id="topic-2.2.2.1.3-1"></a>

###### Indications for and choice of nonsteroidal immunosuppressive agents: international consensus guidance

> “A nonsteroidal IS agent should be used alone when corticosteroids are contraindicated or refused. A nonsteroidal IS agent should be used initially in conjunction with corticosteroids when the risk of steroid side effects is high based on medical comorbidities. A nonsteroidal IS agent should be added to corticosteroids when: a. Steroid side effects, deemed significant by the patient or the treating physician, develop; b. Response to an adequate trial (table e-1) of corticosteroids is inadequate; or c. The corticosteroid dose cannot be reduced due to symptom relapse.”
> “Nonsteroidal IS agents that can be used in MG include azathioprine, cyclosporine, mycophenolate mofetil, methotrexate, and tacrolimus. The following factors should be considered in selecting among these agents: a. There is widespread variation in practice with respect to choice of IS agent since there is little literature comparing them. b. Expert consensus and some RCT evidence support the use of azathioprine as a first-line IS agent in MG. c. Evidence from RCTs supports the use of cyclosporine in MG, but potential serious adverse effects and drug interactions limit its use. d. Although available RCT evidence does not support the use of mycophenolate and tacrolimus in MG, both are widely used, and one or both are recommended in several national MG treatment guidelines”
> “For nonsteroidal IS agents, once treatment goals have been achieved and maintained for 6 months to 2 years, the IS dose should be tapered slowly to the minimal effective amount.”

Source: [Sanders et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4977114/)

<a id="topic-2.2.2.1.3-2"></a>

###### Methotrexate as a steroid-sparing agent: 2020 consensus update

> “An RCT enrolled 50 patients with AChR-Ab+ MG taking prednisone at a dose of ≥10 mg/d. 34 Patients were randomized 1:1 to MTX 20 mg/wk or placebo. There was no difference in the primary outcome measure, the area under the prednisone dose-time curve between months 4 and 12, and the mean 12-month change in QMG, MMT, MG-Quality of life, MG-ADL, and MGC was no different between treatment groups.”
> “Although evidence from RCTs is lacking, oral MTX may be considered as a steroid-sparing agent in patients with generalized MG who have not tolerated or responded to steroid-sparing agents that are better supported by RCT data”

Source: [Narayanaswami et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7884987/)

<a id="topic-2.2.2.1.3-3"></a>

###### Azathioprine first choice and onset of effect: Nordic guidance

> “These drugs have a delayed response of 1 to 6 months, and the full effect is sometimes reached after more than 1 year.”
> “In the Nordic countries, azathioprine (2–3 mg/kg) is usually the first‐line treatment in both adults and children. Mycophenolate (1–2 g daily), methotrexate (20 mg/week), and tacrolimus (3 mg daily) are secondary alternatives.”
> “Azathioprine is recommended as the first‐choice non‐steroidal immunosuppressant drug. Mycophenolate, methotrexate, and tacrolimus are recommended as secondary immunosuppressants.”

Source: [Gilhus et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11236053/)

<a id="heading-2.2.2.1.4"></a>

###### 2.2.2.1.4 Thymectomy

<a id="topic-2.2.2.1.4-1"></a>

###### Thymectomy in nonthymomatous AChR antibody-positive disease: 2020 consensus update

> “In nonthymomatous, generalized MG patients with AChR-Ab, aged 18–50 years, thymectomy should be considered early in the disease to improve clinical outcomes and to minimize immunotherapy requirements and the need for hospitalizations for disease exacerbations (median 9, range 2–9).”
> “Thymectomy should be strongly considered in patients with AChR-Ab+ generalized MG if they fail to respond to an initial adequate trial of immunotherapy or have intolerable side effects from that therapy”
> “Current evidence does not support an indication for thymectomy in patients with MuSK, low-density lipoprotein receptor–related protein 4, or agrin antibodies”

Source: [Narayanaswami et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7884987/)

<a id="topic-2.2.2.1.4-2"></a>

###### MGTX randomized trial: 3-year results

> “A total of 126 patients underwent randomization between 2006 and 2012 at 36 sites. Patients who underwent thymectomy had a lower time-weighted average Quantitative Myasthenia Gravis score over a 3-year period than those who received prednisone alone (6.15 vs. 8.99, P<0.001); patients in the thymectomy group also had a lower average requirement for alternate-day prednisone (44 mg vs. 60 mg, P<0.001). Fewer patients in the thymectomy group than in the prednisone-only group required immunosuppression with azathioprine (17% vs. 48%, P<0.001) or were hospitalized for exacerbations (9% vs. 37%, P<0.001).”
> “Thymectomy improved clinical outcomes over a 3-year period in patients with nonthymomatous myasthenia gravis.”

Source: [Wolfe et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5189669/)

<a id="topic-2.2.2.1.4-3"></a>

###### MGTX extension: 5-year results

> “Of 111 subjects who completed the 3-year MGTX trial, 68 (61%) entered the extension study between September 1, 2009 and August 26, 2015 (33 prednisone alone; 35 prednisone plus thymectomy).”
> “At 5 years, patients randomised to thymectomy plus prednisone continued to demonstrate improved clinical status compared to patients in the prednisone alone group based on time-weighted average QMG (5.47±3.87 vs. 9.34±5.08; 95% CI for the difference 0.71–7.04; p=0.0007) and lower average alternate-day prednisone requirements (24 mg±21 mg vs. 48±29 mg; 95% CI for the difference 12–36 mg; p=0.0002). The proportion of patients requiring hospitalisation for MG exacerbation (6% vs. 30%; 95% CI for the difference 7.1–42.1%; p=0.0105) was lower in the thymectomy group.”

Source: [Wolfe et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6774753/)

<a id="topic-2.2.2.1.4-4"></a>

###### AAN practice advisory on thymectomy

> “For patients with nonthymomatous AChR ab+ generalized MG, treatment with thymectomy plus prednisone is probably more effective than treatment with prednisone alone for increasing the chance of attaining minimal manifestation status (risk difference at 36 months, 20%; 95% confidence interval, 1.6%-37%; moderate confidence in the evidence).”
> “Clinicians should discuss thymectomy treatment with patients with AChR ab+ generalized MG (Level B).”

Source: [Gronseth et al. (2020)](https://pubmed.ncbi.nlm.nih.gov/32213645/)

<a id="topic-2.2.2.1.4-5"></a>

###### Timing of thymectomy by age: Nordic guidance

> “In patients with non‐thymoma, generalized MG, AChR antibodies, and age below 50 years, thymectomy should be performed within 4 months from diagnosis.”
> “In patients with non‐thymoma generalized MG, AChR antibodies, and age 50–65 years, early thymectomy should be considered if minimal manifestations are not reached, or the patient has substantial side effects from treatment.”
> “Minimally invasive techniques are preferred with fewer perioperative complications, shorter hospitalization time, and minimal scars.”

Source: [Gilhus et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11236053/)

<a id="heading-2.2.2.1.5"></a>

###### 2.2.2.1.5 Intravenous Immunoglobulin and Plasma Exchange

<a id="topic-2.2.2.1.5-1"></a>

###### Short-term and maintenance use: international consensus guidance

> “PLEX and IVIg are appropriately used as short-term treatments in patients with MG with life-threatening signs such as respiratory insufficiency or dysphagia; in preparation for surgery in patients with significant bulbar dysfunction; when a rapid response to treatment is needed; when other treatments are insufficiently effective; and prior to beginning corticosteroids if deemed necessary to prevent or minimize exacerbations.”
> “IVIg and PLEX are probably equally effective in the treatment of severe generalized MG.”
> “The use of IVIg as maintenance therapy can be considered for patients with refractory MG or for those in whom IS agents are relatively contraindicated.”
> “PLEX and IVIg are the mainstay of management in myasthenic crisis.”

Source: [Sanders et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4977114/)

<a id="topic-2.2.2.1.5-2"></a>

###### Crisis treatment and maintenance immunoglobulin: Nordic guidance

> “Plasma exchange and intravenous immunoglobulin are the primary treatments recommended for crisis.”
> “Immunoglobulins, given intravenously or subcutaneously, are rarely used as maintenance therapy. A recent study found no steroid‐sparing effect of intravenous immunoglobulin”

Source: [Gilhus et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11236053/)

<a id="topic-2.2.2.1.5-3"></a>

###### Randomized trials of immunoglobulin in myasthenia gravis: 12 trials and 515 participants

> “We included 12 RCTs (11 with usable data; 515 participants) conducted between 1997 and 2025 in Europe, North America, and Asia. All studies assessed IVIg; none assessed SCIg. Comparators included PLEX (six trials), placebo (five trials), and corticosteroids (one trial).”
> “We found low‐certainty evidence that IVIg may improve symptoms and functional capacity in the medium term in people with MG, compared to placebo, though the effects did not reach commonly used thresholds for clinical significance and were based on sensitivity analyses. Based on moderate‐certainty evidence, IVIg probably also increases the incidence of headache. Based on very low to low‐certainty evidence, IVIg may be less beneficial than PLEX for short‐term improvement in symptoms and may prolong hospital stay, though we found no differences in adverse events.”

Source: [Manolopoulos et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12522184/)

<a id="heading-2.2.2.1.6"></a>

###### 2.2.2.1.6 Complement C5 Inhibitors

<a id="topic-2.2.2.1.6-1"></a>

###### Eculizumab in refractory AChR antibody-positive disease: 2020 consensus update

> “In a phase III international multicenter RCT of 125 patients with refractory generalized nonthymomatous AChR-Ab+ MG (REGAIN), the primary outcome measure of change in the MG-ADL score from baseline to week 26, measured by worst-rank analysis of covariance, was not significantly different ( p = 0.0698) between eculizumab and placebo arms.”
> “Eculizumab should be considered in the treatment of severe, refractory, AChR-Ab+ generalized MG (median 9, range 2–9). The role of eculizumab in the treatment of MG is likely to evolve over time. Until further data become available to allow comparisons of cost and efficacy with other treatments, eculizumab should be considered after trials of other immunotherapies have been unsuccessful in meeting treatment goals (median 9, range 5–9).”

Source: [Narayanaswami et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7884987/)

<a id="topic-2.2.2.1.6-2"></a>

###### Complement inhibitors and FcRn blockers as second-line treatments: Nordic guidance

> “Several inhibitors of complement proteins have appeared within the last 5 years as a new treatment modality for refractory or difficult‐to‐treat MG patients”
> “The treatment effect is seen within the first 2 weeks and maximal effect appears within the first 2 months.”
> “Due to high drug costs, complement and FcRn inhibitors are recommended only for difficult‐to‐treat patients with severe MG not responding to standard immunosuppressive treatment. Complement and FcRn inhibitors act fast, have a proven effect with an acceptable safety profile, with a selective impact on the immune system. If costs permit and are acceptable, they should be recommended as alternative second‐line treatments.”

Source: [Gilhus et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11236053/)

<a id="topic-2.2.2.1.6-3"></a>

###### Eculizumab: FDA-labeled indication, dosing, and pivotal trial

> “900 mg weekly for the first 4 weeks, followed by • 1,200 mg for the fifth dose 1 week later, then • 1,200 mg every 2 weeks thereafter.”
> “A statistically significant difference favoring SOLIRIS was observed in the mean change from baseline to Week 26 in MG-ADL total scores [-4.2 points in the SOLIRIS-treated group compared with -2.3 points in the placebo-treated group (p=0.006)].”

Source: [Soliris prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/125166s454lbl.pdf)

<a id="topic-2.2.2.1.6-4"></a>

###### Eculizumab biosimilars: FDA-labeled indication

> “The treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) antibody positive.”

Source: [Bkemv prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/761333s008lbl.pdf)

> “the treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) antibody positive.”

Source: [Epysqli prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/761340s024lbl.pdf)

<a id="topic-2.2.2.1.6-5"></a>

###### Ravulizumab: FDA-labeled indication, dosing, and pivotal trial

> “with maintenance doses administered every 4 or 8 weeks, starting 2 weeks after loading dose.”
> “Patients were randomized 1:1 to either receive ULTOMIRIS (n=86) or placebo (n=89) for 26 weeks.”
> “Treatment with ULTOMIRIS demonstrated a statistically significant change in the MG-ADL and QMG total scores from baseline at Week 26 as compared to placebo”
> “Primary Endpoint MG-ADL -1.4 -3.1 -1.6 (-2.6, -0.7) < 0.001”

Source: [Ultomiris prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/761108s046lbl.pdf)

<a id="topic-2.2.2.1.6-6"></a>

###### Zilucoplan: FDA-labeled indication, dosing, and pivotal trial

> “ZILBRYSQ is indicated for the treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) antibody positive.”
> “A total of 174 patients were enrolled in Study 1 and were randomized 1:1 to receive either ZILBRYSQ 0.3 mg/kg (n=86) or placebo (n=88) once daily by subcutaneous injection.”
> “At week 12, treatment with ZILBRYSQ demonstrated a statistically significant improvement from baseline compared to placebo for MG-ADL total score and QMG total score”
> “MG-ADL Total Score -4.39 (-5.28, -3.50) -2.30 (-3.17, -1.43) -2.09 (-3.24, -0.95) < 0.001”

Source: [Zilbrysq prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/216834s015lbl.pdf)

<a id="topic-2.2.2.1.6-7"></a>

###### Target of approved complement inhibitors

> “To date, all FDA-approved drugs in this category focus on targeting the C5 convertase enzyme.”
> “Zilucoplan is a small macrocyclic peptide that not only binds to C5 to inhibit its cleavage, but also interferes with C5b binding to C6.”

Source: [Kaminski et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11178544/)

<a id="topic-2.2.2.1.6-8"></a>

###### Eculizumab: REGAIN phase 3 trial in refractory AChR antibody-positive disease, 26 weeks

> “Eligible patients were aged at least 18 years, with a Myasthenia Gravis-Activities of Daily Living (MG-ADL) score of 6 or more, Myasthenia Gravis Foundation of America (MGFA) class II-IV disease, vaccination against Neisseria meningitides, and previous treatment with at least two immunosuppressive therapies or one immunosuppressive therapy and chronic intravenous immunoglobulin or plasma exchange for 12 months without symptom control.”
> “Between April 30, 2014, and Feb 19, 2016, we randomly assigned and treated 125 patients, 62 with eculizumab and 63 with placebo. The primary analysis showed no significant difference between eculizumab and placebo (least-squares mean rank 56·6 [SEM 4·5] vs 68·3 [4·5]; rank-based treatment difference -11·7, 95% CI -24·3 to 0·96; p=0·0698).”
> “Myasthenia gravis exacerbations were reported by six (10%) patients in the eculizumab group and 15 (24%) in the placebo group. Six (10%) patients in the eculizumab group and 12 (19%) in the placebo group required rescue therapy.”
> “The use of a worst-rank analytical approach proved to be an important limitation of this study since the secondary and sensitivity analyses results were inconsistent with the primary endpoint result; further research into the role of complement is needed.”

Source: [Howard et al. (2017)](https://pubmed.ncbi.nlm.nih.gov/29066163/)

<a id="topic-2.2.2.1.6-9"></a>

###### Ravulizumab: CHAMPION MG phase 3 trial, 26 weeks

> “In this randomized, double-blind, placebo-controlled, multinational trial, we randomly assigned (1:1) patients with anti-AChR antibody-positive gMG to intravenous ravulizumab or placebo for 26 weeks.”
> “In total, 175 patients were enrolled. Ravulizumab significantly increased the magnitude of mean changes from baseline to week 26 versus placebo in MG-ADL (−3.1 vs. −1.4; P<0.001) and QMG (−2.8 vs. −0.8; P<0.001) total scores.”
> “QMG total scores improved by 5 points or more in a significantly greater proportion of ravulizumab-treated patients than of those receiving placebo (30.0% vs. 11.3%; P=0.005).”

Source: [Vu et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/38319212/)

<a id="topic-2.2.2.1.6-10"></a>

###### Zilucoplan: RAISE phase 3 trial, modified intention-to-treat population, 12 weeks

> “Between Sept 17, 2019, and Sept 10, 2021, 239 patients were screened for the study, of whom 174 (73%) were eligible. 86 (49%) patients were randomly assigned to zilucoplan 0·3 mg/kg and 88 (51%) were assigned to placebo.”
> “Patients assigned to zilucoplan showed a greater reduction in MG-ADL score from baseline to week 12, compared with those assigned to placebo (least squares mean change -4·39 [95% CI -5·28 to -3·50] vs -2·30 [-3·17 to -1·43]; least squares mean difference -2·09 [-3·24 to -0·95]; p=0·0004).”
> “TEAEs occurred in 66 (77%) patients in the zilucoplan group and in 62 (70%) patients in the placebo group. The most common TEAE was injection-site bruising (n=14 [16%] in the zilucoplan group and n=8 [9%] in the placebo group).”

Source: [Howard et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/37059508/)

<a id="topic-2.2.2.1.6-11"></a>

###### Gefurulimab: FDA-labeled mechanism, pivotal trial responder rates, and adverse reactions

> “Gefurulimab-gaks binding to C5 inhibits its cleavage to C5a and C5b thus preventing the formation and deposition of membrane attack complex (MAC or C5b-9) at the neuromuscular junction.”
> “Patients were randomized 1:1 to either receive KLYGEFA (n=131) or placebo (n=129) for 26 weeks.”
> “The proportion of MG-ADL responders with at least a 3-point improvement at Week 26 was greater for KLYGEFA (65.5%) compared to placebo (52.2%), p = 0.037. The proportion of QMG responders with at least a 5-point improvement at Week 26 was greater for KLYGEFA (46.3%) compared to placebo (25.2%), p = 0.002.”
> “The most common adverse reactions in the gMG placebo-controlled clinical study (at least 10%) were injection site reactions.”

Source: [Klygefa prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/761488s000lbl.pdf)

<a id="topic-2.2.2.1.6-12"></a>

###### Gefurulimab: PREVAIL phase 3 trial, 26 weeks

> “This randomized clinical trial, PREVAIL, was a phase 3, double-blind, placebo-controlled study conducted at 113 sites in 20 countries.”
> “Of 405 patients screened, 145 were excluded; 260 met eligibility criteria and were randomized (gefurulimab, n = 131; placebo, n = 129); 249 patients completed the 26-week randomized controlled treatment period.”
> “Least-squares mean change from baseline at week 26 for MG-ADL and QMG total scores for gefurulimab vs placebo were −4.2 vs −2.6 (treatment difference, −1.6; 95% CI, −2.4 to −0.8; P < .001) and −4.5 vs −2.4 (treatment difference, −2.1; 95% CI, −3.1 to −1.1; P < .001), respectively.”
> “The incidence of adverse events (AEs) was similar between groups. Most common treatment-emergent AEs with gefurulimab were injection site reactions, headache, back pain, and nasopharyngitis. No meningococcal infections were reported.”

Source: [Gwathmey et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13409125/)

<a id="topic-2.2.2.1.6-13"></a>

###### Complement C5 inhibitor initiation, monotherapy, and response assessment: German-Austrian expert recommendations

> “Recommendation (consensus): Add‐on therapy with C5‐I should be considered for patients with (highly) active gMG (including therapy‐refractory disease) who are positive for AChR autoantibodies.”
> “Recommendation (consensus): The use of C5‐I as monotherapy should be considered only in exceptional cases, for example, when standard immunotherapies are ineffective, associated with intolerable AEs, or contraindicated, including in the context of chronic infection or malignancy.”
> “Recommendation (strong consensus): Treatment response should be assessed after 12 weeks of C5‐I therapy, as clinical response or non‐response can usually be determined by this time and used to guide further treatment planning.”

Source: [Meisel et al. (2026b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13559022/)

<a id="heading-2.2.2.1.7"></a>

###### 2.2.2.1.7 Neonatal Fc Receptor Blockers

<a id="topic-2.2.2.1.7-1"></a>

###### Mechanism, onset, and comparative effect of FcRn blockers: Nordic guidance

> “Monoclonal antibodies directed at the FcRn receptor's binding site for IgG block recycling and lead to a 60%–70% reduction in circulating IgG.”
> “The treatment can be tailored according to the disease state; new treatment cycles can be administered with signs of symptom worsening or according to a fixed schedule.”
> “The number of treatment responders and the magnitude of the treatment response for FcRn blockers and complement inhibitors seem to be similar. No prospective and controlled head‐to‐head studies have been undertaken.”

Source: [Gilhus et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11236053/)

<a id="topic-2.2.2.1.7-2"></a>

###### Efgartigimod intravenous: FDA-labeled indication, dosing, and pivotal trials

> “VYVGART is indicated for the treatment of adult patients with generalized myasthenia gravis (gMG).”
> “The recommended dosage of VYVGART is 10 mg/kg administered as an intravenous infusion over one hour once weekly for 4 weeks.”
> “A statistically significant difference favoring VYVGART was observed in the MG-ADL responder rate during the first treatment cycle (67.7% in the VYVGART-treated group vs 29.7% in the placebo- treated group [p <0.0001]).”
> “A statistically significant difference favoring VYVGART was observed (LS mean difference [95% CI] = - 1.46 [-2.50 to -0.41]; p-value = 0.0068).”

Source: [Vyvgart prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/761195s016lbl.pdf)

<a id="topic-2.2.2.1.7-3"></a>

###### Efgartigimod alfa and hyaluronidase subcutaneous: FDA-labeled indication and dosing

> “VYVGART HYTRULO is indicated for the treatment of adult patients with: • generalized myasthenia gravis (gMG)”
> “The recommended dosage of VYVGART HYTRULO prefilled syringe is 1,000 mg / 10,000 units (1,000 mg efgartigimod alfa and 10,000 units hyaluronidase) administered subcutaneously over approximately 20 seconds to 30 seconds in cycles of once weekly injections for 4 weeks.”
> “VYVGART HYTRULO prefilled syringe may be administered by patients and/or caregivers after proper instruction in subcutaneous injection technique”
> “In Study 3, VYVGART HYTRULO demonstrated a comparable pharmacodynamic effect as compared to the efgartigimod alfa-fcab intravenous formulation, which established the efficacy of VYVGART HYTRULO”

Source: [Vyvgart Hytrulo prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/761304s018lbl.pdf)

<a id="topic-2.2.2.1.7-4"></a>

###### Rozanolixizumab: FDA-labeled indication, dosing, and pivotal trial

> “RYSTIGGO (rozanolixizumab-noli) is a neonatal Fc receptor blocker indicated for the treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) or anti- muscle-specific tyrosine kinase (MuSK) antibody positive.”
> “Administer the recommended dosage as a subcutaneous infusion using an infusion pump at a rate of up to 20 mL/hour once weekly for 6 weeks.”
> “A statistically significant difference favoring RYSTIGGO was observed in the MG-ADL total score change from baseline [-3.4 points in RYSTIGGO-treated group at either dose vs -0.8 points in the placebo-treated group (p<0.001)].”

Source: [Rystiggo prescribing information (2025)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/761286s007lbl.pdf)

<a id="topic-2.2.2.1.7-5"></a>

###### Nipocalimab: FDA-labeled indication, dosing, and pivotal trial

> “generalized myasthenia gravis (gMG) in adult and pediatric patients 12 years of age and older who are anti-acetylcholine receptor (AChR) or anti- muscle-specific tyrosine kinase (MuSK) antibody positive.”
> “30 mg/kg administered once via intravenous infusion over at least 30 minutes. Two weeks after the initial dose administer a maintenance dose of 15 mg/kg via intravenous infusion over at least 15 minutes. Continue the maintenance dose every two weeks thereafter.”
> “In gMG Study 1, a total of 196 patients were randomized 1:1 to receive IMAAVY (n=98) or placebo (n=98).”
> “Primary Endpoint MG-ADL Total Score1 -4.7 (0.33) -3.3 (0.34) -1.5 (-2.4, -0.5) 0.002”

Source: [Imaavy prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/761430s002lbl.pdf)

<a id="topic-2.2.2.1.7-6"></a>

###### Incomplete response to FcRn inhibition

> “Trials of efgartigimod and rozanolixizumab in MG reported a subset of patients who responded poorly despite a reduction in circulating antibodies.”

Source: [Kaminski et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11178544/)

<a id="topic-2.2.2.1.7-7"></a>

###### Efgartigimod intravenous: ADAPT phase 3 trial, AChR antibody-positive modified intention-to-treat population, first treatment cycle

> “The primary endpoint was proportion of acetylcholine receptor antibody-positive patients who were MG-ADL responders (≥2-point MG-ADL improvement sustained for ≥4 weeks) in the first treatment cycle.”
> “Between Sept 5, 2018, and Nov 26, 2019, 167 patients (84 in the efgartigimod group and 83 in the placebo group) were enrolled, randomly assigned, and treated. 129 (77%) were acetylcholine receptor antibody-positive. Of these patients, more of those in the efgartigimod group were MG-ADL responders (44 [68%] of 65) in cycle 1 than in the placebo group (19 [30%] of 64), with an odds ratio of 4·95 (95% CI 2·21-11·53, p<0·0001).”
> “Four (5%) efgartigimod-treated patients and seven (8%) patients in the placebo group had a serious adverse event.”

Source: [Howard et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/34146511/)

<a id="topic-2.2.2.1.7-8"></a>

###### Efgartigimod alfa and hyaluronidase subcutaneous: ADAPT-SC noninferiority trial, total IgG reduction at week 4

> “The ADAPT-SC primary endpoint was met. The LSM estimate of percentage change from baseline in total IgG level at week 4 was −66.4% for the efgartigimod PH20 SC arm vs −62.2% for the efgartigimod IV arm (Table 2), giving a LSM difference of −4.2% (95% CI, −7.73 to −0.66).”
> “Analysis of AChR-Ab+ participants in the efgartigimod PH20 SC and efgartigimod IV arms demonstrated similar percentages of MG-ADL responders (efgartigimod PH20 SC: 71.1%; efgartigimod IV: 71.7%)”

Source: [Howard et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11579873/)

<a id="topic-2.2.2.1.7-9"></a>

###### Rozanolixizumab: MycarinG phase 3 trial, intention-to-treat population, day 43

> “Between June 3, 2019, and June 30, 2021, 300 patients were assessed for eligibility, of whom 200 were enrolled. 66 (33%) were randomly assigned to rozanolixizumab 7 mg/kg, 67 (34%) to rozanolixizumab 10 mg/kg, and 67 (34%) to placebo.”
> “Reductions in MG-ADL score from baseline to day 43 were greater in the rozanolixizumab 7 mg/kg group (least-squares mean change -3·37 [SE 0·49]) and in the rozanolixizumab 10 mg/kg group (-3·40 [0·49]) than with placebo (-0·78 [0·49]; for 7 mg/kg, least-squares mean difference -2·59 [95% CI -4·09 to -1·25], p<0·0001; for 10 mg/kg, -2·62 [-3·99 to -1·16], p<0·0001).”
> “The most frequent TEAEs were headache (29 [45%] patients in the rozanolixizumab 7 mg/kg group, 26 [38%] in the rozanolixizumab 10 mg/kg group, and 13 [19%] in the placebo group), diarrhoea (16 [25%], 11 [16%], and nine [13%]), and pyrexia (eight [13%], 14 [20%], and one [1%]).”

Source: [Bril et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/37059507/)

<a id="topic-2.2.2.1.7-10"></a>

###### Nipocalimab: Vivacity-MG3 phase 3 trial, antibody-positive intention-to-treat population, weeks 22 to 24

> “Between July 15, 2021, and Nov 17, 2023, 199 patients were enrolled, and 196 patients received study drug (98 in the nipocalimab group and 98 in the placebo group); of these, 153 (77 in the nipocalimab group and 76 in the placebo group) were antibody-positive.”
> “The least-squares mean change in MG-ADL score from baseline to weeks 22, 23, and 24 was -4·70 (SE 0·329) in the nipocalimab group versus -3·25 (0·335) in the placebo group (difference -1·45 [95% CI -2·38 to -0·52]; p=0·0024).”
> “Serious adverse events were reported for nine (9%) of 98 patients in the nipocalimab group and 14 (14%) of 98 patients in the placebo group, three of which had a fatal outcome (nipocalimab: myasthenic crisis; placebo: cardiac arrest and myocardial infarction).”

Source: [Antozzi et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/39862879/)

<a id="topic-2.2.2.1.7-11"></a>

###### FcRn inhibitor initiation, cycle timing, and IgG monitoring: German-Austrian expert recommendations

> “Recommendation (strong consensus): Add‐on therapy with FcRn‐I should be considered for patients with (highly) active gMG (including therapy‐refractory disease) who are positive for AChR‐ and MuSK‐autoantibodies.”
> “Recommendation (strong consensus): Timing of a new FcRn‐I cycle should be individualised.”
> “Recommendation (strong consensus): FcRn‐I therapy should be accompanied by monitoring of infections and IgG levels, particularly before initiation and, if needed, at the beginning and end of individual treatment cycles depending on the values obtained.”

Source: [Meisel et al. (2026b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13559022/)

<a id="heading-2.2.2.1.8"></a>

###### 2.2.2.1.8 B-cell Depleting Antibodies

<a id="topic-2.2.2.1.8-1"></a>

###### Rituximab in MuSK and refractory AChR antibody-positive disease: 2020 consensus update

> “A phase II RCT of RTX (Beat-MG) enrolled 52 patients with generalized nonthymomatous AChR-Ab+ MG on a stable regimen of prednisone for 4 weeks or prednisone plus another IS agent for 6 months. 27 Two cycles of RTX 6 months apart were compared to placebo with the primary outcome being a steroid-sparing effect (≥75% reduction in mean daily prednisone requirements in the 4 weeks before week 52 compared with the 4-week period before randomization). The study was designed to assess futility (nonsuperiority). Preliminary results reported that the area under the curve for prednisone was not significantly different between RTX and placebo groups, with 60% on RTX and 56% on placebo achieving the primary outcome.”
> “Rituximab should be considered as an early therapeutic option in patients with MuSK-Ab+ MG who have an unsatisfactory response to initial immunotherapy (median 9, range 4–9). The efficacy of RTX in refractory AChR-Ab+ MG is uncertain. It is an option if patients fail or do not tolerate other IS agents (median 8, range 4–9)”

Source: [Narayanaswami et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7884987/)

<a id="topic-2.2.2.1.8-2"></a>

###### Rituximab as a first-line option in new-onset disease: Nordic guidance

> “In RINOMAX, 47 Swedish patients with new‐onset generalized MG (96% AChR‐antibody MG) were randomized to receive 500 mg rituximab or placebo as an add‐on to the standard of care. [ 43 ] Minimal disease manifestations at 16 weeks, defined as a Quantitative Myasthenia Gravis (QMG) score of 4 or less with a prednisolone dose ≤10 mg and no rescue treatment, was the primary endpoint. This was met by 71% in the active arm and 29% in the placebo group ( p = 0.007).”
> “Rituximab should be considered a first‐line immunosuppressive drug in newly onset disease, as an alternative to steroids and azathioprine. Rituximab should be considered for treatment‐refractory symptoms, although evidence for its effectiveness is weaker than in newly onset disease.”

Source: [Gilhus et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11236053/)

<a id="topic-2.2.2.1.8-3"></a>

###### Early rituximab: British guideline update

> “Randomised controlled trial evidence now supports early use of rituximab (within 1 year of generalised disease onset), although the evidence is less robust, but still likely to be useful, in established treatment-refractory MG.”

Source: [Jacob et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/40940171/)

<a id="topic-2.2.2.1.8-4"></a>

###### Randomized trials of rituximab in myasthenia gravis: two trials and 99 participants

> “We included two RCTs with a total of 99 participants.”
> “Rituximab's effects on symptom severity and functional ability in the long‐term are uncertain. The evidence suggests that rituximab results in little to no difference in its steroid‐sparing effect; however, it probably results in a large reduction in relapse requiring rescue therapy over nine months, based on results from two studies.”

Source: [Dodd et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12224225/)

<a id="topic-2.2.2.1.8-5"></a>

###### Inebilizumab: FDA-labeled indication, dosing, and pivotal trial

> “UPLIZNA is indicated for the treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) or anti-muscle specific tyrosine kinase (MuSK) antibody positive.”
> “Initial dose: 300 mg intravenous infusion followed 2 weeks later by a second 300 mg intravenous infusion. • Subsequent doses (starting 6 months from the first infusion): single 300 mg intravenous infusion every 6 months.”
> “In Study 3, a total of 238 patients with gMG were randomized in a 1:1 ratio to receive UPLIZNA or placebo.”
> “A statistically significant difference favoring UPLIZNA was observed in the mean change from baseline in MG-ADL total score (−4.2 points in the UPLIZNA-treated group compared to −2.2 points for placebo, difference of −1.9, 95% CI: −2.9, −1.0; p-value < 0.0001).”

Source: [Uplizna prescribing information (2025)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/761142s004lbl.pdf)

<a id="topic-2.2.2.1.8-6"></a>

###### Inebilizumab: MINT phase 3 trial with glucocorticoid taper, week 26

> “Glucocorticoid therapy was tapered, starting at week 4, to a target of 5 mg per day by week 24.”
> “A total of 238 participants underwent randomization (119 per group). Participants who received inebilizumab had a greater reduction in the MG-ADL score than those who received placebo (least-squares mean change, -4.2 vs. -2.2; adjusted difference, -1.9; 95% confidence interval [CI], -2.9 to -1.0; P<0.001) at week 26.”
> “Participants who received inebilizumab had a greater reduction in the QMG score than those who received placebo (least-squares mean change, -4.8 vs. -2.3; adjusted difference, -2.5; 95% CI, -3.8 to -1.2; P<0.001).”
> “Inebilizumab was not associated with a higher incidence of serious adverse events.”

Source: [Nowak et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/40202593/)

<a id="heading-2.2.2.1.9"></a>

###### 2.2.2.1.9 Limitations of Current Therapies

<a id="topic-2.2.2.1.9-1"></a>

###### Summary

- Refractory disease: Refractory MG has been defined as a post-intervention status unchanged or worse after corticosteroids and at least 2 other immunosuppressive agents used in adequate doses for an adequate duration, with persistent symptoms or side effects that limit functioning. An estimated 10% to 20% of patients continue to have long-standing moderate or severe weakness after treatment with at least two different immunosuppressive drugs at high doses, and about 20,000 patients with generalized MG are estimated to be intolerant of or to have an inadequate response to conventional treatment.
- Incomplete response to targeted biologics: Upward of thirty percent of patients do not benefit from complement inhibition. No head-to-head prospective studies have compared the novel therapies; in one analysis, FcRn inhibitors carried greater odds of treatment-related adverse events than placebo (odds ratio 2.20 [1.52-3.38]), while C5 inhibitors and CD19+ B-cell depletion showed odds comparable to placebo.
- Glucocorticoid toxicity: Incident glucocorticoid toxicities occurred in 61.9% of patients with any glucocorticoid use and 52.3% of those without; common acute toxicities included nausea and vomiting, pneumonia, fungal infections, sepsis, and urinary tract infection, and chronic toxicities included dyslipidemia, sleep disturbances, obesity, cardiac arrhythmias, and hypertension. Toxicities and costs tended to increase with increasing glucocorticoid use.
- Infection risk and REMS: Eculizumab, a complement inhibitor, increases the risk of serious infections caused by Neisseria meningitidis, meningococcal vaccination is required at least 2 weeks before the first dose of eculizumab, and eculizumab and zilucoplan are available only through restricted REMS programs. One case of meningococcal meningitis occurred despite vaccination in the eculizumab open-label extension. In Study 1 of efgartigimod, urinary tract infections occurred in 10% of efgartigimod-treated and 5% of placebo-treated patients, and respiratory tract infections in 33% and 29%.
- Administration burden: Reported limitations include the need for meningococcal vaccination and regular intravenous or subcutaneous injections; eculizumab is infused intravenously over 35 minutes in adults, and the safety of starting rozanolixizumab cycles sooner than 63 days after the start of the previous cycle has not been established. Current targeted therapies generally require lifelong repeated administration and “rarely induce durable treatment-free remission”.
- Cost: In one cost-effectiveness analysis, eculizumab at an estimated annual cost of $653,100 had an incremental cost-effectiveness ratio of $5,210,000 per QALY/evLYG, and efgartigimod at a placeholder price of $418,400 had $2,076,000 per QALY/evLYG. Very high drug costs have limited access to complement and FcRn inhibitors in most countries. Annual all-cause costs were $76,381 among patients with any glucocorticoid use and $35,309 among those without.

Source: [Sanders et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4977114/); [Gilhus et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11236053/); [Tice et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10373007/); [Kaminski et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11178544/); [McLaren et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/42467874/); [Silvestri et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13008238/); [Soliris prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/125166s454lbl.pdf); [Zilbrysq prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/216834s015lbl.pdf); [Narayanaswami et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7884987/); [Vyvgart prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/761195s016lbl.pdf); [Rystiggo prescribing information (2025)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/761286s007lbl.pdf); [Hegelmaier et al. (2026b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13589498/)

<a id="topic-2.2.2.1.9-2"></a>

###### Refractory disease despite conventional immunosuppression

> “Definition of refractory MG. PIS3 is unchanged or worse after corticosteroids and at least 2 other IS agents, used in adequate doses for an adequate duration, with persistent symptoms or side effects that limit functioning, as defined by patient and physician.”

Source: [Sanders et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4977114/)

> “Currently, it is estimated that about 20,000 patients with generalized MG are intolerant or have an inadequate response to conventional treatment options.”

Source: [Tice et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10373007/)

<a id="topic-2.2.2.1.9-3"></a>

###### Incomplete response to targeted biologics

> “There remain upward of thirty percent of patients who do not benefit from complement inhibition, which demonstrates the importance of other mechanisms of autoantibody action.”
> “There is a pressing need for such advancements, especially considering the proliferation of multiple costly treatment options with substantial minorities of patients showing a poor response.”

Source: [Kaminski et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11178544/)

<a id="topic-2.2.2.1.9-4"></a>

###### Glucocorticoid toxicity and associated costs

> “Incident GC toxicities were higher in patients with any GC use than those without (61.9% vs 52.3%). Common acute toxicities included nausea and vomiting, pneumonia, fungal infections, sepsis, and urinary tract infection; chronic toxicities were dyslipidemia, sleep disturbances, obesity, cardiac arrhythmias, and hypertension.”

Source: [Silvestri et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13008238/)

> “although prednisone is still the most consistently effective drug for MG, its side effect burden and that of immunosuppressive as well as the poor response in a large minority”

Source: [Kaminski et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11178544/)

<a id="topic-2.2.2.1.9-5"></a>

###### Meningococcal infection risk, vaccination, and REMS with complement C5 inhibitors

> “SOLIRIS, a complement inhibitor, increases the risk of serious infections caused by Neisseria meningitidis [see Warnings and Precautions (5.1)]. Life-threatening and fatal meningococcal infections have occurred in patients treated with complement inhibitors. These infections may become rapidly life-threatening or fatal if not recognized and treated early.”
> “Complete or update vaccination for meningococcal bacteria (for serogroups A, C, W, Y, and B) at least 2 weeks prior to the first dose of SOLIRIS”
> “Because of the risk of serious meningococcal infections, SOLIRIS is available only through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS) called ULTOMIRIS and SOLIRIS REMS”

Source: [Soliris prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/125166s454lbl.pdf)

> “ZILBRYSQ is available only through a restricted program called ZILBRYSQ REMS.”

Source: [Zilbrysq prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/216834s015lbl.pdf)

> “One case of meningococcal meningitis occurred, despite vaccination in the OLE and the patient was successfully treated.”
> “Vaccination against Neisseria meningitidis (both meningococcal conjugate Men ACWY and serogroup B or MenB) is required at least 2 weeks before starting treatment with eculizumab.”

Source: [Narayanaswami et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7884987/)

<a id="topic-2.2.2.1.9-6"></a>

###### Infection risk with FcRn blockade

> “VYVGART may increase the risk of infection. The most common infections observed in Study 1 were urinary tract infection (10% of VYVGART-treated patients compared to 5% of placebo-treated patients) and respiratory tract infections (33% of VYVGART-treated patients compared to 29% of placebo-treated patients)”

Source: [Vyvgart prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/761195s016lbl.pdf)

<a id="topic-2.2.2.1.9-7"></a>

###### Administration burden: infusion schedules and repeated injections

> “Limitations include the need for meningococcal vaccination before starting treatment, pneumococcal vaccination which is recommended, and regular intravenous or subcutaneous injections.”

Source: [Gilhus et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11236053/)

> “Administer the SOLIRIS admixture by intravenous infusion over 35 minutes in adults and 1 to 4 hours in pediatric patients”

Source: [Soliris prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/125166s454lbl.pdf)

> “The safety of initiating subsequent cycles sooner than 63 days from the start of the previous treatment cycle has not been established.”

Source: [Rystiggo prescribing information (2025)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/761286s007lbl.pdf)

<a id="topic-2.2.2.1.9-8"></a>

###### Cost and cost-effectiveness of targeted biologics

> “For eculizumab, with an estimated annual cost of $653,100, the incremental cost-effectiveness ratio was $5,210,000 per QALY/evLYG (Table 2). For analyses of efgartigimod, we used a placeholder price of $418,400, which is the midpoint of the potential price range cited by the manufacturer.11 At this estimated price, efgartigimod has an the incremental cost per QALY/evLYG of $2,076,000 (Table 2).”
> “The price for eculizumab is extremely high and is distinctive for the amount by which it exceeds the price needed to reach traditional cost-effectiveness thresholds in the United States.”

Source: [Tice et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10373007/)

> “Very high drug costs have limited the accessibility to treatment in most countries.”
> “In common with complement inhibitors, the availability of FcRn blockers is limited by high drug costs.”

Source: [Gilhus et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11236053/)

<a id="topic-2.2.2.1.9-9"></a>

###### No head-to-head trials and higher odds of treatment-related adverse events with FcRn inhibitors

> “In the past decade, several novel therapies have shown promise in treating generalized myasthenia gravis (MG); however, no head-to-head prospective studies have compared their efficacy and safety.”
> “Patients treated with FcRn inhibitors had greater odds of treatment-related adverse events (odds ratio 2.20 [1.52-3.38]) compared with the placebo group, while C5i and CD19+ BCDT showed odds comparable to placebo.”

Source: [McLaren et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/42467874/)

<a id="topic-2.2.2.1.9-10"></a>

###### Lifelong repeated administration of targeted therapies

> “Despite recent advances, current targeted therapies generally require lifelong repeated administration and rarely induce durable treatment-free remission.”

Source: [Hegelmaier et al. (2026b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13589498/)

<a id="heading-2.2.2.2"></a>

##### 2.2.2.2 Place in Treatment, Anticipated Use, and Care Setting

<a id="topic-2.2.2.2-1"></a>

###### Summary

- Guideline positioning of targeted biologics: Guidance states that clinicians should seek to initiate available targeted therapies in patients with gMG who have active symptoms and for whom conventional therapy does not achieve symptom control within 6 to 12 months or results in excessive treatment-related burden, with use as initial treatment driven by clinician judgment. Complement and FcRn inhibitors are recommended as second- or third-line treatment in severe MG exacerbations and crisis, and their roles are being established especially in patients unresponsive to conventional therapy. Expert recommendations state that an interclass switch should be considered for inefficacy, intolerable side effects, or patient preferences regarding type and frequency of administration, and that a switch to IVIg interval therapy should be considered when targeted immunotherapies fail.
- Intended population and setting for Descartes-08: The phase 3 AURORA trial enrolls adults with acetylcholine receptor autoantibody-positive generalized MG and administers six once-weekly outpatient infusions without preconditioning chemotherapy. The company states that the current standard of care consists of chronic steroids and other immunosuppressants and that complement and FcRn inhibitors are typically administered continually, estimates that MG affects over 106,000 patients in the U.S., and describes Descartes-08 as the only CAR-T in autoimmune disease it is aware of that is designed for outpatient administration without preconditioning chemotherapy. The company states that conventional DNA cell therapies are administered under close monitoring in an inpatient setting. Investigators of an earlier Descartes-08 study reported the feasibility of preparing the cells for patients on immunosuppressive therapy, using them without lymphodepletion chemotherapy, and administering them in the outpatient setting with minimal post-infusion monitoring, and a later publication describes a “biologic-like approach that involves an initial leukapheresis”. An investigator quoted by the company described outpatient retreatment without lymphodepleting chemotherapy as a potential option for patients who have cycled through multiple therapies.
- Recommendations on cellular therapy: EBMT recommendations state that cellular therapy in autoimmune diseases should be performed within a clinical trial whenever possible, at expert centres with JACIE accreditation for immune effector cell administration, that the need for and dose of lymphodepletion are not established, and that repeated dosing of BCMA CAR-T has been efficacious in MG without lymphodepletion. A 2026 article on CAR-T therapy in autoimmune disease states that current neurological evidence is limited to small early-phase studies and case reports, with one placebo-controlled trial (generalised MG), and that CAR-T therapy should be considered experimental and delivered in specialised centres.
- Other CAR-T approaches in MG: In a study of anti-BCMA/CD19 bispecific CAR-T cells given as a single infusion after fludarabine and cyclophosphamide lymphodepletion, 18 participants were enrolled; grade 1 cytokine release syndrome occurred in 39%, and among 17 who completed follow-up, MG-ADL improved by −8.6 (95% CI −10.2 to −7.0) and QMG by −15.4 (−17.6 to −13.2) by day 180, and 14 (82%) achieved minimal manifestations. Three patients with treatment-resistant MG treated with anti-CD19 CAR-T cells (KYV-101) after cyclophosphamide and fludarabine lymphodepletion achieved sustained remission for at least 19 months, and BCMA-directed CAR-T cells in two patients (one AChR-IgG, one MuSK-IgG) produced clinical improvement over 18 months. KYV-101 is being compared with standard-of-care immunosuppressive therapy in the phase 2/3 KYSA-6 study, and CABA-201 is being evaluated with cyclophosphamide and fludarabine and, at escalating doses, without that preconditioning.
- REMS change for approved CAR-T therapies: The FDA eliminated the REMS for currently approved BCMA- and CD19-directed autologous CAR T cell immunotherapies, removing the requirements for specially certified dispensing sites with on-site, immediate access to tocilizumab. Labeling now calls for monitoring for at least two weeks, including daily monitoring for at least one week, remaining near a healthcare facility for at least two weeks, and avoiding driving for two weeks. In 58 patients with myeloma, lymphoma, or acute lymphoblastic leukemia who received CAR T-cell infusion as outpatients and were seen daily for the first 7 to 10 days, 17 (41%), 16 (38%), and 9 (21%) were admitted between days 0 to 3, 4 to 7, and 8 to 30.

Source: [Narayanaswami et al. (2026b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13352217/); [Gilhus et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11236053/); [Jacob et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/40940171/); [Meisel et al. (2026b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13559022/); [ClinicalTrials.gov NCT06799247](https://clinicaltrials.gov/study/NCT06799247); [Cartesian Therapeutics third quarter 2026 results (2026)](https://ir.cartesiantherapeutics.com/news-releases/news-release-details/cartesian-therapeutics-reports-third-quarter-2026-financial); [Cartesian Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1453687/000145368726000064/rnac-20251231.htm); [Cartesian Therapeutics K2 HealthVentures financing press release (2026)](https://ir.cartesiantherapeutics.com/news-releases/news-release-details/cartesian-therapeutics-secures-150-million-non-dilutive); [Granit et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10416207/); [Fedak et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13004674/); [Cartesian Therapeutics retreatment data press release (2026)](https://ir.cartesiantherapeutics.com/news-releases/news-release-details/cartesian-therapeutics-announces-additional-retreatment-data); [Greco et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10867419/); [Bradhurst et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13630046/); [Zhang et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12615342/); [Hegelmaier et al. (2026b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13589498/); [Tian et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11018773/); [ClinicalTrials.gov NCT06193889](https://clinicaltrials.gov/study/NCT06193889); [ClinicalTrials.gov NCT06359041](https://clinicaltrials.gov/study/NCT06359041); [FDA news release on CAR T cell REMS elimination (2025)](https://www.fda.gov/news-events/press-announcements/fda-eliminates-risk-evaluation-and-mitigation-strategies-rems-autologous-chimeric-antigen-receptor); [FDA safety communication on CAR T cell REMS elimination (2025)](https://www.fda.gov/vaccines-blood-biologics/safety-availability-biologics/fda-eliminates-risk-evaluation-and-mitigation-strategies-rems-autologous-chimeric-antigen-receptor); [Furqan et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11372811/)

<a id="topic-2.2.2.2-2"></a>

###### Company statement of unmet need with chronic immunosuppression and continually administered biologics

> “There are no known cures for MG and the current standard of care consists of chronic use of steroids and other immunosuppressants.”
> “These treatments must be administered continually and carry risks such as infection, osteoporosis, and metabolic diseases.”
> “Newer agents, such as those that block the complement pathway or inhibit FcRn, are typically administered continually.”

Source: [Cartesian Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1453687/000145368726000064/rnac-20251231.htm)

<a id="topic-2.2.2.2-3"></a>

###### Company estimate of the U.S. myasthenia gravis population and market opportunity

> “It is estimated to affect over 106,000 patients in the U.S.”

Source: [Cartesian Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1453687/000145368726000064/rnac-20251231.htm)

> “Current gMG market lacks disease modifying treatments creating the potential to access a $1B+ market opportunity for Descartes-08 in the US”
> “Significant unmet need remains given current treatment options, creating a potential $1B opportunity”

Source: [Cartesian Therapeutics corporate presentation, November 2026 (2026)](https://ir.cartesiantherapeutics.com/static-files/6ba3bfe0-f3be-4487-add3-b56dd535e456)

<a id="topic-2.2.2.2-4"></a>

###### Positioning as an outpatient CAR-T without preconditioning chemotherapy

> “Descartes-08 remains the only CAR-T in autoimmune disease that we are aware of that is designed for outpatient administration without preconditioning chemotherapy, and our prior data demonstrate deep and durable responses after a single course of therapy.”

Source: [Cartesian Therapeutics K2 HealthVentures financing press release (2026)](https://ir.cartesiantherapeutics.com/news-releases/news-release-details/cartesian-therapeutics-secures-150-million-non-dilutive)

> “We believe this profile has the potential to meaningfully change how MG is treated.”

Source: [Cartesian Therapeutics third quarter 2026 results (2026)](https://ir.cartesiantherapeutics.com/news-releases/news-release-details/cartesian-therapeutics-reports-third-quarter-2026-financial)

<a id="topic-2.2.2.2-5"></a>

###### Care setting compared with conventional DNA-based CAR-T cell therapy

> “Given these risks and requirements, conventional DNA cell therapies are administered under close monitoring in an inpatient setting, increasing their cost and limiting their reach to only the sickest patients.”

Source: [Cartesian Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1453687/000145368726000064/rnac-20251231.htm)

> “This study demonstrated the feasibility of preparing autologous RNA CAR T-cells (rCAR-T) for patients on immunosuppressive therapy, of using the cells without lymphodepletion chemotherapy, and of administering rCAR-T in the outpatient setting with minimal post-infusion monitoring due to the notable safety profile of the product.”
> “While DNA-based CAR T-cell therapies are also moving to the outpatient setting, they still require close post-infusion monitoring with daily clinic visits as well as reservation of hospital beds in case severe toxicities develop.”

Source: [Granit et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10416207/)

> “This set of features creates a biologic-like approach that involves an initial leukapheresis but is otherwise similar with respect to patient experience.”

Source: [Fedak et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13004674/)

<a id="topic-2.2.2.2-6"></a>

###### Investigator statement on use after multiple prior therapies

> “For patients who have already cycled through multiple therapies, the option to retreat a CAR-T cell therapy, in an outpatient setting and without lymphodepleting chemotherapy, represents an exciting potential advancement in the field of MG.”

Source: [Cartesian Therapeutics retreatment data press release (2026)](https://ir.cartesiantherapeutics.com/news-releases/news-release-details/cartesian-therapeutics-announces-additional-retreatment-data)

<a id="topic-2.2.2.2-7"></a>

###### Guideline positioning of complement and FcRn therapies

> “several clinical trials have been published for newer targeted therapies in MG, predominantly those that inhibit the complement and neonatal Fc gamma receptor pathways, the roles of which are being slowly established especially in patients unresponsive to conventional therapy.”

Source: [Jacob et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/40940171/)

> “Complement and FcRn inhibitors are recommended as second‐ or third‐line treatment in severe MG exacerbations and crisis.”

Source: [Gilhus et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11236053/)

<a id="topic-2.2.2.2-8"></a>

###### Targeted therapies after 6 to 12 months of conventional therapy without symptom control: 2026 international consensus

> “Clinicians should seek to initiate available targeted therapies* in patients with gMG who have active symptoms and for whom conventional therapy† does not achieve symptom control within 6–12 months or results in excessive treatment-related burden. Use of available targeted therapies as initial treatment (together with standard therapy where indicated) should be driven by clinician judgment.”
> “Clinicians should refer a patient with MG to (or comanage with) a specialist with expertise in MG management if there is no sustained clinical improvement within 3–6 months of treatment initiation.”

Source: [Narayanaswami et al. (2026b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13352217/)

<a id="topic-2.2.2.2-9"></a>

###### Switching after inadequate response to targeted therapies: German-Austrian expert recommendations

> “Recommendation (consensus): An interclass switch should be considered if therapy is ineffective at the appropriate dosage and duration, if intolerable side effects occur, or for patient preferences regarding type and frequency of administration.”
> “Recommendation (strong consensus): A switch to IVIg interval therapy should be considered in cases where targeted immunotherapies fail to provide adequate clinical efficacy.”
> “Recommendation (strong consensus): Patients who are clinically stable on IVIg or SCIg interval therapy without intolerable side effects should not be switched to C5‐I or FcRn‐I.”

Source: [Meisel et al. (2026b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13559022/)

<a id="topic-2.2.2.2-10"></a>

###### Cellular therapy for severe refractory autoimmune disease within clinical trials at accredited centers: EBMT recommendations

> “Whenever possible, CT in ADs should be performed in the context of a clinical trial with well-defined end points and eligibility criteria in accordance with GCPs and appropriate regulatory requirements.”
> “Such expert centres should have a JACIE accreditation for Immune Effector Cells (IEC) administration and established multidisciplinary team meetings and/or similar processes for CT as for HCT, involving AD specialists and haematologists working in tandem in the same place to support thorough assessment, treatment and follow-up of these high-risk fragile patients.”

Source: [Greco et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10867419/)

<a id="topic-2.2.2.2-11"></a>

###### Lymphodepletion requirement for CAR T-cell therapy in autoimmune disease not established: EBMT recommendations

> “Of note, repeated dosing of BCMA CART has been efficacious in MG without LD”
> “If and at what dose LD is needed for effective CART in AD is currently not established. As such, LD follows oncological guidelines.”

Source: [Greco et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10867419/)

<a id="topic-2.2.2.2-12"></a>

###### CAR T-cell therapy in autoimmune neurological disease: experimental status, specialized centers, and complications

> “Possible complications from CAR-T cells (box 1) are extensive and limit the use of these therapies to patients with ‘severe’ or ‘refractory’ autoimmune disease that is not otherwise responsive to existing treatment paradigms.”
> “Current neurological evidence is limited to small early-phase studies and case reports, with only one placebo-controlled trial (generalised myasthenia gravis).”
> “At present, CAR-T therapy should be considered experimental and delivered in specialised centres, pending longer term safety and durability data.”

Source: [Bradhurst et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13630046/)

<a id="topic-2.2.2.2-13"></a>

###### BCMA/CD19 bispecific CAR T-cell therapy after fludarabine and cyclophosphamide lymphodepletion: single-arm phase 1 trial, 18 participants with refractory gMG

> “Participants received lymphodepleting chemotherapy with fludarabine (30 mg/m2/day) and cyclophosphamide (300 mg/m2/day) for three consecutive days (days −5 to −3).”
> “Between May 3, 2023, and June 19, 2024, 18 patients were enrolled and received apheresis and a single CAR T cell infusion.”
> “The anti-BCMA/CD19 bispecific CAR T cells were generally safe, with no dose-limiting toxicities, no immune effector cell-associated neurotoxicity syndrome, and only grade 1 cytokine release syndrome (39% of patients). The most common grade 3 or worse adverse events within 28 days were hematological toxicities, including three leukopenia, three neutropenia, one anaemia, and one thrombocytopenia.”
> “17 participants completed follow-up. Clinical improvements by day 180 were −8.6 (95% CI −10.2 to −7.0) for MG-ADL score and −15.4 (−17.6 to −13.2) for QMG score. 14 participants (82%) achieved minimal manifestations, 15 (88%) stopped glucocorticoids, all stopped non-steroidal immunosuppressants, and eight (47%) had anti-acetylcholine receptor antibody negative seroconversion.”

Source: [Zhang et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12615342/)

<a id="topic-2.2.2.2-14"></a>

###### CD19 CAR T-cell therapy after lymphodepletion: case series of 3 participants with refractory AChR antibody-positive MG

> “We report on three patients with severe, treatment-resistant MG, including one patient with concomitant rheumatoid arthritis, treated with autologous, fully human anti-CD19 CAR T cells. All three patients achieve rapid, sustained clinical MG remission for at least 19 months, allowing discontinuation of MG-specific immunotherapies and substantial improvement in clinical and functional outcomes despite persistent detectable anti-AChR autoantibody titers.”
> “A second-generation investigational CAR T cell product (KYV-101, Kyverna Therapeutics) was used.”
> “Instead, it may at least partially be attributed to the effects of lymphodepletion (cyclophosphamide and fludarabine), which from approximately day −6 before CAR T cell infusion markedly reduces circulating immune effector cells capable of mediating antibody-dependent inflammation.”

Source: [Hegelmaier et al. (2026b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13589498/)

<a id="topic-2.2.2.2-15"></a>

###### BCMA CAR T-cell therapy after lymphodepletion: 2 participants with refractory AChR or MuSK antibody-positive MG

> “We reported here chimeric antigen receptor (CAR) T cells targeting BCMA in two patients with highly relapsed and refractory myasthenia gravis (one with AChR-IgG, and one with MuSk-IgG). Both patients exhibited favorable safety profiles and persistent clinical improvements over 18 months.”
> “Participants stopped all immunosuppressants and steroid one to three days before treatment initiation.”

Source: [Tian et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11018773/)

<a id="topic-2.2.2.2-16"></a>

###### CD19 CAR T-cell therapy in concomitant MG and Lambert-Eaton myasthenic syndrome: 2 participants

> “Two women diagnosed with concomitant MG/LEMS experienced severe, increasing disease activity despite multiple immunotherapies.”
> “Within 2 months, both patients returned to everyday life, from wheelchair dependency to bicycling and mountain hiking, and remain stable at 6 and 4 months post-CAR T cell infusion, respectively.”

Source: [Motte et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/38697115/)

<a id="topic-2.2.2.2-17"></a>

###### Ongoing CD19 CAR T-cell trials in gMG with and without lymphodepletion: KYSA-6 and RESET-MG

> “KYSA-6: A Phase 2/3, Open-Label, Randomized, Controlled, Multicenter Study of KYV-101, an Autologous Fully Human Anti-CD19 Chimeric Antigen Receptor T-cell (CD19 CAR T) Therapy, Versus Ongoing Standard-Of-Care Immunosuppressive Therapy in Patients With Generalized Myasthenia Gravis”

Source: [ClinicalTrials.gov NCT06193889](https://clinicaltrials.gov/study/NCT06193889)

> “A single dose of CABA-201 in combination with cyclophosphamide (CY) and fludarabine (FLU) will be evaluated. In addition, escalating doses of CABA-201 will be evaluated in patients without CY and FLU preconditioning.”

Source: [ClinicalTrials.gov NCT06359041](https://clinicaltrials.gov/study/NCT06359041)

<a id="topic-2.2.2.2-18"></a>

###### FDA elimination of REMS for approved autologous CAR T-cell therapies, June 2025

> “The U.S. Food and Drug Administration announced today that it has eliminated the Risk Evaluation and Mitigation Strategies (REMS) for currently approved BCMA- and CD19-directed autologous chimeric antigen receptor CAR T cell immunotherapies.”
> “The elimination of REMS for the above products removes the requirements that hospitals and their associated clinics that dispense products must be specially certified and have on-site, immediate access to tocilizumab.”

Source: [FDA news release on CAR T cell REMS elimination (2025)](https://www.fda.gov/news-events/press-announcements/fda-eliminates-risk-evaluation-and-mitigation-strategies-rems-autologous-chimeric-antigen-receptor)

> “Specifically, labeling update included revision to language to monitor patients for at least two weeks including daily monitoring for at least one week; to instruct patients to remain within proximity of a healthcare facility for at least two weeks; and to advise patients to avoid driving for two weeks following product administration”
> “FDA expects that the REMS elimination, and these labeling updates, will help improve access to these products, particularly for patients who live in rural areas, while ensuring safe and effective administration to patients who need them.”

Source: [FDA safety communication on CAR T cell REMS elimination (2025)](https://www.fda.gov/vaccines-blood-biologics/safety-availability-biologics/fda-eliminates-risk-evaluation-and-mitigation-strategies-rems-autologous-chimeric-antigen-receptor)

<a id="topic-2.2.2.2-19"></a>

###### Outpatient administration of commercial CAR T-cell therapy in hematologic malignancies: 58 participants, 2022 to 2023

> “Patients were seen daily in the cancer center day hospital for the first 7 to 10 days and then twice weekly through day 30.”
> “Fifty-eight patients received outpatient CAR T-cell infusion (33 myeloma, 24 lymphoma, and 1 acute lymphoblastic leukemia). Of these, 17 (41%), 16 (38%), and 9 patients (21%) were admitted between days 0 to 3, 4 to 7, and 8 to 30 after CAR T-cell infusion, respectively.”
> “Hospitalization was prevented in 15 of 35 patients who received tocilizumab for CRS as an outpatient.”

Source: [Furqan et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11372811/)

Additional sources: [Haghikia et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/37977704/)

<a id="heading-2.2.2.3"></a>

##### 2.2.2.3 Heterogeneity of Treatment Effect

<a id="topic-2.2.2.3-1"></a>

###### Descartes-08: AChR antibody-positive subgroup, MGC response at month 3, mITT population (phase 2b)

> “Similar results were observed for the participants comprising the AChR autoantibody-positive population, with significantly more MGC responders in the Descartes-08 group than in the placebo group (63.6% versus 12.5%, P = 0.025815; Extended Data Table 1).”
> “The mean (s.d.) change from baseline in the MGC score at month 3 for those who were AChR autoantibody-positive was −5.0 (5.62) for the Descartes-08 group and 0.1 (4.85) for those treated with placebo.”
> “Minimum improvements in MGC and MG-ADL scores were higher for the Descartes-08 group than the placebo group at month 3 (Fig. 3), with 81.8% versus 37.5% of participants achieving a minimum of a 3-point improvement in the MGC score and 63.6% versus 25.0% of participants achieving a minimum of a 3-point reduction in the MG-ADL score.”

Source: [Vu et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13004676/)

> “The proportion of MGC score responders (≥5-point improvement) was significantly higher in the Descartes-08 AChR+ cohort vs placebo at Month 3: 63.6% vs 12.5% in placebo group (p=0.0258)”

Source: [Vu et al. (2026b)](https://www.cartesiantherapeutics.com/wp-content/uploads/260303_AChRP2B_Cartesian_MDA_oral-presentation_v4.0-Final.pdf)

<a id="topic-2.2.2.3-2"></a>

###### Descartes-08: AChR antibody-positive subgroup, MG-ADL change at month 3 and through month 12 (phase 2b)

> “There was a significant and clinically meaningful reduction in the mean (s.d.) MG-ADL score at month 3 for the Descartes-08 group compared to the placebo group (−3.4 (2.84) versus 0.6 (2.93), P = 0.0409) (Extended Data Fig. 1).”
> “This reduction in the MG-ADL score was maintained up to month 12 for those in the Descartes-08 group.”

Source: [Vu et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13004676/)

> “There was a significant and clinically meaningful reduction in mean [SD] MG-ADL score at Month 3 for the Descartes-08 AChR+ group versus placebo (-3.4 [2.8] vs -0.6 [2.9], p=0.0409)”

Source: [Vu et al. (2026b)](https://www.cartesiantherapeutics.com/wp-content/uploads/260303_AChRP2B_Cartesian_MDA_oral-presentation_v4.0-Final.pdf)

<a id="topic-2.2.2.3-3"></a>

###### Descartes-08: AChR antibody status as a marker of response (phase 2b)

> “Similar trends in MGC response were observed between the overall cohort and the AChR autoantibody-positive population.”
> “Together, these results confirm that, while anti-AChR antibody status is useful in classifying disease, its relevance as a marker to track progression or response to treatment is limited”

Source: [Vu et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13004676/)

> “In line with this limitation, anti-AChR antibody titer did not correlate with change in clinical disease, as measured by the Myasthenia Gravis Activities of Daily Living (MG-ADL) scale (n = 21) (Fig. 3l and Extended Data Table 2).”

Source: [Fedak et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13004674/)

<a id="topic-2.2.2.3-4"></a>

###### Descartes-08: biologic-naive versus biologic-exposed participants, post hoc analysis, mITT population (phase 2b)

> “A post hoc analysis was conducted to evaluate the magnitude of response to Descartes-08 in participants who were biologic-naive and those with prior biologic exposure.”
> “Participants with no prior exposure to complement inhibitors, FcRn inhibitors or CD19/CD20-targeting monoclonal antibodies (biologic-naive) demonstrated an improved response to Descartes-08 compared to those with prior biologic exposure, with 55.6% (n = 5/9) of participants achieving MSE by month 6, which was maintained through month 12.”
> “Additionally, the biologic-naive group had a greater proportion of MGC responders at month 3 compared to the group with prior biologic exposure (88.9% versus 33.3%).”
> “There were also notable reductions in MG severity scores from baseline to month 3 for the biologic-naive group versus those with prior biologic exposure (mean (s.d.) score: MGC −7.7 (5.24) versus 1.0 (6.96); MG-ADL −5.2 (3.27) versus −2.5 (3.08); QMG −5.0 (3.84) versus −2.2 (4.92)), with scores further improved by month 12 (MGC −11.0 (4.0), MG-ADL −7.1 (1.9), QMG −9.4 (2.6)) (Extended Data Table 5 and Extended Data Fig. 2).”
> “Notably, 100.0% of biologic-naive participants maintained at least a clinically meaningful response at month 12.”
> “Biologic-exposed participants were non-responders to prior FcRn or complement inhibitor treatment.”
> “Among biologic-naive patients, 55.60% achieved MSE by month 6, which was maintained through month 12 without additional treatment.”

Source: [Vu et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13004676/)

<a id="topic-2.2.2.3-5"></a>

###### Descartes-08: authors' interpretation of the biologic-exposure difference (phase 2b)

> “There was a notable difference in response between participants who had prior treatment with—and poor response to—complement and FcRn inhibitors and those who were biologic-naive.”
> “This may represent a true difference in biology due to a yet-to-be-determined mechanism, an artifact of a small sample size or a reflection of more treatment-refractory disease.”
> “However, it is notable that, even in the cohort of patients who were nonresponders to biologics, a proportion achieved a clinically meaningful improvement in the MGC score after Descartes-08, in contrast to those who were randomized to placebo.”

Source: [Vu et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13004676/)

<a id="topic-2.2.2.3-6"></a>

###### Descartes-08: biologic-naive participants with follow-up beyond month 3 (7 participants), company release, April 2025

> “The subset of participants who did not have exposure to prior biologic therapies, including complement or neonatal fragment crystallizable receptor (FcRn) inhibitors, were observed to exhibit a deepening of responses throughout the year, with an average MG-ADL reduction of 6.6 (±1.5) at Month 4 and 7.1 (±1.9) at Month 12.”
> “The participants treated with Descartes-08 without exposure to prior biologic therapies were observed to have an average QMG reduction of 5.9 (±2.4) points at Month 4, which deepened through Month 12 (9.4±2.6).”
> “57% (4/7) of these participants were observed to achieve MSE at Month 6 which was maintained through Month 12.”
> “100% (7/7) of these participants were observed to maintain at least a clinically meaningful response through Month 12.”

Source: [Cartesian Therapeutics phase 2b 12-month results press release (2025)](https://ir.cartesiantherapeutics.com/news-releases/news-release-details/cartesian-therapeutics-descartes-08-observed-provide-deep-and)

<a id="topic-2.2.2.3-7"></a>

###### Descartes-08: early-onset versus late-onset disease, prespecified analysis, mITT population (phase 2b)

> “In a prespecified analysis stratifying participants by disease onset, 80.0% (n = 4/5) of those treated with Descartes-08 who had early-onset MG, defined as the development of symptoms before the age of 50 years, were MGC responders at month 3, compared to 20.0% (n = 1/5) in the placebo group (Extended Data Table 2).”
> “Reductions in MG severity were generally consistent between participants with early-onset MG and those with late-onset MG who were treated with Descartes-08.”

Source: [Vu et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13004676/)

<a id="topic-2.2.2.3-8"></a>

###### Descartes-08: triple seronegative participants and the placebo response (phase 2b)

> “The most pronounced improvements in MG severity scales in the placebo group—including one case of MSE—were observed in participants with triple seronegative MG, consistent with larger placebo-controlled studies that included this cohort of patients”

Source: [Vu et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13004676/)

<a id="topic-2.2.2.3-9"></a>

###### Descartes-08: postinfusion fever and response, mITT population (phase 2b)

> “There were no notable differences in demographics or disease characteristics among participants randomized to Descartes-08 who developed a fever.”
> “However, those who developed a fever may have been more likely to respond and experience more pronounced symptom improvement, as measured by the MG-ADL score, than those who did not (Extended Data Table 3).”

Source: [Vu et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13004676/)

<a id="topic-2.2.2.3-10"></a>

###### Descartes-08: cell dose and MGC response, post hoc analysis (phase 2b)

> “A second post hoc analysis was conducted to assess cell dose infusion and MGC response.”
> “Overall, the mean cell dose per infusion was similar among those treated with Descartes-08, irrespective of whether they achieved a response or not (Extended Data Table 6).”

Source: [Vu et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13004676/)

<a id="topic-2.2.2.3-11"></a>

###### Descartes-08: response across MG types and severity, phase 1b/2a long-term follow-up

> “The initial report of Descartes‐08 noted deep responses across MG types and degrees of severity [8].”

Source: [Chahin et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12623823/)

<a id="topic-2.2.2.3-12"></a>

###### MuSK antibody-positive disease: response to conventional therapies

> “Many patients with MuSK-MG respond poorly to ChEIs, and conventional pyridostigmine doses frequently induce side effects.”
> “Patients with MuSK-MG appear to respond well to corticosteroids and to many steroid-sparing IS agents. They tend to remain dependent on prednisone despite concomitant treatment with steroid-sparing agents.”
> “MuSK-MG responds well to PLEX, while IVIg seems to be less effective.”

Source: [Sanders et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4977114/)

<a id="topic-2.2.2.3-13"></a>

###### MuSK antibody-positive disease: complement independence and thymectomy

> “The observation of predominant IgG4 antibodies in patients with MuSK MG is indicative of immune response that corresponds with the IgG4 autoimmune diseases ( 9 ) and the antiinflammatory properties of the IgG4 that include the inability to activate complement.”
> “The thymus is normal ( 116 ), and thymectomy does not benefit patients with MuSK with MG”

Source: [Kaminski et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11178544/)

<a id="topic-2.2.2.3-14"></a>

###### Rituximab response by antibody status

> “A retrospective combined analysis of previously published case reports of 169 patients between January 2000 and August 2015 reported that 72% of MuSK-Ab + MG and 30% of AChR-Ab+ MG patients treated with RTX achieved MM status or better.”

Source: [Narayanaswami et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7884987/)

<a id="topic-2.2.2.3-15"></a>

###### Inebilizumab effect by antibody status

| Week 26 outcome | Overall population | Anti-AChR antibody positive | Anti-MuSK antibody positive |
| --- | --- | --- | --- |
| MG-ADL difference from placebo | “-1.9” | “-1.8” | “-2.2” |
| MG-ADL p-value | “<0.0001” | “0.0015” | “0.0297” |
| QMG difference from placebo | “-2.5” | “-2.5” | “-2.3” |
| QMG p-value | “0.0002” | “0.0011” | “NS” |

Source: [Uplizna prescribing information (2025)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/761142s004lbl.pdf)

<a id="topic-2.2.2.3-16"></a>

###### Seronegative disease: efgartigimod in anti-AChR antibody-negative adults

> “The efficacy of VYVGART for the treatment of adult patients with gMG who are anti-AChR antibody negative was established in an 8-week, randomized double-blind, placebo-controlled study (Study 2 Part A; NCT06298552).”
> “In Study 2 Part A, a total of 119 patients were randomized 1:1 to receive once-weekly infusions for 4 weeks of either VYVGART 10 mg/kg (1,200 mg for those weighing 120 kg or more) (n=58) or placebo (n=61).”
> “Sixty-one percent of patients were triple seronegative (i.e., anti-AChR, anti-MuSK, and anti-low- density lipoprotein receptor-related protein 4 [LRP4] antibodies negative). Thirty-four percent of patients were positive for anti-MuSK antibodies, and 5% of patients were positive for anti-LRP4 antibodies.”

Source: [Vyvgart prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/761195s016lbl.pdf)

<a id="topic-2.2.2.3-17"></a>

###### Antibody subgroups enrolled in FcRn blocker trials

> “The majority of patients, 89.5% (n=179) were positive for AChR antibodies and 10.5% (n=21) were positive for MuSK antibodies.”

Source: [Rystiggo prescribing information (2025)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/761286s007lbl.pdf)

> “Eighty-eight percent (n=134) of patients were positive for AChR antibodies and 10% (n=16) were positive for MuSK antibodies.”

Source: [Imaavy prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/761430s002lbl.pdf)

<a id="topic-2.2.2.3-18"></a>

###### Ocular versus generalized disease

> “The efficacy of IVIg is less certain in milder MG or in ocular MG.”

Source: [Sanders et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4977114/)

> “Corticosteroids should be used as the initial IS agent in ocular MG. Steroid-sparing IS agents may be needed when corticosteroids alone are ineffective, contraindicated, or not tolerated”

Source: [Narayanaswami et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7884987/)

<a id="topic-2.2.2.3-19"></a>

###### Age and thymectomy benefit

> “In a post hoc analysis, neither the prednisone dose nor QMG scores were significantly different between the 2 treatment groups in patients 50 years or older.”

Source: [Narayanaswami et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7884987/)

<a id="topic-2.2.2.3-20"></a>

###### Potential confounding of network meta-analysis treatment effects by age and sex

> “Sensitivity analyses detected potential confounding of treatment effects by age and sex.”
> “Our findings also highlight how differences between trial populations may confound the interpretation of study outcomes.”

Source: [McLaren et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/42467874/)

<a id="topic-2.2.2.3-21"></a>

###### Delayed response to C5 inhibition in therapy-refractory patients: German-Austrian expert guidance

> “A clinical response is generally observed within the first 4 weeks after treatment initiation. In patients who do not achieve clinically meaningful improvement within 12 weeks, the decision to continue treatment or switch to an alternative therapy should be individualised [15, 17, 18, 20], as long‐term observational data from non‐placebo‐controlled studies suggest that delayed responses may occur, particularly in therapy‐refractory gMG patients treated with eculizumab or ravulizumab for several months or longer [39, 40].”

Source: [Meisel et al. (2026b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13559022/)

<a id="heading-2.2.2.4"></a>

##### 2.2.2.4 Care Management Intervention Strategies

<a id="topic-2.2.2.4-1"></a>

###### Treatment goal of minimal manifestation status: international consensus guidance

> “Goals for the treatment of MG. MGFA Task Force Post-Intervention Status (PIS) classification Minimal Manifestation Status (MMS) or better,3 with no more than grade 1 Common Terminology Criteria for Adverse Events (CTCAE) medication side effects.”

Source: [Sanders et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4977114/)

<a id="topic-2.2.2.4-2"></a>

###### Minimal symptom expression as a patient-reported treatment goal

> “‘Minimal symptom expression’ was defined as MG-ADL total score of 0–1 or MG-QOL15 total score of 0–3.”

Source: [Vissing et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7320935/)

> “MSE using the MG‐ADL shows promise in helping to determine success of treatment and may be the aspirational goal of MG treatment for the future once validated, particularly given the evolving treatment landscape in MG.”

Source: [Muppidi et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9302997/)

> “MSE, as a patient‐centric endpoint, can be used alongside clinician‐assessed measures and safety measures to support an integrated treatment goal that encompasses both efficacy and tolerability for the treatment of gMG.”

Source: [Meisel et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13093530/)

<a id="topic-2.2.2.4-3"></a>

###### Steroid-sparing strategy and tapering

> “Tapering of IS drugs is associated with risk of relapse, which may necessitate upward adjustments in dose. The risk of relapse is higher in patients who are symptomatic, or after rapid taper. d. It is usually necessary to maintain some immunosuppression for many years, sometimes for life.”

Source: [Sanders et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4977114/)

> “Patients with generalized MG should be given a non‐steroid immunosuppressant to achieve a better clinical response and enable steroid dose reduction.”
> “Tapering of corticosteroids, and non‐steroidal immunosuppressants, should be considered after 1–2 years in patients in stable remission or with minimal symptoms.”

Source: [Gilhus et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11236053/)

<a id="topic-2.2.2.4-4"></a>

###### Monitoring for adverse effects of immunosuppression

> “Patients must be monitored for potential adverse effects and complications from IS drugs. Changing to an alternative IS agent should be considered if adverse effects and complications are medically significant or create undue hardship for the patient.”

Source: [Sanders et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4977114/)

> “All patients on steroids should be monitored for blood pressure, body weight, bone mineral density, blood glucose levels, sleep, and mood problems.”
> “Due to spontaneous disease fluctuations, comorbidities, and changes in life conditions, regular long‐term specialized follow‐up is needed.”

Source: [Gilhus et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11236053/)

<a id="topic-2.2.2.4-5"></a>

###### Monitoring disease activity with MG-ADL and QMG

> “The QMG takes up to 25 min to complete and requires technician training, a hand‐held dynamometer, a spirometer, and a stopwatch.”
> “The MG‐ADL is easy to administer, requires no additional training, is quick to complete (<10 min), and can be used in routine clinical practice or in clinical trials.”
> “A 2‐point change seemed to provide the best balance between sensitivity (77%) and specificity (82%); thus, this analysis revealed that a 2‐point improvement in MG‐ADL score best indicated clinical improvement.”

Source: [Muppidi et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9302997/)

<a id="topic-2.2.2.4-6"></a>

###### Physical training and shared goal setting: Nordic guidance

> “Adapted physical training is recommended.”
> “Patients and doctors should together define ambitious treatment goals”

Source: [Gilhus et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11236053/)

<a id="topic-2.2.2.4-7"></a>

###### Monitoring for CRS, ICANS, and hematotoxicity after CAR T-cell therapy in autoimmune disease: EBMT recommendations

| Topic | EBMT recommendation for autoimmune disease |
| --- | --- |
| CRS, ICANS, and ICAHT | “As hematological patients. The early and prompt treatment of these complications is highly recommended in AD setting.” |
| Blood counts | “As for hematological patients; monitoring of blood counts is mandatory in ADs (e.g. at every visit and as clinically indicated, including long-term follow up to evaluate risk of ICAHT).” |
| Prophylactic G-CSF | “Administration of G-CSF may induce disease flare in ADs. Prophylactic use of G-CSF is not recommended.” |

Source: [Greco et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10867419/)

<a id="topic-2.2.2.4-8"></a>

###### Hospitalization, distance to the treating center, and caregiver presence after CAR T-cell therapy: EBMT recommendations

> “For hospitalization and distance to the accredited treating center, we refer to current EBMT guidelines for CT and ideally up to 14 days for AD patients without severe reactions. Patients should be located within 60 min of the center with the continuous presence of a caregiver educated to identify the potential complications maintained for a year.”

Source: [Greco et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10867419/)

<a id="topic-2.2.2.4-9"></a>

###### Daily CRS and ICANS monitoring and myelotoxicity surveillance: CD19 CAR T-cell case series in MG

> “Patients were monitored daily for the development of CRS and immune effector cell–associated neurotoxicity syndrome (ICANS) during the first 10 days following anti-CD19 CAR T cell infusion.”
> “Myelotoxicity was defined as grade III or IV neutropenia or leukocytopenia persisting for more than 28 days and was monitored prospectively using regular laboratory assessments, performed several times per week during the first 30 days, approximately biweekly between days 30 and 90, and at longer intervals thereafter.”
> “Long-term observation revealed an episode of pneumonia in patient MG3, associated with B cell aplasia and hypogammaglobulinemia.”

Source: [Hegelmaier et al. (2026b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13589498/)

<a id="topic-2.2.2.4-10"></a>

###### Neutropenia, infection, and hypogammaglobulinemia management after lymphodepletion and CAR T-cell infusion: phase 1 trial in refractory gMG

> “For neutrophil deficiency (absolute neutrophil count less than 1.0 × 109/L), granulocyte colony-stimulating factor and prophylactic antibiotics (mostly sulfamethoxazole and cephalosporins) were given.”
> “For those with severe infections or hypogammaglobulinemia (IgG less than 4 g/L), 0.4–0.6 g/kg of intravenous immunoglobulin was administered.”

Source: [Zhang et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12615342/)

<a id="topic-2.2.2.4-11"></a>

###### Antimicrobial prophylaxis after CAR T-cell therapy: EBMT recommendations

> “The risk of infection depends on the AD and degree of immunosuppression, and management should be carefully discussed upfront by a multidisciplinary team meeting (disease specialist, infection-disease specialist, hematologists and CART experts). A follow-up of potential infectious complications should be considered mandatory.”
> “Sufficiently long anti-viral and antibacterial prophylaxis should be maintained according to patient individual risk and in line with institutional guidelines and current EBMT guidelines.”

Source: [Greco et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10867419/)

<a id="topic-2.2.2.4-12"></a>

###### Vaccination before and after CAR T-cell therapy: EBMT recommendations

> “Vaccinations status should be assessed and updated before LD.”
> “Vaccination after CART therapy is effective and risk consideration should guide the decision to vaccinate before the procedure.”
> “Live vaccines are contraindicated in AD patients.”

Source: [Greco et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10867419/)

<a id="topic-2.2.2.4-13"></a>

###### Vaccination before immunosuppressive therapy and before complement inhibitors: 2026 international consensus

> “Clinicians should refer patients with MG to their primary care clinician or appropriate specialty (e.g., infectious disease) to complete immunization schedules, per local/national/World Health Organization guidelines and per local prescribing information for MG therapies as part of immunosuppressive therapy planning.”
> “Clinicians should refer patients with gMG for whom complement inhibitor therapies may be a future consideration to their primary care clinician or appropriate specialist to complete meningococcal vaccination and other treatment-specific vaccination, per local/national/World Health Organization guidelines and per local drug prescribing information.”

Source: [Narayanaswami et al. (2026b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13352217/)

<a id="topic-2.2.2.4-14"></a>

###### Leukapheresis: T-cell counts, venous access, and immunosuppressant washout: EBMT recommendations

> “To achieve a good product, drug-specific washout periods before leukapheresis have to be considered to optimize T cell fitness as listed in Table 5. Usual recommendations for a successful CART production advice for 200/mcl CD3+ T cell counts, but CD3+ T cell counts >50/mcl can be sufficient. Secure venous access has to be guaranteed in ADs, when planning leukapheresis and lymphodepleting conditioning (LD).”

Source: [Greco et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10867419/)

<a id="topic-2.2.2.4-15"></a>

###### Washout of MG-relevant immunotherapies before leukapheresis: EBMT recommendations

| Therapy | Recommendation in autoimmune disease |
| --- | --- |
| Steroids | “May be administered at dosages ≤10 mg/day prednisone (or equivalent), by 7 days before leukapheresis and before LD;” |
| Mycophenolate mofetil, azathioprine, calcineurin inhibitors, mTOR inhibitors, and JAK inhibitors | “Discontinued at least 2 weeks before leukapheresis” |
| Cyclophosphamide and methotrexate | “Discontinued at least 3 weeks before leukapheresis” |
| Belimumab and B cell targeting antibodies (e.g. anti CD20) | “Discontinued at least 1 week before leukapheresis” |

Source: [Greco et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10867419/)

<a id="topic-2.2.2.4-16"></a>

###### Timing of immunosuppressants around apheresis and lymphodepletion, and pre-lymphodepletion assessment of pulmonary reserve and bulbar function in MG

> “EULAR–EBMT guidance allows low‐dose prednisone up to 7.5 mg 1 day prior to apheresis but advises tapering cell‐cycle blockers 4 weeks before lymphodepletion so that transduced T‐cells expand without pharmacologic brakes”
> “Trial registries for autoimmune cellular therapies therefore recommend a meticulous pre‐diagnostic evaluation that captures comorbid infection, pulmonary reserve and bulbar function before lymphodepletion is even considered”
> “Application of the Immune Effector Cell‐Associated Encephalopathy (ICE) score beside continuous EEG was able to detect subclinical seizures in almost half of the patients whose formal ICANS grade had remained 0–1, suggesting that conventional grading alone is insufficient once neuromuscular weakness complicates the examination”

Source: [Hegelmaier et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13138368/)

<a id="topic-2.2.2.4-17"></a>

###### Prolonged B-cell aplasia, hypogammaglobulinemia, and infections after CAR T-cell therapy

> “A frequent long‐term consequence of anti‐CD19 CAR T‐cell therapy is prolonged B cell aplasia, persisting for years in up to 38% of patients and often resulting in hypogammaglobulinemia and increased infection risk requiring immunoglobulin replacement”

Source: [Hegelmaier et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13138368/)

> “Severe infections are frequent in the early period following CAR-T reinfusion, warranting antimicrobial prophylaxis.”
> “Hypogammaglobulinaemia is typically prolonged and may necessitate treatment of supplemental Immunoglobulin Replacement Therapy.”

Source: [Bradhurst et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13630046/)

<a id="topic-2.2.2.4-18"></a>

###### Frequency of CRS, ICANS, hypogammaglobulinemia, cytopenias, and infection after CAR-based therapy in autoimmune disease: meta-analysis of 56 studies

> “Of 3367 records screened, 56 studies met the inclusion criteria (15 eligible for meta-analysis; 41 synthesized qualitatively).”
> “Across all AIDs, CRS of any grade occurred in 0·63, but grade ≥ 3 CRS and any grade of ICANS were negligible (both 0·00). Hypogammaglobulinaemia of any grade occurred in 0·47, while grade ≥ 3 events were rare. Cytopenias were common: neutropenia and anemia of any grade were most frequent. Severe cytopenias occurred in ≤0·3. Infection within 3 months occurred in 0·29.”

Source: [Wong et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/42167622/)

<a id="topic-2.2.2.4-19"></a>

###### Regular assessment of symptom burden, treatment burden, and quality of life; shared decision making: 2026 international consensus

> “Clinicians should regularly assess a patient with MG at all disease stages for symptom burden, treatment burden, and quality of life, using the same measures to build an ongoing, overall picture of the disease and its impact.”
> “Clinicians should engage patients with MG and their family/caregivers, as appropriate, to play an active role in shared decision making, so that patients' personal goals, values, and preferences are considered when discussing treatment plans.”
> “In patients receiving glucocorticoids, clinicians should aim to reduce the glucocorticoid dose to prednisone equivalent ≤10 mg/d and optimally to ≤5 mg/d, using alternative agents as necessary, and monitor patients closely for MG worsening.”

Source: [Narayanaswami et al. (2026b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13352217/)

<a id="topic-2.2.2.4-20"></a>

###### IgG monitoring under FcRn inhibitors and rituximab: German-Austrian expert guidance

> “Drug‐specific safety parameters must be assessed before initiation and at every switch of immunotherapy. These include monitoring of IgG levels under FcRn‐I and RTX therapy (especially when used in combination).”

Source: [Meisel et al. (2026b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13559022/)

<a id="topic-2.2.2.4-21"></a>

###### Living consensus recommendations on CAR T-cell therapy for autoimmune diseases: 2026 EBMT, ISCT, and JACIE update

> “In 2024, an international expert panel from the European Society for Blood and Marrow Transplantation (EBMT), the International Society for Cell and Gene Therapy (ISCT), and the Joint Accreditation Committee of ISCT and EBMT (JACIE) released the first best-practice recommendations on CAR T cells for autoimmune diseases.”
> “The 2026 consensus reviews current evidence and expert practices on CAR T cells for rheumatic, neurological, haematological, other autoimmune diseases, and paediatric indications, providing updated, expert-based recommendations on patient selection, diagnostic investigation, clinical management, follow up, and immune monitoring for each disease group.”

Source: [Greco et al. (2026)](https://www.thelancet.com/journals/lanrhe/article/PIIS2665-9913%2826%2900249-3/fulltext)

<a id="heading-2.2.2.5"></a>

##### 2.2.2.5 Other Product Development or Post-marketing Obligations Required by the FDA

Not applicable.

<a id="heading-2.2.2.6"></a>

##### 2.2.2.6 Ongoing Post-approval Monitoring

Not applicable.

<a id="heading-2.2.2.7"></a>

##### 2.2.2.7 Expected Outcomes of Therapy

<a id="topic-2.2.2.7-1"></a>

###### Summary

- Clinically meaningful change: A 2-point improvement in the MG-ADL best predicted clinical improvement (correlation with physician impression of change r = 0.70), and anchor-based and distribution-based minimal clinically important difference cut-offs for the QMG were below a change of 3.0.
- Treatment goals: Guidance states that the ongoing goal is to achieve and sustain minimal symptoms and treatment-related adverse events with a patient-acceptable quality of life, and to reassess treatment when these cannot be sustained. A consensus definition of adequately controlled gMG requires an MGFA post-intervention status of clinical stable remission, pharmacologic remission, or minimal manifestations stable for a year, an MG-ADL score of 2 or less, no exacerbation in the last year requiring a change in immunosuppressive or rescue therapy, and no or mild adverse events to therapy.
- Effect sizes of targeted therapies: An analysis of 27 placebo-controlled randomized trials (placebo n = 1,086; treatment n = 1,232) estimated QMG reductions beyond placebo and standard of care of -3.63 (95% credible interval -4.43 to -2.77) points for FcRn inhibitors, -2.59 (-3.92 to -1.28) for C5 complement inhibitors, and -2.50 (-5.11 to 0.12) for CD19+ B-cell depletion, and MG-ADL effects of -1.93 (-2.21 to -1.65), -1.84 (-2.48 to -1.19), and -1.91 (-2.97 to -0.84); meaningful differences between classes were not observed. In an Argenx-funded study, intravenous efgartigimod had the lowest number needed to treat versus placebo for 3-point and 5-point QMG reductions and a 5-point MG-ADL reduction, rozanolixizumab had the lowest for a 3-point MG-ADL reduction, and the number needed to harm was similar across treatments. With eculizumab, minimal symptom expression on the MG-ADL was reached by 21.4% of patients versus 1.7% with placebo at REGAIN week 26, and by 22.9% and 27.8% of the eculizumab/eculizumab and placebo/eculizumab groups at extension week 130.
- Company expectations for Descartes-08: The company states that Descartes-08 is being developed with the goal of providing “sustained clinical benefit following a finite course of treatment”, that sustained benefits were observed through 12 months in the phase 2b trial, and that it believes a single course has the potential to transform the MG treatment paradigm. The company states that its cell therapies are designed to be dosed repeatedly like conventional drugs, in an outpatient setting and without pre-treatment chemotherapy, that retreatment is possible if symptoms return, and that achievement of minimal symptom expression over time remains a key treatment goal for physicians.

Source: [Muppidi et al. (2011)](https://pubmed.ncbi.nlm.nih.gov/22006686/); [Katzberg et al. (2014)](https://pubmed.ncbi.nlm.nih.gov/24810970/); [Narayanaswami et al. (2026b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13352217/); [Reyes-Leiva et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13714894/); [McLaren et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/42467874/); [Smith et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11550228/); [Vissing et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7320935/); [Cartesian Therapeutics retreatment data press release (2026)](https://ir.cartesiantherapeutics.com/news-releases/news-release-details/cartesian-therapeutics-announces-additional-retreatment-data); [Cartesian Therapeutics AURORA first participant press release (2025)](https://ir.cartesiantherapeutics.com/news-releases/news-release-details/cartesian-therapeutics-announces-first-participant-enrolled); [Cartesian Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1453687/000145368726000064/rnac-20251231.htm); [Cartesian Therapeutics corporate presentation, November 2026 (2026)](https://ir.cartesiantherapeutics.com/static-files/6ba3bfe0-f3be-4487-add3-b56dd535e456)

<a id="topic-2.2.2.7-2"></a>

###### Company statement of sustained benefit after a finite course without chronic dosing

> “Unlike currently approved therapies that generally require cyclical dosing to maintain effect, Descartes-08 is being developed with the goal of providing sustained clinical benefit following a finite course of treatment.”

Source: [Cartesian Therapeutics retreatment data press release (2026)](https://ir.cartesiantherapeutics.com/news-releases/news-release-details/cartesian-therapeutics-announces-additional-retreatment-data)

> “Based on efficacy and safety data observed in our clinical trials thus far, we believe our cell therapies have the potential to deliver deep and durable clinical benefit to a broad group of patients with autoimmune diseases after a single course of therapy.”

Source: [Cartesian Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1453687/000145368726000064/rnac-20251231.htm)

> “With sustained benefits observed through 12 months in our Phase 2b trial, we believe Descartes-08 has the potential to transform the current MG treatment paradigm with just a single course of therapy.”

Source: [Cartesian Therapeutics AURORA first participant press release (2025)](https://ir.cartesiantherapeutics.com/news-releases/news-release-details/cartesian-therapeutics-announces-first-participant-enrolled)

<a id="topic-2.2.2.7-3"></a>

###### Retreatment if symptoms recur

> “We believe the combination of sustained symptom improvement, the ability to retreat if symptoms return, and the quality-of-life benefits of outpatient administration without lymphodepleting chemotherapy sets Descartes-08 apart and has the potential to meaningfully change the way MG is treated.”

Source: [Cartesian Therapeutics retreatment data press release (2026)](https://ir.cartesiantherapeutics.com/news-releases/news-release-details/cartesian-therapeutics-announces-additional-retreatment-data)

> “Our cell therapies are designed to be dosed repeatedly like conventional drugs, administered in an outpatient setting and given without pre-treatment chemotherapy required with many conventional cell therapies.”

Source: [Cartesian Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1453687/000145368726000064/rnac-20251231.htm)

> “The favorable safety profile of mRNA cell therapy enables repeat dosing if needed, providing flexibility”

Source: [Cartesian Therapeutics corporate presentation, November 2026 (2026)](https://ir.cartesiantherapeutics.com/static-files/6ba3bfe0-f3be-4487-add3-b56dd535e456)

<a id="topic-2.2.2.7-4"></a>

###### Treatment goal named in company materials: minimal symptom expression

> “Achievement of minimal symptom expression over time remains a key treatment goal for physicians”

Source: [Cartesian Therapeutics corporate presentation, November 2026 (2026)](https://ir.cartesiantherapeutics.com/static-files/6ba3bfe0-f3be-4487-add3-b56dd535e456)

<a id="topic-2.2.2.7-5"></a>

###### Ongoing treatment goal: minimal symptoms and treatment-related adverse events, 2026 international consensus

> “The ongoing treatment goal in MG is to work toward, achieve, and sustain minimal symptoms and treatment-related adverse events, with a patient-acceptable quality of life (using validated measures).”
> “In patients with MG, if minimal symptoms, minimal treatment-related adverse events, and patient-acceptable quality of life cannot be sustained, clinicians should reassess treatment and make changes to achieve treatment goals.”

Source: [Narayanaswami et al. (2026b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13352217/)

<a id="topic-2.2.2.7-6"></a>

###### Minimal clinically important difference of the MG-ADL: 2-point improvement

> “Correlation of the delta MG-ADL score and physician impression of change between the visits was strong (r = 0.70, P < 0.0001). A 2-point improvement in the MG-ADL best predicted clinical improvement.”
> “A 2-point improvement in the MG-ADL indicates clinical improvement.”

Source: [Muppidi et al. (2011)](https://pubmed.ncbi.nlm.nih.gov/22006686/)

<a id="topic-2.2.2.7-7"></a>

###### Minimal clinically important difference of the QMG: anchor-based and distribution-based estimates

> “One anchor-based and 3 distribution-based techniques were used to identify quantitative myasthenia gravis score (QMGS), repetitive nerve stimulation (RNS), and single-fiber electromyography (SFEMG) MCID cut-offs.”
> “MCID cut-offs were below a QMGS change of 3.0.”

Source: [Katzberg et al. (2014)](https://pubmed.ncbi.nlm.nih.gov/24810970/)

<a id="topic-2.2.2.7-8"></a>

###### Minimal symptom expression attained with eculizumab: REGAIN week 26 and open-label extension week 130

> “At REGAIN week 26, more eculizumab-treated patients achieved ‘minimal symptom expression’ versus placebo [MG-ADL: 21.4% vs 1.7%; difference 19.8%; 95% confidence interval (CI) 8.5, 31.0; p = 0.0007; MG-QOL15: 16.1% vs 1.7%; difference 14.4%; 95% CI 4.3, 24.6; p = 0.0069].”
> “At extension study week 130, similar proportions of patients in the eculizumab/eculizumab and placebo/eculizumab groups achieved ‘minimal symptom expression’ (MG-ADL: 22.9% and 27.8%, respectively, p = 0.7861; MG-QOL15: 14.3% and 19.4%, respectively, p = 0.7531).”

Source: [Vissing et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7320935/)

<a id="topic-2.2.2.7-9"></a>

###### Consensus definition of adequately controlled generalized myasthenia gravis

> “Adequately controlled gMG was defined as achieving Myasthenia Gravis Foundation of America Post-Intervention Status classification of clinical stable remission, pharmacologic remission, or minimal manifestations stable for a year; having an MG-ADL score ≤2; experiencing no clinical exacerbations during the last year requiring a change in immunosuppressive therapy or rescue therapy; and having no or mild AE to therapies (100% of experts in agreement or total agreement).”

Source: [Reyes-Leiva et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13714894/)

<a id="topic-2.2.2.7-10"></a>

###### Expected effect sizes of FcRn inhibitors, C5 inhibitors, and CD19 B-cell depletion on MG-ADL and QMG: 27 placebo-controlled randomized trials

> “Of 4,823 eligible studies, 27 placebo-controlled randomized trials (placebo n = 1,086; treatment n = 1,232) were included that targeted B cells, neonatal Fc receptor (FcRn), complement activity, CD40, and interleukin-6 signaling, as well as immunoglobulin G and broad immunosuppression therapy.”
> “Compared to those treated with placebo and standard of care, QMG scores decreased by an average of -3.63 (95% credible interval -4.43 to -2.77) points more in patients treated with FcRn inhibitors, -2.59 (-3.92 to -1.28) points more in patients treated with C5 complement inhibitors (C5i), and -2.50 (-5.11 to 0.12) points more in patients treated with CD19+ B-cell depletion therapy (BCDT). The MG-ADL treatment effects were -1.93 (-2.21 to -1.65) for FcRn inhibitors, -1.84 (-2.48 to -1.19) for C5i, and -1.91 (-2.97 to -0.84) for CD19+ BCDT.”
> “FcRn inhibitors, C5i, and CD19+ BCDT showed comparable efficacy in terms of QMG and MG-ADL reduction because meaningful differences were not observed between treatment classes.”

Source: [McLaren et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/42467874/)

<a id="topic-2.2.2.7-11"></a>

###### Number needed to treat for 3-point and 5-point MG-ADL and QMG improvements: analysis funded by Argenx

> “Efgartigimod IV had the lowest NNT versus placebo for achieving a ≥ 3- and ≥ 5-point reduction in QMG, as well as a ≥ 5-point reduction in MG-ADL, whereas rozanolixizumab had the lowest NNT for a ≥ 3-point reduction in MG-ADL. The NNH versus placebo was similar across comparator treatments.”
> “This study was funded by Argenx.”

Source: [Smith et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11550228/)

## Related pages
- [Descartes-08: Generalized myasthenia gravis](https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis) · [Markdown](https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis.md)
- [Descartes-08 in Generalized myasthenia gravis: Terms and abbreviations](https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis/terms-and-abbreviations.md)
- [Descartes-08: Generalized myasthenia gravis](https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis/executive-summary) · [Markdown](https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis/executive-summary.md)
- [Descartes-08 in Generalized myasthenia gravis: Clinical evidence](https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis/clinical-evidence.md)
- [Descartes-08 in Generalized myasthenia gravis: Economic information and modeling report](https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis/economics) · [Markdown](https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis/economics.md)
- [Descartes-08 in Generalized myasthenia gravis: References](https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis/references) · [Markdown](https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis/references.md)
